



Stock Code: 1783

MAXIGEN BIOTECH INC.

2024 Annual Report

Annual Report Inquiry Website:

<http://mops.twse.com.tw>

Company Website: <http://www.mbi.com.tw>

Printed on April 30, 2025

1. Spokesperson and Deputy Spokesperson of This Company:

Spokesperson:

Name: Yen-Chuan Chen

Title: Chief Marketing Officer

Phone: (02) 8797-7811

Email: anitayj.chen@tci-bio.com

Deputy Spokesperson:

Name: Po-Hong Lai

Title: Deputy General Manager

Phone: (03) 328-7222

Email : phlai@mbi.com.tw

2. Address and Phone Number of Headquarters and Factory:

Headquarters: Maxigen Biotech Inc.

Address: No. 88, Keji 1st Road, Guishan District, Taoyuan City

Phone: (03) 328-7222

3. Stock Transfer Agency:

Name: Yuanta Securities Co., Ltd. Stock Agency Department

Address: No. 210, Section 3, Chengde Rd, Datong District, Taipei City

Phone: (02) 2586-5859

Website: <http://www.yuanta.com.tw>

4. Name, address, website and telephone number of the accountant and firm that issued the most recent annual financial report:

Name of accountants: Ping-Chun Chih, Tsung-Hsi Lai

Name of firm: PwC Taiwan

Address: 27th Floor, No. 333, Section 1, Keelung Road, Xinyi District, Taipei City

Phone: (02) 2729-6666

Website: <http://www.pwc.tw>

5. Name of the exchange where the overseas marketable securities are listed and how to check the information of the overseas marketable securities: None

6. Company Website: <http://www.mbi.com.tw>

Table of Contents

I. Letter to Shareholders	1
II. Corporate Governance Report	5
1. Information on Directors, Supervisors, General Manager, Vice Presidents, Assistant Managers, and Supervisors of Various Departments and Branch Offices.....	5
2. Recent Fiscal Year Remuneration Paid to Directors, Supervisors, General Manager, and Vice Presidents	17
3. Corporate Governance Operational Situation	24
4. Information on the Public Fees of the Certified Public Accountant	86
5. Information on Change of Accountant	86
6. The chairman of the board, general manager, or manager responsible for finance or accounting affairs of the company, who has served in the office of the certified public accountant or its related enterprises within the last year, shall disclose their name, title, and the duration of their service in the office of the certified public accountant or its related enterprises	87
7. Changes in the shares held and pledged by directors, supervisors, managers, and major shareholders holding over 10% of outstanding shares in the most recent year and up to the publication of the annual report	88
8. Information on whether the top ten shareholders by shareholding ratio are related parties or have spousal or second-degree kinship relationships with each other.....	89
9. The number of shares held by the company's directors, supervisors, managerial officers, and enterprises directly or indirectly controlled by the company in the same reinvested enterprise, with the total shareholding ratio calculated on a consolidated basis.	89
III. Fundraising Activities	90
1. Capital and Shares.....	90
2. Corporate Bonds.....	96
3. Preferred Stock Issued	96
4. Overseas Depository Receipts Issued.....	96
5. Employee Stock Option Issued.....	97
6. Merger or Acquisition of Shares of other Companies and Issuance of New Shares.....	98
7. Restricted Employee Shares.....	98
8. Capital Utilization Plan Implementation.....	98

IV. Overview of Operations	99
1. Business Activities.....	99
2. Market and Production and Sales Overview	128
3. Employee Information.....	135
4. Information on environmental protection expenditures.....	135
5. Labor Relations	136
6. Information Security Management.....	138
7. Significant Contracts	140
V. Review of Financial Conditions, Financial Performance, and Risk Management	141
1. Financial Condition.....	141
2. Financial Performance	142
3. Cash Flow	143
4. The Impact of Recent Major Capital Expenditures on Financial Operations	143
5. Recent year’s investment policy, the main reason for its profit or loss, improvement and investment plan for the next year	144
6. Risks and assessments for the latest year and up to the date of publication of the annual report.....	144
7. Other Important Matters	149
VI. Special Notes	150
1. Information of the company’s affiliates	150
2. The status of issuing private placement securities in the most recent year and up to the publication of the annual report.....	153
3. Recent year and as of the date of publication of the annual report, the subsidiaries held or disposed of the Company’s shares.....	154
VII. The occurrence of any events as stated in Section 3 Paragraph 2 in Article 36 of the Securities Exchange Act and had significant impact on shareholders’ equity or securities prices in the most recent year and up to the publication of the annual report	154

I. Letter to Shareholders

Maxigen Biotech Inc. Business Report

Dear Shareholders,

The core technologies of Maxigen Biotech Inc. include collagen and Hyaluronic Acid (also known as Hyaluronic Acid), which are utilized in biomedical materials and health products. After years of effort, MBI has successfully developed 24 advanced implantable medical devices for use in Orthopedics, Dentistry, Ophthalmology, Medical aesthetics, Surgery, and Otolaryngology, and has obtained a total of 92 product licenses from Taiwan, the European Union, the United States, Australia, Indonesia, Malaysia, the Philippines, the Middle East, Russia, and China.

As of November 2024, the population aged 65 and older in Taiwan is approximately 4.29 million, accounting for 18.35% of the total population. As of 2021, the global population aged 65 and older is approximately 759 million, and it is projected to reach 1.6 billion by 2050, representing 16% of the global population. This reflects the rapidly accelerating trend of aging.

MBI upholds the vision of 'Joining and Improving Human Life,' focusing on addressing the health needs associated with aging. Our product range encompasses areas such as arthritis, bone defects, cataracts, dental implants, medical aesthetics, and surgery, dedicated to helping individuals maintain good health and quality of life at various stages of life.

In Fiscal Year 2025, we will continue our operational policy of 'Delivering Quality Products, Serving Global Clients, and Supporting Client Globalization,' while leveraging AI applications to accelerate product innovation and development. Together with our partners, we will confront challenges and contribute to the advancement of the global health industry.

The following are MBI's operational policies for 2025:

1. Accelerate the promotion of a global certification strategy

In 2024, we established certifications in several emerging markets, including the Middle East, Philippines, Thailand, Indonesia, Peru, Brazil, and Australia. In collaboration with local clients, we continue to promote quality products to the global market. We have obtained TGA certification and will implement a more comprehensive strategy for Australia in 2025. Currently, our business is diversified into three segments: Taiwan, China, and overseas, and we collaborate with TCI Group's various business locations to participate in events such as Hospitalar, Intercharm, and Supply Site West, as well as client interactions, to maximize group benefits.

2. International Marketing

The website employs AI to enhance the availability of new language options, including Spanish, Portuguese, French, and Arabic, while also introducing multilingual electronic product manuals. We aim to increase international engagement through seminars and webinars, bringing overseas KOLs to Taiwan and facilitating Taiwanese KOLs to speak and promote products globally. Additionally, we leverage the unique advantages of the Group to enhance the implementation videos of VR and the company profile, thereby increasing client confidence in our products and the Company.

3. Development of Innovative and Differentiated Products.

By identifying differentiating factors, we create product niches, achieve breakthrough innovations, and develop superior and more efficient products for the market. In the fields of Hyaluronic Acid and collagen, in addition to the existing Class III Medical Device, we are also developing new products in the direction of Class I and Class II Medical Device, which have relatively shorter development times, with the expectation of accelerating the launch of new products. In 2024, we invested in three new clinical experiments, and in 2025, we will continue to expand into new specialties and indications. Simultaneously, several products have progressed to the trial production stage, with launches scheduled to occur successively from 2025 to 2026.

4. Secure and precise information, integrated with AI applications.

In April 2024, we upgraded our original ERP system to the world-class operating system SAP. Following the launch, we continue to optimize and enhance the collection and application of various types of information. It is anticipated that from 2025 to 2026, production data at each stage, raw material management and forecasting, as well as automated scheduling, will reach new heights. Simultaneously, we continue to enhance cybersecurity measures by implementing multiple layers of protection: firewalls, IPS, and EDR, while collaborating with PWC to initiate a project focused on trade secrets. In November, MBI-Venus officially launched, integrating the existing lexicon and knowledge base, with ChatGPT providing support. In 2025, we will fully increase the application of AI.

5. Comprehensive enhancement of intelligence, high performance, and production capacity.

The production line underwent several rectifications and adjustments in 2024, including addressing the bottleneck in collagen freeze-drying capacity and increasing the formulation capacity for Hyaluronic Acid products. In 2025, we will reorganize packaging materials and introduce automated packaging production equipment. In 2025, the collagen production line is anticipated to implement an automated packaging system, and the syringes will be assessed for the acquisition of the finest filling and packaging equipment available globally, while the cleanroom space will be readjusted to meet the layout and demands of the global market.

6. Quality Enhancement with Comprehensive International Certifications

In 2025, the factory will adopt HALAL and GDP certifications, significantly improving product quality and management standards. HALAL certification ensures that products comply with halal requirements, facilitating expansion into the Middle East and Muslim markets; GDP certification enhances logistics and warehousing management, ensuring compliance within the supply chain. These initiatives not only satisfy the demands of the international market but also enhance the brand's competitiveness in the global market.

7. Effective cost control to generate improved gross margins.

Following the implementation of SAP, the company employs the Master Production Schedule (MPS) and Material Requirements Planning (MRP) systems to forecast market demand and enhance the accuracy of production planning. Simultaneously, leveraging SAP's data analysis capabilities, it provides multidimensional management reports to assist management in optimizing decision-making, thereby achieving precise production and procurement management.

Furthermore, we continue to enhance the Company's operational efficiency and generate greater operating profits and gross margins for the Company and Shareholders through effective cost control strategies, which include reducing operational waste, negotiating better pricing, and implementing cost-saving initiatives, as well as formulating annual procurement strategies.

8. Happy Enterprise, Sustainable Growth

The hours dedicated to Training and Education continue to increase, and we are digitizing and translating the training materials into English to provide more flexible learning opportunities. In 2025, we will implement a talent grid to customize development plans for potential employees. The TCI Coin activities will diversify further, encompassing travel, dining, hair care, laundry, automobile maintenance, sports courses, and family days, enabling MBI employees to continue adding value and enjoying life beyond work.

We are also actively advancing carbon reduction initiatives to showcase our commitment to sustainable development. Through the implementation of e-IFU, we aim to minimize paper resource consumption. We aim to reduce the volume of packaging materials, thereby decreasing plastic usage while enhancing space utilization. Through the improvement of packaging processes and equipment, we also achieve effective resource utilization, reduce energy consumption, and lower overall carbon emissions. We will continue to collaborate with suppliers and clients to promote green production and the circular economy, contributing to a sustainable future for our planet.

In line with our comprehensive operational plan, MBI will center its efforts on the vision of 'joining and improving human life' as we strive to become the world's leading biotechnology company. We will continuously enhance product quality and market competitiveness through global certification strategies, innovative product development, intelligent production upgrades, and a commitment to sustainable development. At the same time, we uphold our responsibilities to employees, clients, and shareholders by improving human health through exceptional technology and services, striving to become the most trusted partner in the global health industry, and collaboratively creating a better future.

2024 Financial Performance

1. Operational Results

Unit: New Taiwan Dollar (thousands)

Maxigen Biotech Inc.				
Consolidated Income Statement				
Item	2024	2023	Difference	%
Net Revenue	680,651	622,115	58,536	9.4%
Operating Costs	197,326	198,021	(695)	-0.4%
Gross Profit	483,325	424,094	59,231	14.0%
Operating Expenses	303,419	274,244	29,175	10.6%
Income from Operations	179,906	149,850	30,056	20.1%
Other Operating Income and Expenses	45,639	43,292	2,347	5.4%
Pre-tax Income	225,545	193,142	32,403	16.8%
Income Tax Expense	35,378	27,314	8,064	29.5%
Net Income	190,167	165,828	24,339	14.7%

2. Financial Profitability Analysis

- (1) The Company's net operating revenue for fiscal year 2024 was NT\$680,651 thousand, representing an increase of NT\$58,536 thousand or 9% compared to NT\$622,115 thousand in 2023. Revenue from biomedical products amounted to NT\$663,898 thousand, an increase of NT\$62,197 thousand or 10% from NT\$601,701 thousand in 2023, mainly attributable to significant growth in the Taiwan and European markets.
- (2) In 2024, operating expenses amounted to NT\$303,419 thousand, representing an increase of NT\$29,175 thousand compared to NT\$274,244 thousand in 2023. The increase was mainly due to a significant rise in R&D service expenses incurred for conducting clinical trials and regulatory registrations in various countries.
- (3) The gross profit for 2024 is NT\$483,325 thousand, reflecting an increase of NT\$59,231 thousand compared to NT\$424,094 thousand in 2023, which represents a growth of 14%. The net profit after tax for 2024 is NT\$190,167 thousand, showing an increase of NT\$24,339 thousand compared to NT\$165,828 thousand in 2023, which represents a growth of 14.7%.

Chairman: Yung-Hsiang Lin



Manager: Ching-Ting Chen



Accounting Manager: Rueil-Yi Wu



II. Corporate Governance Report

1. Information on Directors, Supervisors, General Manager, Vice Presidents, Assistant Managers, and Supervisors of Various Departments and Branch Offices

1.1 Directors and Supervisors

(1) Director Information

April 13, 2025

Title	Nationality or Place of registration	Name	Gender Age	Elect (in) Date	Term	Date First Elected	Shareholding When Elected		Current Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Education and Experience	Selected Current Positions Other Companies	Other Heads, Directors, or Supervisors as Spouse or Kin within the Second Degree			If the chairman of the board of directors and the president or equivalent (top manager) are the same person, spouses or relatives of one another, the reasons, reasonableness, necessity and measures to be taken shall be stated.
							Number of shares (shares)	%	Number of shares (shares)	%	Shares (Shares)	%	Shares (Shares)	Shareholding Ratio (%)			Title	Name	Relationship	
Chairman	R.O.C.	TCI Co., Ltd.	Legal entity	2024.6.13	3 years	2021.7.12	20,304,762	22.8	24,670,762	27.51	0	0	0	0	Not applicable	Not Applicable	None	None	None	None
	R.O.C.	Yung-Hsiang Lin	Male 46-50	2024.6.13	3 years	2021.7.12	0	0	464,000	0.52	0	0	1,755,705	1.96	Bachelor Degree in Botany, National Chung Hsing University Deputy General Manager, TCI Co., Ltd. Former Manager, Biomedical Department, TCI Co., Ltd. Former Deputy Manager, Marketing Department, Hsin-Fa International Biotechnology Inc.	(Note 1)	None	None	None	None
Director	R.O.C.	China Investment and Development Co., Ltd.	Legal entity	2024.6.13	3 years	2021.7.12	1,376,688	1.54	1,376,688	1.54	0	0	0	0	Not Applicable	Not Applicable	None	None	None	None
	R.O.C.	Xiu-Yuan Li	Female 56-60	2024.6.13	3 years	2015.6.22	0	0	0	0	0	0	0	0	Master's degree in Economics, San Jose State University, USA Senior Deputy General Manager, China Investment and Development Co., Ltd. Associate, Everfame Consultants Ltd. Project Manager, China Investment and Development Co., Ltd. Securities Analyst, International Department, CITIC Securities Project Manager, Institute of Electronics, ITRI	General Manager, China Investment & Development	None	None	None	None

Title	Nationality or Place of registration	Name	Gender Age	Elect (in) Date	Term	Date First Elected	Shareholding When Elected		Current Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Education and Experience	Selected Current Positions Other Companies	Other Heads, Directors, or Supervisors as Spouse or Kin within the Second Degree			If the chairman of the board of directors and the president or equivalent (top manager) are the same person, spouses or relatives of one another, the reasons, reasonableness, necessity and measures to be taken shall be stated.
							Number of shares (shares)	%	Number of shares (shares)	%	Shares (Shares)	%	Shares (Shares)	Shareholding Ratio (%)			Title	Name	Relationship	
Director	R.O.C.	TCI Co., Ltd.	Legal entity	2021.7.12	3 years	2021.7.12	20,304,762	22.8	24,670,762	27.51	0	0	0	0	Not Applicable	Not Applicable	None	None	None	None
	R.O.C.	Chen-Chen Fu	Female 51-55	2024.6.13	3 years	2021.7.12	0	0	0	0	0	0	0	0	Bachelor of Finance and Taxation, Feng Chia University Accounting Manager, TCI Co., Ltd.	Director, TCI Gene Inc. Supervisor, TCI Living Inc. Supervisor, Quantum Biology Inc. Supervisor, SMY INTERNET OF PACKAGE CO., LTD.	None	None	None	None
Director	R.O.C.	TCI Co., Ltd.	Legal entity	2024.6.13	3 years	2021.7.12	20,304,762	22.8	24,670,762	27.51	0	0	0	0	Not Applicable	Not Applicable	None	None	None	None
	R.O.C.	Ching-Ting Chen	Female 36-40	2024.6.13	3 years	2021.11.3	0	0	146,402	0.16	2,310	0	0	0	Master of Chemistry, National Taiwan University Bachelor of Chemistry, National Tsing Hua University Manager, TCI Co., Ltd.	General Manager, Maxigen Biotech Inc. Member of Risk Management Committee, Maxigen Biotech Inc.	None	None	None	None
Director	R.O.C.	TCI Co., Ltd.	Legal entity	2024.6.13	3 years	2022.6.21	20,304,762	22.8	24,670,762	27.51	0	0	0	0	Not Applicable	Not Applicable	None	None	None	None
	R.O.C.	Chih-Cheng Tsai	Male 56-60	2024.6.13	3 years	2024.6.13	0	0	0	0	0	0	0	0	EMBA, National Chengchi University, Director of Production Planning Center, Techpros International Co., Ltd. Deputy General Manager, Xiamen Plant, Seagull Group Franz Collection Head of Materials Management Section, En Chu Kong Hospital	Director, TCI Living Inc.	None	None	None	None
Director	R.O.C.	Formosa Biomedical Technology Corp.	Legal entity	2024.6.13	3 years	2022.6.21	8,702,040	9.70	8,702,040	9.70	0	0	0	0	Not Applicable	Not Applicable	None	None	None	None
	R.O.C.	Shih-Ming Lai	Male 46-50	2024.6.13	3 years	2022.6.21	0	0	0	0	0	0	0	0	MBA, University of Portland General Manager's Office of the General Management Office, Formosa Plastic Group. Purchasing Department, General Management Office, Formosa Plastic Group Formosa Lithium Iron Oxide Corp Deputy Team Leader of Medical Business Development Center, General Management Office, Formosa Plastic Group	Deputy Head of the Investment Management Team, General Management Office, Formosa Plastic Group	None	None	None	None

Title	Nationality or Place of registration	Name	Gender Age	Elect (in) Date	Term	Date First Elected	Shareholding When Elected		Current Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Education and Experience	Selected Current Positions Other Companies	Other Heads, Directors, or Supervisors as Spouse or Kin within the Second Degree			If the chairman of the board of directors and the president or equivalent (top manager) are the same person, spouses or relatives of one another, the reasons, reasonableness, necessity and measures to be taken shall be stated.
							Number of shares (shares)	%	Number of shares (shares)	%	Shares (Shares)	%	Shares (Shares)	Shareholding Ratio (%)			Title	Name	Relationship	
Independent Director	R.O.C.	Sung-Yuan Liao	Male 76-80	2024.6.13	3 years	2021.7.12	0	0	0	0	0	0	0	0	Ph.D., National Chung Hsing University Associate Professor, Department of Life Sciences, National Chung Hsing University	Member of Audit Committee, Maxigen Biotech Inc. Member of Remuneration Committee, Maxigen Biotech Inc. Member of Nomination Committee, Maxigen Biotech Inc. Member of Risk Management Committee, Maxigen Biotech Inc. Independent Director, TCI Co., Ltd.	None	None	None	None
Independent Director	R.O.C.	Tseng Chung-Ming	Male 51-55	2024.6.13	3 years	2021.7.12	0	0	0	0	0	0	0	0	Master's degree in Industrial Engineering, National Chiao Tung University Bachelor of Science, Department of Industrial Engineering Management, National Chiao Tung University Chairman, GAME SPARCS Ltd. Fullerton Technology Co., Ltd. Director of Director of the Mobile Value-Added Services Division Director of Telecommunications, ISAOLUTION INC.	Member of Audit Committee, Maxigen Biotech Inc. Member of Remuneration Committee, Maxigen Biotech Inc. Member of Nomination Committee, Maxigen Biotech Inc. Member of Risk Management Committee, Maxigen Biotech Inc. Founder and Chief Executive Officer, Best Moment Inc.	None	None	None	None

Title	Nationality or Place of registration	Name	Gender Age	Elect (in) Date	Term	Date First Elected	Shareholding When Elected		Current Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Education and Experience	Selected Current Positions Other Companies	Other Heads, Directors, or Supervisors as Spouse or Kin within the Second Degree			If the chairman of the board of directors and the president or equivalent (top manager) are the same person, spouses or relatives of one another, the reasons, reasonableness, necessity and measures to be taken shall be stated.
							Number of shares (shares)	%	Number of shares (shares)	%	Shares (Shares)	%	Shares (Shares)	Shareholding Ratio (%)			Title	Name	Relationship	
Independent Director	R.O.C.	Shih-Ming Li (Note 2)	Male 66-70	2024.6.13	3 years	2021.7.12	0	0	0	0	0	0	0	0	Reproductive Endocrinology and infertility Researcher, University of California, USA Physician at Liming Obstetrics and Gynecology Clinic Director of Obstetrics and Gynecology Department, Air Force General Hospital Head of Reproductive Medicine Center, Air Force General Hospital Vice President, Chung Shan Hospital	Member of Audit Committee, Maxigen Biotech Inc. Member of Remuneration Committee, Maxigen Biotech Inc. Member of Nomination Committee, Maxigen Biotech Inc. Member of Risk Management Committee, Maxigen Biotech Inc. Independent Director, TCI Co., Ltd. Head of Reproductive Center, Chung Shan Hospital Attending Physician, Department of Obstetrics and Gynecology, Chung Shan Hospital	None	None	None	None

Note 1: Chairman and General Manager at TCI Co., Ltd.; Chairman at Scientific American Taiwan Co., Ltd.; Chairman at TCI Living Co., Ltd.; Chairman at TCI LIVING Shanghai Co., Ltd.; Chairman and General Manager at TCI Firstek Corp.; Chairman at BioTrade, Shanghai BioTech Group; Chairman and General Manager at BioScience, Shanghai BioTech Group; Chairman at BioCosme, Shanghai Biotech Group; Chairman at BioFunction, Shanghai BioTech Group; Chairman at Genetech, Shanghai Biotech Group; Chairman at Maxigen Biotech Inc. (Shanghai); Chairman at Horay Inc.; Chairman at SMY INTERNET OF PACKAGE CO., LTD.; Chairman at Quantum Biology Inc.; Chairman at Quantum Biology Inc.; Chairman at Petfood Biotechnology Co., Ltd.; Chairman at Scientific American Taiwan Co., Ltd.; Director at TCI BIOTECH USA LLC; Director at TCI Biotech Netherlands B.V.; Director at TCI JAPAN CO., LTD. (大江生醫JAPAN株式会社); Director at TCI HK LIMITED; Director at GLUX HK LIMITED;

Note 2: Independent Director, Shih-Ming Li, resigned on December 13, 2024, due to personal reasons.

(2) Major shareholders of corporate shareholders

April 13, 2025

Name of Corporate Shareholder	Major Shareholders
TCI Co., Ltd.	Yong Jiang Investment Co. (5.73%)
Formosa Biomedical Technology Corp.	Formosa Chemicals & Fibre Co. (8.86%)

(3) If the major shareholder is a legal entity, its major shareholders

April 13, 2025

Name of Legal Entity	Major Shareholders of the Legal Entity
Yong Jiang Investment Co.	Yung-Hsiang Lin (70.07%), Yung-Hao Lin (29.91%)
Formosa Chemicals & Fibre Co.	Nan Ya Plastics Co. (2.40%) Wen-Yuan Wang (2.20%), Formosa Petrochemical Co. (0.83%)

(4) Director Information

A. Disclosure of Professional Qualifications and Independence of Directors and Supervisors:

Name	Conditions	Professional Qualifications and Experience (Note 1)	Independent Director Independence Status (Note 2)	Concurrent Positions in Other Publicly Listed Companies
TCI Co., Ltd. Representative: Yung-Hsiang Lin (Nomination) Member (Risk) Convenor		Professional qualifications and experience: The Company's Chairman of the Board and Chief Strategic Officer (concurrent), The Chairman of the Board and General Manager (please refer to page 5 for detailed table of education and experience) of TCI Co., Ltd. Possesses the necessary working experience and leadership in running the company and leading the Group to become a global enterprise. There are no circumstances under Article 30 of the Company Act.	Not Applicable	
China Investment & Development Representative Xiu-Yuan Li		Professional qualifications and experience: Representative of the Company's legal director and other duties (please refer to page 5 for detailed table of education and experience). Possesses the work experience necessary for the Company's business. There are no circumstances under Article 30 of the Company Act.		

Conditions Name	Professional Qualifications and Experience (Note 1)	Independent Director Independence Status (Note 2)	Concurrent Positions in Other Publicly Listed Companies
Formosa Biomedical Technology Corp. Representative : Shih-Ming Lai (Risk) Member	Professional qualifications and experience: Representative of the Company's legal director and other duties (please refer to page 6 for detailed table of education and experience). Possesses the work experience necessary for the Company's business. There are no circumstances under Article 30 of the Company Act.	Not Applicable	
TCI Co., Ltd. Representative: Chen-Chen Fu	Professional qualifications and experience: Representative of the Company's legal director and other duties (please refer to page 5 for detailed table of education and experience). Possesses the work experience necessary for the Company's business. There are no circumstances under Article 30 of the Company Act.		
TCI Co., Ltd. Representative: Ching-Ting Chen (Risk) Member	Professional qualifications and experience: Representative of the Company's legal director and other duties (please refer to page 6 for detailed table of education and experience). Possesses the work experience necessary for the Company's business. There are no circumstances under Article 30 of the Company Act.		
TCI Co., Ltd. Representative: Chih-Cheng Tsai (Risk) Member	Professional qualifications and experience: Representative of the Company's legal director and other duties (please refer to page 6 for detailed table of education and experience). Possesses the work experience necessary for the Company's business. There are no circumstances under Article 30 of the Company Act.		

Name	Conditions	Professional Qualifications and Experience (Note 1)	Independent Director Independence Status (Note 2)	Concurrent Positions in Other Publicly Listed Companies
Sung-Yuan Liao (Audit) Convener (Nomination) Convener (Remuneration) Member (Risk) Member		Professional qualifications and experience: Lecturer or above from a public or private college or university in a relevant discipline necessary for the Company's business (please refer to page 6 for detailed table of education and experience).	1. The three independent directors listed on the left have, during the two years prior to their appointment and throughout their term of office, met the qualification requirements stipulated in the "Regulations Governing Appointment of Independent Directors and Compliance Matters for Public Companies" (Note 2) issued by the Financial Supervisory Commission, and Article 14-2 of the Securities and Exchange Act. All independent directors have also been granted full authority to participate in decision-making and express their opinions in accordance with Article 14-3 of the Securities and Exchange Act, thereby independently exercising their duties. 2. None of the independent directors, their spouses, or minor children hold any shares in the Company, whether in their own name or under the name of another person. 3. In the past two years, none of the independent directors have received remuneration for providing audit, commercial,	1
Zhong-Ming Zeng (Remuneration) Convener (Audit) Member (Nomination) Member (Risk) Member		Professional qualifications and experience: Possesses relevant experience in business or necessary for the Company's business (please refer to page 7 for detailed table of education and experience).		
Shih-Ming Li (Remuneration) Member (Audit) Member (Nomination) Member (Risk) Member		Professional qualifications and experience: A judge, prosecutor, lawyer, accountant, or other professional and technical person who has passed the national examination required for the Company's business and has the necessary work experience for the Company's business (please refer to page 10 for detailed table of education and experience). There are no circumstances under Article 30 of the Company Act. Note: Resigned on December 13, 2024, due to personal reasons.		

Note 1: Functional committee: (Remuneration) Remuneration Committee, (Audit) Audit Committee, (Nomination) Nomination Committee, (Risk) Risk Management Committee

Note 2: 1. Not a government entity, legal entity, or its representative as stipulated in Article 27 of the Company Act.

2. Serving as an independent director for no more than three other publicly traded companies in Taiwan.

3. No circumstances listed below during the two years prior to election and during the term of office:

(1) Employee of the Company or its related enterprises.

(2) Directors and supervisors of the Company or its related enterprises.

(3) Individuals who are shareholders holding more than 1% of the total issued shares of the Company in their own name or in the name of others, including themselves, their spouses, and minor children, or those who rank among the top ten shareholders.

(4) Spouses, second-degree relatives, or direct blood relatives within the third degree of the individuals listed in (1) as managers or those identified in (2) and (3).

(5) Directors, supervisors, or employees of legal shareholders who directly hold more than 5% of the total issued shares of the Company, are among the top five shareholders, or are appointed representatives serving as directors of the Company in accordance with Article 27 of the Company Act.

(6) The majority of the seats on the Company's board of directors or shares with voting rights are controlled by the same individual who serves as a director, supervisor, or employee of another company.

(7) Individuals who are directors (or council members), supervisors (or inspectors), or employees of another company or institution, who are the same person as the Company's chairman, general manager, or an equivalent position, or their spouses.

(8) Directors (or council members), supervisors (or inspectors), managers, or shareholders holding more than 5% of shares from specific companies or institutions that have financial or business dealings with the Company.

(9) Professionals, sole proprietors, partners, company owners, directors, supervisors, managers, and their spouses who have provided audit or related services, including business, legal, financial, and accounting services, to the Company or related enterprises, with a cumulative compensation exceeding fifty thousand New Taiwan Dollars in the past two years.

B. Diversity and Independence of the Board of Directors:

(A) Diversity of the Board of Directors:

Among the current 8 directors of this Company, 3 are female directors, accounting for one-third of the total board seats, thereby ensuring gender diversity on the board. Both the board of directors and the management team have a clear strategy and consensus regarding the Company's long-term growth positioning and objectives, and are actively seeking suitable successors in alignment with these goals.

Additionally, there is 1 member of the board of directors aged between 36 and 45 years, 2 members aged between 46 and 50 years, 4 members aged between 51 and 60 years, and 1 member aged between 75 and 80 years. The age distribution among the members of the board of directors is balanced, with experienced directors possessing many years of experience and those with new ideas and youthful energy each representing approximately half of the board. (Note: Independent Director, Shih-Ming Li, resigned on December 13, 2024, due to personal reasons.)

(B) Independence of the Board of Directors:

Among the 8 directors of this Company, there are no circumstances as stipulated in Article 26-3, Paragraphs 3 and 4 of the Securities Trading Act, and there are no relationships among directors involving spouses or relatives within the second degree.

(C) Diversity Policy and Specific Objectives of the Board of Directors

1) Diversity Policy:

According to our company's "Code of Corporate Governance," the composition of the board of directors should consider diversity.

The policy is as follows: the composition of the board members should consider diversity. Except for directors who also serve as company managers, no more than one-third of the board seats should be held by them, and an appropriate diversity strategy should be formulated based on its own operations, operational model, and development needs, which should include but not be limited to the following two main areas of standards:

- a) Basic Conditions and Values: Gender, age, nationality, ethnicity, and culture, etc.
- b) Professional Knowledge and Skills: Professional background (such as law, accounting, industry, finance, marketing, or technology), professional skills, and industry experience, etc.

2) The specific management objectives of the diversity policy are as follows:

This current board of directors has diverse backgrounds, including three female directors; members come from fields covering chemistry, taxation,

economics, and other professional and practical backgrounds. The other directors encompass areas such as botany, life sciences, industrial engineering, and investment management. Among all directors, four director shareholders account for 44.44%, two external directors account for 22.22%, and three independent directors account for 33.33%.

The composition of the board is a diverse professional combination that meets the current operational development and strategic goals of the company.

(D) Director Selection Criteria

Selection Standards for DirectorsOur company has established a "Nomination Committee" and adopts a "Candidate Nomination System." The suggested candidate list for directors and independent directors is reviewed by the Nomination Committee and approved by the board before being provided for election at the shareholders' meeting.

According to our company's "Code of Corporate Governance," the composition of the board members should consider diversity. Except for directors who also serve as company managers, no more than one-third of the board seats should be held by them. Talents with different professional backgrounds should be recruited, including (but not limited to) skills, regions, professional experiences, cultural and educational backgrounds, gender, and other characteristics to enhance the operational capability of the board. Our board of directors consists of 9 directors, including 6 directors and 3 independent directors, with members possessing rich experience and expertise in finance, business, and management.

(E) Required Professional Qualifications and Experience

For the BoardBoard members should generally possess the knowledge, skills, and qualities necessary to perform their duties. To achieve the ideal goals of corporate governance, the board as a whole should have the following capabilities:

- 1) Operational judgment ability.
- 2) Accounting and financial analysis capability.
- 3) Management ability.
- 4) Crisis management ability.
- 5) Industry knowledge.
- 6) Global market perspective.
- 7) Leadership ability.
- 8) Decision-making ability.

(F) Nationality and Cultural Diversity Elements

The members of this board of directors are all of local nationality, but possess a multicultural attribute. The directors have rich industry experience, including in biotechnology and healthcare, asset management, post-investment management, industrial engineering, technology networks, finance, and more. Two external directors have degrees from well-known.

(G) Specific Goals of the Board Diversity Policy:

1) Explanation of the proportion of employee directors and independent directors:

Among the nine directors, one is an employee director, accounting for 11.11%, and three are independent directors, accounting for 33.33%. The composition of the board represents a diverse professional combination that meets the current operational development and strategic goals of the company.

2) Distribution of directors' industry experience/professional background:

Please refer to the information on pages 8 to 9.

3) Distribution of the terms of independent directors:

Independent Director Liao Songyuan:

First appointed on 2021.07.12

Comprehensive re-election on 2024.06.13 (re-appointed)

Independent Director Zeng Zhongming:

First appointed on 2021.07.12

Comprehensive re-election on 2024.06.13 (re-appointed)

Independent Director Li Shiming:

Resigned on 2024.12.13 for personal reasons.

Disclosure of the Independence of the Board:

(H) Disclosure of board independence

The directors of this company adhere to a high level of self-discipline. For proposals listed at board meetings, they disclose significant content of their interests in the company or on behalf of their represented entities. In cases where such interests harm the interests of the company, they are not allowed to participate in discussions or voting and must refrain from such interests.

- C. Explanation of the proportion of employee directors and independent directors:
Among the nine directors, one employee director accounts for 11.11%, and three independent directors account for 33.33%. The composition of the board is a diverse professional combination that meets the current operational development and strategic goals of the company.
- D. Distribution of directors' industry experience/professional background:
This information is listed in the annual report on pages 8 to 9 in the form of a table.
- E. Distribution of independent directors' tenure:
Independent Director Liao Songyuan:
Initially elected on July 12, 2021;
Comprehensive reelection on June 13, 2024 (reappointed).
Independent Director Zeng Zhongming:
Initially elected on July 12, 2021;
Comprehensive reelection on June 13, 2024 (reappointed).
Independent Director Li Shiming:
Resigned on December 13, 2024 due to personal reasons.
- F. About Independence of the Board of Directors:
All directors of this company uphold a high degree of self-discipline. In the case of proposals listed by the board of directors that involve interests related to themselves or their represented entities, they must explain the important contents of those interests during the board meeting. If the interests are detrimental to the company's interests, they are not allowed to participate in the discussion and voting and must engage in interest avoidance.

1-2 Information on the General Manager, Vice President, Assistant Manager, and Supervisors of Each Department and Branch Office

April 13, 2025

Title	Nationality	Name	Gender	Elect (in) Date	Shareholding		Spouse & Minor Shareholding		Shareholding by Nominee Arrangement		Education and Experience Title	Education and Experience	Selected Current Positions at Other Companies			Note: If the chairman of the board of directors and the president or equivalent (top manager) are the same person, spouses or relatives of one another, the reasons, reasonableness, necessity, and measures to be taken shall be stated.
					Shares	%	Shares	% Ratio	Shares	% Ratio			Title	Name	Relationship	
General Manager	R.O.C.	Ching-Ting Chen	Female	2021.09.13	146,402	0.16	2,310	0	0	0	National Tsing Hua University, Department of Chemistry. General Manager, Maxigen Biotech Inc. Chief of Research and Development, TCI Co., Ltd.	None	None	None	None	Not Applicable
Deputy General Manager	R.O.C.	Po-Hong Lai	Male	2017.06.01	85,997	0.10	0	0	0	0	Ph.D. from the Department of Chemical Engineering, National Tsing Hua University. Assistant Director, Maxigen Biotech Inc. Manager, Maxigen Biotech Inc. Researcher in Drug Delivery at the Institute of Biomedical Engineering, Industrial Technology Research Institute	None	None	None	None	Not Applicable
Supervisor of the Precision Manufacturing Center	R.O.C.	Hao-Jun Wang	Male	2023.10.01	0	0	0	0	0	0	Ph.D. in Computer Science from National Taipei University of Technology Manager, Maxigen Biotech Inc. Chief Strategy Officer, TCI Co., Ltd. Director, Lepida Digital Technology Co., Ltd. Manager, Huahong Information Technology Co., Ltd.	None	None	None	None	Not Applicable
Finance and Accounting Supervisor	R.O.C.	Ruei-Yi Wu	Male	2023.03.22	0	0	0	0	0	0	Master's Degree from the Graduate Institute of National Taipei University Bachelor's Degree in Accounting from Chung Yuan Christian University Manager, Maxigen Biotech Inc. Accounting Manager, Turn Cloud Technology Service Inc. Deputy Accounting Manager, Hantic Precision Technology, Inc. Audit Assistant Manager, KPMG in Taiwan (KPMG International Ltd.)	None	None	None	None	Not Applicable

2. Recent Fiscal Year Remuneration Paid to Directors, Supervisors, General Manager, and Vice Presidents

2.1 Remuneration Paid to Directors and Supervisors in 2024

(1) Remuneration for General Directors and Independent Directors (disclosed by individual names)

Unit: New Taiwan Dollar thousands, %

Title	Name	Director's Remuneration								A+B+C+D and their proportion to net income after tax (Note 10)		Related Remuneration received by part-time employees						Total Remuneration (A+B+C+D+F+G) and their proportion to net profit after tax (Note 10)		Receive remuneration from a foreign invested business or parent company (Note 11)				
		Remuneration (A) (Note 2)		Retirement pension (B)		Directors' remuneration (C) (Note 3)		Business Execution Expenses (D) (Note 4)				Salaries, bonuses and special expenses, etc. (E) (Note 5)		Retirement pension (F)		Employee remuneration (G) (Note 6)								
		MBI	All companies in the financial report (Note 7)	MBI	All companies in the financial report (Note 7)	MBI	All companies in the financial report (Note 7)	MBI	All companies in the financial report (Note 7)	MBI	All companies in the financial report	MBI	All companies in the financial report (Note 7)	MBI	All companies in the financial report (Note 7)	MBI	All companies in the financial report (Note 7)	Subsidiary of			All companies in the financial report (Note 7)		MBI	All companies in the financial report
																		Cash	Stock		Cash	Stock		
Director	TCI Co., Ltd. (shares) Representative: Yung-Hsiang Lin	0	0	0	0	600	600	60	60	660	660	4,520	4,520	0	0	1,501	0	1,501	0	6,681	6,681	0		
	TCI Co., Ltd. (shares) Representative: Ching-Ting Chen	0	0	0	0	600	600	60	60	660	660	3,440	3,440	108	108	1,855	0	1,855	0	6,063	6,063	0		
	TCI Co., Ltd. (shares) Representative: Zhen-Zhen Fu	0	0	0	0	600	600	50	50	650	650	0	0	0	0	0	0	0	0	650	650	0		
	TCI Co., Ltd. (shares) Representative: Cong-Jie Qiu	0	0	0	0	600	600	20	20	620	620	0	0	0	0	0	0	0	0	620	620	0		
	TCI Co., Ltd. (shares) Representative: Chih-Cheng Tsai	0	0	0	0	0	0	20	20	20	20	0	0	0	0	0	0	0	0	20	20	0		
	China Investment & Development (shares) Representative: Xiu-Yuan Li	0	0	0	0	600	600	50	50	650	650	0	0	0	0	0	0	0	0	650	650	0		
	Formosa Biomedical (shares) Representative: Shih-Ming Lai	0	0	0	0	600	600	50	50	650	650	0	0	0	0	0	0	0	0	650	650	0		
Independent Director	Sung-Yuan Liao	0	0	0	0	600	600	170	170	770	770	0	0	0	0	0	0	0	0	770	770	0		
	Shih-Ming Li	0	0	0	0	500	500	120	120	720	720	0	0	0	0	0	0	0	0	620	620	0		
	Zhong-Ming Zeng	0	0	0	0	600	600	170	170	770	770	0	0	0	0	0	0	0	0	770	770	0		

1. Please describe the policy, system, standards, and structure of compensation for independent directors, and explain the correlation between the amount of compensation and factors such as responsibilities, risks, and time invested: The compensation for directors provided by the company is based on the provisions of the company's articles of incorporation, and is submitted to the annual shareholder meeting report following approval by the compensation committee and the board of directors. The compensation for independent directors of the company is fixed and is issued based on the 'Regulations on Compensation for Directors and Managers,' taking into consideration their time invested and responsibilities assumed.
2. In addition to the disclosures in the above table, the compensation received by directors for services provided in the recent fiscal year (such as serving as consultants for the parent company / all companies within the financial report / investee companies that are not classified as employees, etc.): Directors receiving compensation lower than NT\$1,000,000 from the parent company include Lin Yongxiang and Chen Jingting.

(2) Remuneration Scale

Remuneration Ranges Paid to Individual Directors	Director's Name			
	Total Remuneration for the First Four Items (A+B+C+D)		Total Remuneration for the First Seven Items (A+B+C+D+E+F+G)	
	From Maxigen Biotech Inc. (Note 8)	All companies in the financial statements (Note 9) H.	From Maxigen Biotech Inc. (Note 8)	All companies included in the financial statements (Note 9) I.
Below 1,000,000	Yung-Hsiang Lin, Ching-Ting Chen, Zhen-Zhen Fu, Cong-Jie Qiu, Chih-Cheng Tsai, Shiou-Yuan Li, Shih-Ming Lai, Song-Yuan Liao, Shih-Ming Li, Zhong-Ming Zeng	Yung-Hsiang Lin, Ching-Ting Chen, Zhen-Zhen Fu, Cong-Jie Qiu, Chih-Cheng Tsai, Shiou-Yuan Li, Shih-Ming Lai, Song-Yuan Liao, Shih-Ming Li, Zhong-Ming Zeng	Zhen-Zhen Fu, Cong-Jie Qiu, Chih-Cheng Tsai, Shiou-Yuan Li, Shih-Ming Lai, Song-Yuan Liao, Zhong-Ming Zeng, Shih-Ming Li	Zhen-Zhen Fu, Cong-Jie Qiu, Chih-Cheng Tsai, Shiou-Yuan Li, Shih-Ming Lai, Song-Yuan Liao, Zhong-Ming Zeng, Shih-Ming Li
NTD 1,000,000 (inclusive) to NTD 2,000,000 (exclusive)				
NTD 2,000,000 (inclusive) to NTD 3,500,000 (exclusive)				
NTD 3,500,000 (inclusive) to NTD 5,000,000 (exclusive)				
NTD 5,000,000 (inclusive) to NTD 10,000,000 (exclusive)			Yung-Hsiang Lin, Ching-Ting Chen	Yung-Hsiang Lin, Ching-Ting Chen
NTD 10,000,000 (inclusive) to NTD 15,000,000 (exclusive)				
NTD 15,000,000 (inclusive) to NTD 30,000,000 (exclusive)				
NTD 30,000,000 (inclusive) to NTD 50,000,000 (exclusive)				
NTD 50,000,000 (inclusive) to NTD 100,000,000 (exclusive)				
Over NTD 100,000,000				
Total	10 persons	10 persons	10 persons	10 persons

Note 1: The names of the directors should be listed individually (legal shareholders should separately list the name of the legal entity and the representative), and both general directors and independent directors should be listed separately, with the amounts disclosed in a summarized format. If a director concurrently serves as the General Manager or Vice President, they should complete this form and the subsequent table (3-1), or the following tables (3-2-1) and (3-2-2).

Note 2: This refers to the compensation of directors for the most recent fiscal year, which includes director salary, job allowance, severance pay, various bonuses, incentive compensation, and so forth.

Note 3: This refers to the amount of director compensation approved by the board of directors for the most recent fiscal year.

Note 4: This refers to the relevant business execution expenses of directors for the most recent fiscal year, including transportation expenses, special expenses, various subsidies, dormitory accommodations, provision of vehicles, and other in-kind benefits. When providing real estate, automobiles, and other means of transportation or personal expenses, the nature and cost of the provided assets, as well as the actual or fair market value of the rent, fuel expenses, and other payments, must be disclosed. Additionally, if a driver is provided, please include a note explaining the compensation paid by the company to that driver; however, this should not be included in the remuneration.

Note 5: This refers to the total compensation received by directors who also serve as employees (including those who concurrently hold the positions of General Manager, Vice President, other managers, and employees) during the most recent fiscal year, which encompasses salary, job allowance, severance pay, various bonuses, incentive compensation, transportation expenses, special expenses, various subsidies, dormitory, and vehicle provision, among other in-kind benefits. When providing real estate, automobiles, and other means of transportation or personal expenses, the nature and cost of the provided assets, as well as the actual or fair market value of the rent, fuel expenses, and other payments, must be disclosed. Additionally, if a driver is provided, please include a note explaining the compensation paid by the company to that driver; however, this should not be included in the remuneration. In accordance with IFRS 2 'Share-based Compensation', the recognized salary expenses, which include the acquisition of Employee Stock Option Certificates, Restrictions on Employee Rights for New Shares, and participation in Cash Capital Increase for purchasing shares, should also be included in the remuneration.

Note 6: This refers to the remuneration received by directors who also serve as employees (including the General Manager, Vice Presidents, other managers, and employees) in the most recent fiscal year. The amount of employee compensation (including stocks and cash) approved by the board of directors for distribution in the most recent fiscal year should be disclosed. If it cannot be estimated, the proposed distribution amount for this year should be calculated based on the actual distribution amount from last year, and Schedule 1-3 should also be completed.

Note 7: The total amount of remuneration paid to the directors of this Company by all companies (including this Company) must be disclosed in the consolidated report.

Note 8: The total amount of remuneration paid to each director by this Company shall be disclosed alongside the names of the directors within the corresponding tier.

Note 9: The total amount of remuneration paid to each director by this Company must be disclosed in the consolidated report, along with the names of the directors within the corresponding tier.

Note 10: Net income after tax refers to the net income after tax from the most recent individual or separate financial report.

Note 11: a. This column should clearly specify the amount of compensation received by the Company's directors from investment transfer businesses or the parent company, excluding those from subsidiaries (if none, please indicate 'none').

b. If the Company's directors receive compensation from investment transfer businesses or the parent company, other than from subsidiaries, such compensation should be included in column I of the remuneration scale, with the column title changed to 'Parent Company and All Investment Transfer Businesses.'

c. Compensation refers to the remuneration, fees (including employee, director, and supervisor compensation), and business execution expenses received by the Company's directors in their roles as directors, supervisors, or managers of investment transfer businesses or the parent company, excluding those from subsidiaries.

*The remuneration disclosed in this table differs from the income concept under the Income Tax Act; therefore, this table is intended for information disclosure only and not for taxation purposes.

2.2 Remuneration paid to the General Manager and Deputy General Manager in 2024

(1) Remuneration of the General Manager and Deputy General Manager (summary disclosure of names according to salary brackets)

Unit: New Taiwan Dollar (thousands), %

Title	Name	Salary (A) (Note 2)		Retirement Pension (B)		Bonuses and allowances (C) (Note 3)		Employees' Compensation (D) (Note 4)				A+B+C+D and their proportion to net income after tax (%) (Note 8)		Receive a remuneration from a foreign invested business or parent company (Note 9)
		MBI	All companies in the financial report (Note 5)	MBI	All companies in the financial report (Note 5)	MBI	All companies in the financial report (Note 5)	MBI		All companies included in the financial statements (Note 5)		MBI	All companies included in the financial statements (Note 5)	
								Cash Amount	Shares Amount	Cash Amount	Shares Amount			
General Manager	Ching-Ting Chen	4,351	4,351	215	215	1676	1676	2515	0	2515	0	8,757 4.6%	8,757 4.6%	None
Deputy General Manager	Po-Hong Lai													

(2) Remuneration Scale

Remuneration Ranges Paid to General Manager and Deputy General Manager	Names of General Managers and Deputy General Manager	
	This Company (Note 6)	All Companies in the Financial Report (Note 7)
Below 1,000,000		
NTD 1,000,000 (inclusive) to NTD 2,000,000 (exclusive)		
NTD 2,000,000 (inclusive) to NTD 3,500,000 (exclusive)	Po-Hong Lai	Po-Hong Lai
NTD 3,500,000 (inclusive) to NTD 5,000,000 (exclusive)		
NTD 5,000,000 (inclusive) to NTD 10,000,000 (exclusive)	Ching-Ting Chen	Ching-Ting Chen
NTD 10,000,000 (inclusive) to NTD 15,000,000 (exclusive)		
NTD 15,000,000 (inclusive) to NTD 30,000,000 (exclusive)		
NTD 30,000,000 (inclusive) to NTD 50,000,000 (exclusive)		
NTD 50,000,000 (inclusive) to NTD 100,000,000 (exclusive)		
Over NTD 100,000,000		
Total	2 Individuals	2 Individuals

Note 1: The names of the General Manager and Vice Presidents should be listed separately, with the amounts of each compensation disclosed in summary. If a director concurrently serves as the General Manager or Vice President, this form and the aforementioned forms (1-1), or (1-2-1) and (1-2-2) should be completed.

Note 2: This pertains to the reporting of the most recent fiscal year's salary, job allowance, and severance pay for the General Manager and Vice President.

Note 3: This pertains to the reporting of various bonuses, incentive compensation, transportation expenses, special expenses, various subsidies, dormitory provisions, company vehicle provisions, and other remuneration amounts for the General Manager and Vice President in the most recent fiscal year. When providing real estate, automobiles, and other means of transportation or personal expenses, the nature and cost of the provided assets, as well as the actual or fair market value of the rent, fuel expenses, and other payments, must be disclosed. Additionally, if a driver is provided, please include a note explaining the compensation paid by the company to that driver; however, this should not be included in the remuneration. In accordance with IFRS 2 'Share-based Compensation', the recognized salary expenses, which include the acquisition of Employee Stock Option Certificates, Restrictions on Employee Rights for New Shares, and participation in Cash Capital Increase for purchasing shares, should also be included in the remuneration.

Note 4: This refers to the amount of Employee Compensation (including Stocks and Cash) for the General Manager and Vice President as approved by the board of directors for the most recent fiscal year. If it cannot be estimated, the proposed amount for this year should be calculated based on the actual distribution amount from last year, and Schedule 1-3 should also be completed.

Note 5: The consolidated report must disclose the total amount of remuneration paid to the General Manager and Vice President of this Company by all companies (including this Company).

Note 6: The total amount of remuneration paid to each General Manager and Vice President by this Company should be disclosed within the respective tier, along with the names of the General Manager and Vice President.

Note 7: The consolidated report must disclose the total remuneration paid by the Company to each General Manager and Vice President, including the names of the General Manager and Vice President within the corresponding tier.

Note 8: Net Income After Tax refers to the net income after tax from the most recent individual financial report.

Note 9: a. This section should clearly specify the amounts of remuneration received by the Company's General Manager and Vice President from investment transfer businesses or the parent company, excluding subsidiaries (if none, please indicate 'None').

b. If the General Manager and Vice President of the Company receive compensation from investment transfer businesses or the parent company outside of the subsidiaries, they should include the compensation received from these sources in column E of the Remuneration Scale, and change the column name to 'Parent Company and All Investment Transfer Businesses.'

c. Compensation refers to the remuneration and rewards (including compensation for employees, directors, and supervisors) received by the General Manager and Vice President of this Company for serving as directors, supervisors, or managers of investment transfer businesses or the parent company outside of the subsidiaries, as well as related business execution expenses.

*The remuneration disclosed in this table differs from the income concept under the Income Tax Act; therefore, this table is intended for information disclosure only and not for taxation purposes.

(3) The top five highest compensated supervisors of Listed Companies (individual disclosure of names and compensation methods)

Title	Name	Salary (A) (Note 2)		Retirement pension (B)		Bonuses and special allowances (C) (Note 3)		Employees' Compensation (D) (Note 4)				Total Remuneration (A+B+C+D) and their proportion to net income after tax (%) (note 6)		Receive a remuneration from a foreign invested business or parent company (note 7)
		MBI	All companies in the financial report (Note 5)	MBI	All companies in the financial report (Note 5)	MBI	All companies in the financial report (Note 5)	MBI		All companies in the financial report (Note 5)		MBI	All companies in the financial report (Note 5)	
								Cash Amount	Shares Amount	Cash Amount	Shares Amount			
Chief Strategy Officer	Yung-Hsiang Lin	2,400	2,400	0	0	2,120	2,120	1,500	0	1,500	0	6,020 3.17%	6,020 3.17%	0
General Manager	Ching-Ting Chen	2,440	2,440	108	108	1,000	1,000	1,854	0	1,854	0	5,402 2.84%	5,402 2.84%	0
Deputy General Manager	Po-Hong Lai	1,911	1,911	107	107	676	676	660	0	660	0	3,354 1.76%	3,354 1.76%	0
Supervisor of the Precision Manufacturing Center	Hao-Jun Wang	1,516	1,516	94	94	375	375	426	0	426	0	2,411 1.27%	2,411 1.27%	0
Chief Financial Officer and Accounting Supervisor	Ruei-Yi Wu	1,140	1,140	69	69	228	228	209	0	209	0	1,646 0.87%	1,646 0.87%	0

Note 1: The term 'top five highest compensated supervisors' refers to the Company's Managers. The criteria for identifying Managers shall be handled in accordance with the provisions of the letter No. 0920001301 issued by the Securities and Futures Bureau of the Ministry of Finance on March 27, 2003, regarding the applicable scope of 'Managers.' Regarding the criteria for calculating the 'Top Five Highest Compensations,' it is based on the total amount of salary, retirement pension, bonuses, and special expenses received by the Company's managers from the consolidated financial reports of all companies, as well as the total employee compensation (i.e., the sum of A+B+C+D). This total is then ranked to identify the top five highest compensations. If a director concurrently serves as a supervisor, they should complete this form and the preceding table (1-1).

Note 2: This refers to the salary, job allowance, and severance pay of the top five highest compensated supervisors from the most recent fiscal year.

Note 3: This refers to the various bonuses, incentive compensations, transportation expenses, special expenses, subsidies, dormitory provisions, vehicle allocations, and other compensation amounts for the top five highest compensated supervisors in the most recent fiscal year. When providing real estate, automobiles, and other means of transportation or personal expenses, the nature and cost of the provided assets, as well as the actual or fair market value of the rent, fuel expenses, and other payments, must be disclosed. Additionally, if a driver is provided, please include a note explaining the compensation paid by the company to that driver; however, this should not be included in the remuneration. In accordance with IFRS 2 'Share-based Compensation', the recognized salary expenses, which include the acquisition of Employee Stock Option Certificates, Restrictions on Employee Rights for New Shares, and participation in Cash Capital Increase for purchasing shares, should also be included in the remuneration.

Note 4: This refers to the total employee compensation amount (including stocks and cash) for the top five highest compensated supervisors as approved by the board of directors in the most recent fiscal year. If an estimate cannot be made, the proposed distribution amount for this year should be calculated based on the actual distribution amount from last year, and Schedule 1-3 should also be completed.

Note 5: The consolidated report must disclose the total compensation paid to the top five highest-paid supervisors of the Company (including this Company) by all companies.

Note 6: Net Income After Tax refers to the net income after tax from the most recent individual or separate financial report.

Note 7: a. This column should clearly specify the amount of compensation received by the top five highest-paid supervisors of the Company from investment transfer businesses or the parent company, excluding subsidiaries (if none, please indicate 'None').

b. Compensation refers to the remuneration, fees (including employee, director, and supervisor compensation), and business execution expenses received by the top five highest-paid supervisors of this Company in their roles as directors, supervisors, or managers of investment transfer businesses or the parent company, excluding subsidiaries.

*The remuneration disclosed in this table differs from the income concept under the Income Tax Act; therefore, this table is intended for information disclosure only and not for taxation purposes.

2.3 Names of Managers Responsible for Employee Compensation and Assignment Details:

Unit: New Taiwan Dollar (thousands), %

	Title	Name	Stock	Cash	Total	The total amount as a net percentage after tax (%)
Manager	General Manager	Ching-Ting Chen	0	2,724	2,724	1.43%
	Deputy General Manager	Po-Hong Lai				
	Accounting Supervisor	Ruei-Yi Wu				

Note 1: Individual names and titles must be disclosed, but profitability assignment details may be presented in aggregate.

Note 2: This refers to the amount of employee compensation (including stocks and cash) assigned to managers as approved by the board of directors for the most recent fiscal year. If an estimate cannot be made, the proposed assignment amount for this year will be calculated based on the actual assignment amount from last year. Net income after tax refers to the net income after tax for the most recent fiscal year; For entities that have adopted International Financial Reporting Standards, net income after tax refers to the net income after tax reported in the most recent fiscal year's individual or separate financial report.

Note 3: The scope of applicability for managers is defined according to the regulations set forth in letter No. 0920001301 issued by the Financial Supervisory Commission on March 27, 2003, and is as follows:

- (1) General Manager and equivalent positions.
- (2) Vice President and equivalent positions.
- (3) Assistant Manager and equivalent positions.
- (4) Supervisor of the Finance Department.
- (5) Supervisor of the Accounting Department.
- (6) Other individuals with authority over company management affairs and signing rights.

Note 4: If directors, the General Manager, and the Vice President receive Employee Compensation (including Stocks and Cash), in addition to completing Schedule 1-2, this form must also be filled out.

2.4 A comparative analysis explaining the total amount of compensation paid to the Company's directors, Supervisors, General Manager, and Vice President as a percentage of Net Income After Tax for the most recent two fiscal years, along with an explanation of the policies, standards, and combinations for compensation, the procedures for determining compensation, and the relationship between compensation, operational performance, and future risks.

(1) The total compensation paid to the directors, supervisors, General Manager, and Deputy General Manager of this Company, as well as all companies included in the consolidated financial statements, in the most recent fiscal year, expressed as a percentage of net income after tax:

Unit: New Taiwan Dollar (thousands)

Title	2023				2024			
	Total remuneration		Percentage of net income after tax (%)		Total remuneration		Percentage of net income after tax (%)	
	MBI	All companies within the consolidated financial statements	MBI	All companies within the consolidated financial statements	MBI	All companies within the consolidated financial statements	MBI	All companies within the consolidated financial statements
Director	18,207	18,207	10.98	10.98	17,474	17,474	9.19	9.19
General Manager and Deputy General Manager	3,170	3,170	1.91	1.91	3,355	3,355	1.76	1.76

(2) The compensation for directors and supervisors includes transportation expenses and remuneration from profit distribution, which is paid in accordance with the provisions of the Articles of Incorporation of this Company.

(3) The compensation for the General Manager and Deputy General Manager is determined based on the principles established for compensation according to the job grades of this Company.

(4) The remuneration standards for the directors, supervisors, general manager, and vice president of this company will be appropriately adjusted based on future environmental changes.

(5) Ms. Ching-Ting Chen, a director of this company, concurrently serves as the general manager, and her remuneration is included in the total calculation for directors.

3. Corporate Governance Operational Situation

3.1 Board of Directors Operational Situation

(1) Fiscal Year 2024 (Term of Office: June 13, 2024, to June 12, 2027), the board of directors held 5 meetings (A), and as of December 31, 2024, the attendance of directors is as follows:

Title	Name	Actual Attendance Count (B)	Proxy Attendance Count Number	Actual Attendance Rate (%) (B/A)	Remarks
Chairman	TCI Co., Ltd. Representative: Yung-Hsiang Lin	5	1	83.33%	Full Re-election of the Board of Directors on June 13, 2024
Director	China INVESTMENT AND DEVELOPMENT Representative: Xiu-Yuan Li	6	0	100%	Full Re-election of the Board of Directors on June 13, 2024
Director	Formosa Biomedical Technology Corp. Representative: Shih-Ming Lai	6	0	100%	Full Re-election of the Board of Directors on June 13, 2024
Director	TCI Co., Ltd. Representative: Ching-Ting Chen	6	0	100%	Full Re-election of the Board of Directors on June 13, 2024
Director	TCI Co., Ltd. Representative: Zhen-Zhen Fu	6	0	100%	Full Re-election of the Board of Directors on June 13, 2024
Director	TCI Co., Ltd. Representative: Cong-Jie Qiu	2	0	100%	Full Re-election of the Board of Directors on June 13, 2024; Resignation on June 13, 2024 Dismissal
Director	TCI Co., Ltd. Representative: Chih-Cheng Tsai	3	1	75%	Full Re-election of the Board of Directors on June 13, 2024
Independent Director	Sung-Yuan Liao	6	0	100%	Full Re-election of the Board of Directors on June 13, 2024
Independent Director	Zhong-Ming Zeng	6	0	100%	Full Re-election of the Board of Directors on June 13, 2024
Independent Director	Shih-Ming Li	4	1	80%	Full Re-election of the Board of Directors on June 13, 2024. Resignation due to personal reasons on December 13, 2024.

(2) Other matters to be recorded

A. If any of the following circumstances occur in the operation of the board of directors, the date of the board meeting, the period, the content of the proposal, the opinions of all independent directors, and the company's handling of the independent directors' opinions must be stated:

(A) Matters listed under Article 14-3 of the Securities Trading Act: This Company has established an Audit Committee, which is not applicable.

(B) Other board resolutions opposed or reserved by Independent Directors with records or written statements: None.

B. The execution of conflict of interest avoidance by directors shall specify the names of the directors, the content of the proposals, the reasons for conflict of interest avoidance, and the voting participation status:

Board of Directors	Content of the Proposal	Conflict of Interest and Reasons	Voting Situation
First Board of Directors Meeting 2024.03.12	Explanation of Employee Compensation Distribution for the Fourth Quarter of 2022	Attendance of Managers for Conflict of Interest Avoidance	After the Managers conducted Conflict of Interest Avoidance, the Chairman consulted the attending Directors, and there were no objections to the proposal, which was approved.
First Board of Directors Meeting 2024.03.12	Proposal for Adjustment of Managerial Salary Compensation	Attendance of Managers for Conflict of Interest Avoidance	After the Managers conducted Conflict of Interest Avoidance, the Chairman consulted the attending Directors, and there were no objections to the proposal, which was approved.
First Board of Directors Meeting 2024.03.12	Compensation Proposal for Certified Public Accountant for 2024	Attendance of Accountants for Conflict of Interest Avoidance Conflict of Interest Avoidance.	After the Accountants conducted Conflict of Interest Avoidance, the proposal was approved with no objections from the attending Directors, as confirmed by the Chairman.
Second Meeting of the Board of Directors 2024.05.03	Explanation of Employee Compensation Distribution for the First Quarter of 2024	Attendance of Managers for Conflict of Interest Avoidance	After the Managers conducted Conflict of Interest Avoidance, the Chairman consulted the attending Directors, and there were no objections to the proposal, which was approved.
Third Meeting of the Board of Directors 2024.07.29	Explanation of Employee Compensation Distribution for 2023	Related Parties to Conduct Conflict of Interest Avoidance	After related parties conducted conflict of interest avoidance, the Chairman consulted with the attending directors, and there were no objections to the proposal.
Fourth Meeting of the Board of Directors 2024.11.07	Explanation of Employee Compensation Distribution for 2023	Attendance of Managers for Conflict of Interest Avoidance	After the Managers conducted Conflict of Interest Avoidance, the Chairman consulted the attending Directors, and there were no objections to the proposal, which was approved.
Fourth Meeting of the Board of Directors 2024.11.07	Adjustment of Matters Related to Manager Salaries	Attendance of Managers for Conflict of Interest Avoidance	After the Managers conducted Conflict of Interest Avoidance, the Chairman consulted the attending Directors, and there were no objections to the proposal, which was approved.
Fifth Meeting of the Board of Directors 2024.12.19	Matters Related to the Distribution of Year-End Bonuses for Managers in 2024	Attendance of Managers for Conflict of Interest Avoidance	After the Managers conducted Conflict of Interest Avoidance, the Chairman consulted the attending Directors, and there were no objections to the proposal, which was approved.

C. Listed Companies shall disclose the assessment cycle and period of the board of directors' self-assessment (or peer assessment), as well as the scope, methods, and content of the assessment:

Assessment Cycle	Assessment Period	Assessment Scope	Assessment Method	Assessment Content
Self-assessment conducted annually	From January 1, 2024, to December 31, 2024	This includes performance evaluations of the overall board of directors, individual board members, and functional committees.	The assessment methods include internal self-evaluation by the board of directors, self-evaluation by board members, self-evaluation by functional committees, and the appointment of external professional organizations, experts, or other appropriate methods for performance evaluation.	This Company should consider its circumstances and the need to establish assessment criteria for the performance evaluation of the board of directors, which should include at least the following five aspects: <ol style="list-style-type: none"> 1. The level of participation in the Company's operations. 2. The improvement of the quality of decision-making by the board of directors. 3. The composition and structure of the board of directors. 4. The selection and ongoing education of directors. 5. Internal Control.

D. Goals for strengthening the functions of the board of directors for the current and recent fiscal years (e.g., establishing an Audit Committee, enhancing information transparency, etc.) and the assessment of their implementation:

(A) Strengthening the functions of the Board of Directors: With respect to the system of independent directors, the Company established an audit committee with three independent directors after the shareholders' meeting on June 29, 2020. The three independent directors attend the Board of Directors' meetings well and use their industry knowledge to provide the Board of Directors with good advice on the motions related to business, financial and legal issues in the Board of Directors' meetings.

(B) To enhance information transparency, the financial statements of the company and its subsidiaries are regularly audited by Deloitte. All information disclosure requirements mandated by law are accurately and promptly fulfilled. A dedicated person is assigned to collect and disclose company information, establishing a spokesperson system to ensure that all significant information is disclosed timely and appropriately. This allows shareholders and stakeholders to access relevant financial and business information about the Company.

3.2 Information on the Operational Situation of the Audit Committee

(1) Fiscal Year 2024 (Term of Office: June 13, 2024, to June 12, 2027), the Audit Committee convened 5 times (A). As of December 31, 2024, the attendance of the committee members is as follows:

Title	Name	Actual Attendance Count (B)	Number of Authorized Attendances	Actual Attendance Rate (%) (B/A) (Note 1, Note 2)	Remarks
Independent Director	Sung-Yuan Liao	5	0	100%	
Independent Director	Zhong-Ming Zeng	5	0	100%	
Independent Director	Shih-Ming Li	4	0	100%	2024.12.13 Resignation due to personal reasons

Other matters to be recorded:

1. If the operation of the Audit Committee involves any of the following circumstances, the dates of the Audit Committee meetings, session numbers, proposal contents, dissenting opinions, reserved opinions, or significant recommendations from Independent Directors, the results of the Audit Committee's resolutions, and the Company's handling of the Audit Committee's opinions should be clearly stated.

(1) Matters listed in Article 14-5 of the Securities Trading Act: Please refer to Section 11 for significant matters as stipulated by other companies or regulatory authorities.

(2) Other resolutions not approved by the Audit Committee but agreed upon by more than two-thirds of all directors: None.

2. The independent directors' avoidance of conflicts of interest regarding proposals should specify the names of independent directors, the contents of the proposals, reasons for avoiding conflicts of interest, and the voting participation situation: None.

All proposals required no conflict of interest avoidance from independent directors.

3. Communication between independent directors and the internal audit supervisor and accountants (should include significant issues discussed regarding the company's financial and business conditions, methods, and results): None.

The company's independent directors communicated with the accountants and the audit supervisor four times in 2024, with the report of the communication situation signed by independent director Liao Songyuan, the convener of the company's audit committee, and made available for review at the Deloitte & Touche accounting firm. The dates and significant issues of the four communication sessions in 2024 are as follows:

March 12, 2024 - approved the company's 2023 annual business report and financial report;

May 3, 2024 - the company's consolidated financial report for the first quarter of 2024;

July 29, 2024 - the company's consolidated financial report for the second quarter of 2024;

November 7, 2024 - the company's consolidated financial report for the third quarter of 2024.

All independent directors acknowledged the above proposals and passed them without objection.

Company handling execution result: No comments were made during these meetings.

Note 1: If an independent director resigns prior to the end of the fiscal year, the resignation date should be noted in the Remarks Column, and the Actual Attendance Rate (%) will be calculated based on the number of Audit Committee meetings held during their tenure and their Actual Attendance Count.

Note 2: If there is a re-election of independent directors before the end of the fiscal year, both the newly appointed and former independent directors should be listed, and the Remarks Column should specify whether the independent director is former, newly appointed, or re-elected, along with the re-election date. The Actual Attendance Rate (%) will be calculated based on the number of Audit Committee meetings held during their tenure and their Actual Attendance Count.

The terms of reference of this committee are as follows:

1. Establish or amend the internal control system in accordance with the provisions of Article 14 of the Securities and Exchange Act.
2. Assessment of the effectiveness of the internal control system.
3. Per Article 36-1 of the Securities and Act, the Company shall establish or amend procedures for handling significant financial transactions involving the acquisition or disposal of assets, derivative transactions, lending of funds to others, or endorsement or guarantee of others.
4. Matters concerning the interests of the Directors.
5. Significant asset or derivative transactions.
6. Substantial capital loan, endorsement or guarantee of funds.
7. Raising, issuing or private placement of securities with equity nature.
8. Appointment, dismissal or compensation of CPAs.
9. Appointment and removal of the supervisor of finance, accounting or internal audit.
10. The annual financial report signed or sealed by the Chairman of the Board of Directors, the manager and the chief accounting officer, and the second quarterly financial report subject to audit and certification by the accountant.
11. Other significant matters as stipulated by the Company or the competent authority.

Meeting Date	Proposal Content	Resolution	MBI's Response to Resolution
1st meeting of 2024 2024.03.12	<p>First Case: This Company's Internal Control System Declaration for Fiscal Year 2023.</p> <p>Second Case: This Company's Business Report and Financial Statements for Fiscal Year 2023.</p> <p>Third Case: Proposal for Allocation of Director Compensation and Employee Compensation for Fiscal Year 2023.</p> <p>Fourth Case: Proposal for Adjustment of Salary Compensation for the Company's Audit Supervisor.</p> <p>Fifth Case: Proposal for Compensation of the Certified Public Accountant for Fiscal Year 2024.</p> <p>Sixth Case: Proposal to Approve the Appointment of a Company under Article 223 of the Company Act by the Audit Committee. Representative Case.</p> <p>Seventh Case: Amendment to the Articles of Incorporation by the Company.</p>	Approved without objection	Approved by the Board of Directors

Meeting Date	Proposal Content	Resolution	MBI's Response to Resolution
2nd meeting of 2024 2024.05.03	<p>First Case: The Company's consolidated financial statements for the first quarter of 2024.</p> <p>Second Case: The Company's earnings distribution for Fiscal Year 2023.</p> <p>Third Case: Amendments to the 'Audit Committee Organization Regulations' and 'Board of Directors Meeting Rules' and other management measures by the Company.</p>	Approved without objection	Approved by the Board of Directors
3rd meeting of 2024 2024.07.29	<p>First Case: The Company's consolidated financial statements for the second quarter of 2024.</p> <p>Second Case: Amendments to the 'Internal Audit System and Implementation Rules' by the Company.</p> <p>Third Case: This Company has established the 'Sustainability Report Preparation and Verification Procedures' proposal.</p> <p>Fourth Case: Proposal to conduct a private placement of common stock for the fiscal year 110 and to apply for public offering and listing.</p>	Approved without objection	Approved by the Board of Directors
4th meeting of 2024 2024.11.07	<p>First Case: This Company's consolidated financial statements for the third quarter of 2024.</p> <p>Second Case: This Company has established the 'Sustainability Information Management Regulations' proposal.</p> <p>Third Case: This Company's amendment proposal for the 'Code of Corporate Governance Practices.'</p> <p>Fourth Case: This Company's amendment proposal for the 'Approval Authority Table.'</p> <p>Fifth Case: Proposal to establish the Capital Increase Record Date.</p>	Approved without objection	Approved by the Board of Directors
5th meeting of 2024 2024.12.19	<p>First Case: This Company's Fiscal Year 2025 Operations Plan and Budget Proposal.</p> <p>Second Case: Proposal to Establish This Company's Fiscal Year 2025 Audit Plan.</p> <p>Third Case: Assessment of the Independence and Competence of This Company's Certified Public Accountant.</p> <p>Fourth Case: Proposal to Apply for Financing Loan Limits from Financial Institutions.</p>	Approved without objection	Approved by the Board of Directors

3.3 Operational Situation of Corporate Governance and Its Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.

Item	Operational Situation			Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No	Summary Explanation	
1. Has the Company established and disclosed its corporate governance practices in accordance with the 'Code of Corporate Governance Practices for Listed Companies'?	V		This Company has established a 'Code of Corporate Governance Practices,' which has been approved by the board of directors and disclosed on the Company's official website and the Public Information Observatory.	No significant differences.
2. Company's equity structure and shareholders' equity. (1) Has the Company established internal operating procedures to address shareholder suggestions, inquiries, disputes, and litigation matters, and implemented these procedures accordingly? (2) Does the Company maintain a list of the Major Shareholders who effectively control the Company and the ultimate controllers of these Major Shareholders? (3) Has the Company established and implemented risk control and firewall mechanisms with Related enterprises? (4) Has the Company established internal regulations that prohibit insiders from trading Securities based on undisclosed information in the Market?	V V V V		(1) This Company has appointed a Spokesperson, Deputy Spokesperson, and a unit to address Shareholder suggestions or disputes. (2) This Company continuously monitors the shareholding status of Directors, Managers, and Major Shareholders holding more than 10% of shares, and reports the shareholding of Major Shareholders in a timely manner. (3) This Company has established relevant control mechanisms in accordance with legislation within its internal regulations and Internal Control System, which will be executed based on the management operations of relevant subsidiaries. (4) This Company has established an 'Internal Major Information Operating Procedure' to prevent Insider Trading.	No significant differences.

Item	Operational Situation		Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.	
	Yes	No		Summary Explanation
<p>3. Composition and Responsibilities of the Board of Directors</p> <p>(1) Does the board of directors intend to formulate a diversity policy, specific management objectives, and ensure their implementation?</p>	V		<p>(1) The composition of the members of the board of directors of this Company complies with the Company's Articles of Incorporation and director election procedures to ensure diversity and independence among the board members.</p> <p>The current directors are all distinguished members of the industry-academia collaboration, possessing practical experience in corporate management of publicly listed companies or holding management positions in government agencies. The key objectives of the board of directors are as follows:</p> <ol style="list-style-type: none"> 1. The directors include professionals in accounting, medicine, and management administration. 2. There are three female directors. <p>(2) The introduction of the directors is as follows:</p> <ol style="list-style-type: none"> 1. Three independent directors: <ol style="list-style-type: none"> 1) Independent director Dr. Song-Yuan Liao graduated from National Chung Hsing University with a doctorate in industrial knowledge and medical professions. 2) Independent director, Zhong-Ming Zeng holds a Master's degree from the Institute of Industrial Engineering, National Taiwan Chiao Tung University, Bachelor's degree in Industrial Engineering Management, National Taiwan Chiao Tung University, Chairman of Longzhong Internet (Stock) Company, Director of the Corporate Action Value-Added Division of Fuerte Technology (Stock), Yaoshuo Director of Telecom Division of Technology (Stock) Company. He possesses expertise in industry knowledge and business management. 	No significant differences.

Item	Operational Situation		Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No	
			<p>3) Independent Director Shih-Ming Li graduated from the University of California, USA, a researcher in reproductive endocrinology and infertility, Liming Obstetrics and Gynecology, director of the Obstetrics and Gynecology Department of the Air Force General Hospital, and head of the Reproductive Medicine Center of the Air Force General Hospital, with a major in medicine. He resigned on December 13, 2024, due to personal reasons.</p> <p>2. 6 General Directors:</p> <p>1) Chairman of the Board Yung-Hsiang Lin holds a Bachelor's Degree in Botany, National Chung Hsing University, Deputy General Manager, TCI Co., Ltd., Manager of Biomedical Department of Ta Chiang International Co., Ltd. Deputy Manager, Marketing Department, Hsin-Fa International Biotechnology Inc. He possesses expertise in business management, finance, and operational judgment.</p> <p>2) Director Xiu-Yuan Li once served as a securities analyst of CITIC Securities and a project manager of the Institute of Electronics, Industrial Technology Research Institute. She has professional skills such as business management, industry knowledge and business judgment.</p> <p>3) Director Shih-Ming Lai graduated with an MBA from the University of Portland, Oregon, USA. He has served in various roles at Formosa Plastics Group, including in the Office of the General Manager, the Procurement Department, and the Medical Business Development Center. He has also been involved with Formosa Lithium Iron Materials Co. Ltd. He possesses expertise in business management, industry knowledge, and operational judgment.</p>

Item	Operational Situation		Summary Explanation	Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No		
			<p>4) Director Zhen-Zhen Fu graduated from Feng Chia University with a bachelor's degree in finance and taxation, and has professional skills in business management, accounting and finance.</p> <p>5) Director Ching-Ting Chen graduated from National Taiwan University with a master's degree in chemistry. She won two gold medals and one special award at the Pittsburgh Invention Exhibition in 2013 and 2016. She has research and development capabilities, industrial knowledge and other professional capabilities.</p> <p>6) Director Cong-Jie Qiu holds a Master's degree in Chemical Engineering from National Cheng Kung University. He is currently the Client Success Manager at TCI Co., Ltd. and serves as a Deputy Researcher at the Food Industry Research and Development Institute. He possesses research and development capabilities and other professional skills; he resigned from his position following the comprehensive re-election of directors on June 13, 2024.</p> <p>7) Director Chih-Cheng Tsai graduated from the EMBA program at National Chengchi University and serves as a director of TCI Living, possessing expertise in management administration. He assumed office following the comprehensive re-election of directors on June 13, 2024.</p> <p>(3) The implementation status of the diverse objectives of each director is as follows:</p> <p>1. As indicated in the above explanation, the current directors are all distinguished individuals from the industry-academia collaboration, possessing practical experience in managing</p>	

Item	Operational Situation			Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.																																																																																																																								
	Yes	No	Summary Explanation																																																																																																																									
(2) In addition to legally establishing a Compensation Committee and an Audit Committee, does the Company voluntarily establish other types of Functional Committees?	V		<p>publicly listed companies or holding management positions in government agencies. They are equipped with leadership decision-making skills, crisis management capabilities, and insights into the international market. The implementation status of diverse objectives is disclosed as follows:</p> <table border="1"> <thead> <tr> <th>Name</th> <th>Gender</th> <th>Nationality</th> <th>Length of time as an Independent Director of the Company</th> <th>Operational Judgment Skills</th> <th>Accounting and financial analysis skills</th> <th>Operational management skills</th> <th>Crisis management skills</th> <th>Industry knowledge</th> <th>International market outlook</th> <th>Leadership skills</th> <th>Decision-making skills</th> </tr> </thead> <tbody> <tr> <td>Yung-Hsiang Lin</td> <td>Male</td> <td>ROC</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Xiu-Yuan Li</td> <td>Female</td> <td>ROC</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Chen-Chen Fu</td> <td>Female</td> <td>ROC</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Ching-Ting Chen</td> <td>Female</td> <td>ROC</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Cong-Jie Qiu</td> <td>Male</td> <td>ROC</td> <td>0</td> <td>V</td> <td></td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Shih-Ming Lai</td> <td>Male</td> <td>ROC</td> <td>0</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Song-Yuan Liao (Independent Director)</td> <td>Male</td> <td>ROC</td> <td>3</td> <td>V</td> <td></td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Zhong-Ming Zeng (Independent Director)</td> <td>Male</td> <td>ROC</td> <td>3</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> <tr> <td>Shih-Ming Li (Independent Director)</td> <td>Male</td> <td>ROC</td> <td>3</td> <td>V</td> <td></td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> <td>V</td> </tr> </tbody> </table> <p>2. he directors of this Company possess not only professional knowledge in business operations but also the latest expertise required for the Company's business and industry, aligning with the current development goals of the Company.</p> <p>3. This Company emphasizes gender equality in the composition of the board of directors. Currently, there are three female directors on the board, achieving the current stage goal. In the future, the number of female directors will be increased according to the operational needs of the Company.</p> <p>(2) To enhance the functions and operations of the board of directors, the Company has voluntarily established various functional committees: This Company has formed a Compensation Committee and an Audit Committee, and has also voluntarily established a Nomination Committee and a Risk Management Committee.</p>	Name	Gender	Nationality	Length of time as an Independent Director of the Company	Operational Judgment Skills	Accounting and financial analysis skills	Operational management skills	Crisis management skills	Industry knowledge	International market outlook	Leadership skills	Decision-making skills	Yung-Hsiang Lin	Male	ROC	0	V	V	V	V	V	V	V	V	Xiu-Yuan Li	Female	ROC	0	V	V	V	V	V	V	V	V	Chen-Chen Fu	Female	ROC	0	V	V	V	V	V	V	V	V	Ching-Ting Chen	Female	ROC	0	V	V	V	V	V	V	V	V	Cong-Jie Qiu	Male	ROC	0	V		V	V	V	V	V	V	Shih-Ming Lai	Male	ROC	0	V	V	V	V	V	V	V	V	Song-Yuan Liao (Independent Director)	Male	ROC	3	V		V	V	V	V	V	V	Zhong-Ming Zeng (Independent Director)	Male	ROC	3	V	V	V	V	V	V	V	V	Shih-Ming Li (Independent Director)	Male	ROC	3	V		V	V	V	V	V	V	
Name	Gender	Nationality	Length of time as an Independent Director of the Company	Operational Judgment Skills	Accounting and financial analysis skills	Operational management skills	Crisis management skills	Industry knowledge	International market outlook	Leadership skills	Decision-making skills																																																																																																																	
Yung-Hsiang Lin	Male	ROC	0	V	V	V	V	V	V	V	V																																																																																																																	
Xiu-Yuan Li	Female	ROC	0	V	V	V	V	V	V	V	V																																																																																																																	
Chen-Chen Fu	Female	ROC	0	V	V	V	V	V	V	V	V																																																																																																																	
Ching-Ting Chen	Female	ROC	0	V	V	V	V	V	V	V	V																																																																																																																	
Cong-Jie Qiu	Male	ROC	0	V		V	V	V	V	V	V																																																																																																																	
Shih-Ming Lai	Male	ROC	0	V	V	V	V	V	V	V	V																																																																																																																	
Song-Yuan Liao (Independent Director)	Male	ROC	3	V		V	V	V	V	V	V																																																																																																																	
Zhong-Ming Zeng (Independent Director)	Male	ROC	3	V	V	V	V	V	V	V	V																																																																																																																	
Shih-Ming Li (Independent Director)	Male	ROC	3	V		V	V	V	V	V	V																																																																																																																	

Item	Operational Situation		Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No	
(3) Has the Company established performance evaluation procedures for the board of directors and its evaluation methods, conducted regular performance evaluations annually, reported the results of these evaluations to the board of directors, and utilized these results as a reference for individual director salary compensation and re-nomination?	V		(3) This Company has established guidelines for the performance evaluation of the board of directors and its assessment methods. Furthermore, at the beginning of 2025, this board conducted the performance evaluation for 2024 (the external performance evaluation report was commissioned to the Taiwan Association of Management Studies).
(4) Does the Company regularly assess the independence of its certified public accountant?	V		(4) This Company conducts an annual assessment of the independence of its Certified Public Accountant, which will be submitted for discussion and approval at the fifth board of directors meeting in 2024. Based on This Company's assessment, accountants Ping-Chun Chih and Tsung-Hsi Lai from PricewaterhouseCoopers Certified Public Accountants meet the independence assessment standards of This Company and are deemed qualified to serve as This Company's Certified Public Accountant. The accounting firm will also issue a declaration letter.
4. Do Listed Companies have appropriately qualified and sufficient corporate governance personnel, and designate a corporate governance supervisor responsible for matters related to corporate governance (including but not limited to providing necessary information for directors and supervisors to execute their duties, assisting directors and supervisors in complying with legislation, handling matters related to board of directors and shareholders' meetings in accordance with the law, and preparing minutes	V		This Company appointed Huang Zhenjia as the Corporate Governance Officer on November 3, 2021, to oversee corporate governance matters. Main Responsibilities 1. To manage matters related to the meetings of the board of directors and shareholders' meetings in accordance with the law. 2. To prepare the minutes for the board of directors and shareholders' meetings. 3. To assist directors with their appointments and ongoing education. 4. To provide directors with the necessary information for executing their duties. 5. To assist directors in complying with applicable legislation.
			No significant differences.

Item	Operational Situation		Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No	
for board of directors and shareholders' meetings)?			6. Other matters as stipulated by the Articles of Incorporation or contracts.
5. Has the Company established communication channels with stakeholders (including but not limited to shareholders, employees, clients, and suppliers), created a dedicated section for stakeholders on the Company website, and appropriately addressed stakeholders' concerns regarding significant corporate social responsibility issues?	V		This Company has established a Spokesperson System and a dedicated section on its Website for stakeholders, providing communication channels for Employees, Suppliers, Clients, and Investors.
6. Has the Company appointed a professional shareholding agency to manage the affairs of the Shareholders' Meeting?	V		This Company has indeed entrusted Yuanta Securities' Shareholding Agency Department with the management of Shareholders' Meeting affairs.
7. Information Disclosure (1) Does the Company have a Website that discloses financial operations and corporate governance information? (2) Does the Company employ other methods of information disclosure (such as establishing an English Website, designating a specific individual responsible for collecting and disclosing Company information, implementing a Spokesperson System, and posting the proceedings of legal entity briefings on the Company Website, etc.)?	V V		(1) This Company announces and reports financial operations and corporate governance matters in accordance with the law, and relevant information can be accessed through the Public Information Observatory. (2) This Company has established a dedicated department responsible for the collection and dissemination of various information, and has implemented a Spokesperson Mechanism as required.

Item	Operational Situation		Summary Explanation	Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No		
(3) Did the Company announce and report the annual financial report within two months after the end of the fiscal year, and did it also announce and report the financial reports for the first, second, and third quarters, along with the operational conditions for each month, ahead of the stipulated deadlines?	V		(3) The Company reports the annual financial report and the financial reports for the first, second, and third quarters, as well as the operational conditions for each month, in compliance with regulations.	
8. Does the Company possess any additional important information that aids in understanding the operational situation of corporate governance (including but not limited to employee rights, employee care, investor relations, supplier relationships, rights of stakeholders, continuing education of directors and supervisors, implementation of risk management policies and risk measurement standards, implementation of client policies, and the purchase of liability insurance for directors and supervisors, etc.)?	V		<p>(1) Employee Rights: This Company has consistently treated employees with integrity and safeguards employee rights in accordance with relevant regulations.</p> <p>(2) Employee Care: This Company strengthens interactive communication and fosters a trusting and mutually dependent relationship with employees through a robust welfare system and training and education.</p> <p>(3) Investor Relations: Information is comprehensively disclosed via the Public Information Observatory and the Company website, enabling investors to gain a thorough understanding of the Company's operational status. Communication with investors is facilitated through the Shareholders' Meeting and the Spokesperson Mechanism, with a strong emphasis on valuing and appropriately addressing investor feedback.</p> <p>(4) Stakeholder Rights:</p> <ol style="list-style-type: none"> 1. Responsibilities to Customers: The Company provides safe and high-quality Products, values customer feedback, and promptly addresses customer complaints to meet their needs. 2. Responsibilities to Shareholders: The Company is committed to creating Shareholders' Equity as its primary objective. 	No significant differences.

Item	Operational Situation		Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No	
			<p>(5) Continuing Education Status of Directors and Supervisors: Continuing education is conducted in accordance with legal requirements.</p> <p>(6) Implementation Status of Risk Management Policy and Risk Measurement Standards: The Company adheres to the principles of internal control design, with each Department conducting regular internal self-assessments, followed by reviews and improvements carried out by auditing personnel to mitigate operational risks.</p> <p>(7) Implementation of Consumer or Client Protection Policies: This Company has obtained ISO 13485, MDSAP audits, and Medical Equipment QMS certification, as well as product certifications from various countries.</p> <p>(8) Status of Liability Insurance Purchased for Directors and Supervisors: This Company has procured liability insurance for its directors and supervisors to mitigate potential risks.</p> <p>(9) Establishment of Information Security Risk Management Framework, Formulation of Information Security Policy, and Specific Management Plans: Since its establishment in 1998, this Company has established an Information Management Department. The Company conducts annual assessments of information security risks, which are reviewed and audited by the External Audit Unit and the Internal Audit Unit. Relevant information is reported monthly to the General Manager during management conferences. The key points of the Company's information security assessment are as follows: 1. Review of Information Architecture, 2. Review of Internet Activities, 3. Inspection of Network Equipment, Servers, and Terminals, 4. Website Security Testing, 5. Review of Security Settings. The main assessment items and specific management plans are detailed as follows:</p>

Item	Operational Situation		Summary Explanation	Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No		
			<p>1. Review of Information Architecture</p> <p>1) Assessing the appropriateness of measures taken for business continuity</p> <p>Reviewing the structure and operational mechanisms of relevant measures to identify any risks associated with single points of failure, and conducting a risk analysis regarding the appropriateness of business continuity measures, such as ERP systems and network equipment, while providing the results and recommendations of the information architecture security assessment.</p> <p>2) Evaluating the maximum impact of single point failures and the risk bearing capacity</p> <p>Evaluate whether the impact falls within the risk tolerance; if not, consider and implement corrective measures.</p> <p>2. Review of Internet Activities</p> <p>1) Examine the access records and account permissions of the devices.</p> <p>2) Assess the access records of network equipment, cybersecurity equipment, and servers, as well as the mechanisms for granting and monitoring account permissions to ensure compliance with internal control operational standards.</p> <p>3. Testing of Network Equipment, Servers, and Terminals</p> <p>1) Conduct vulnerability scanning and repair operations</p> <p>2) Regularly or promptly review the policies for network equipment, servers, and terminals, and implement improvements and repairs for any identified inappropriate policies. Provide assessment recommendations based on the</p>	

Item	Operational Situation		Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No	
			<p>results, with an emphasis on identifying potential weaknesses and vulnerabilities within the architecture for improvement and remediation, thereby reducing overall cybersecurity risks.</p> <p>4. Website Security Testing</p> <ol style="list-style-type: none"> 1) Conduct penetration testing on the website. 2) Penetration testing consists of three steps: data collection, information analysis, and target penetration. The execution method simulates hacker attack behavior by utilizing safety testing tools to conduct penetration testing on websites with open external links, examining for vulnerabilities and implementing necessary repairs. <p>5. Review of Security Settings</p> <ol style="list-style-type: none"> 1) Server Security Principle Settings 2) Regularly review the settings related to 'Password Setting Principles' and 'Account Lockout Policy' for servers (e.g., Domain Services Active Directory) through manual operations to ensure that the relevant domain security principle settings comply with internal control regulations. 3) In 2018, external professional vendors conducted cybersecurity assessments, established firewalls, and implemented data backup systems. To enhance information security awareness among all employees, cybersecurity training courses were held on October 20, 2021, with a total of 80 participants; on October 26, 2022, with a total of 120 participants; in October 2023, with a total of 127 participants; and in October 2024, with a total of 137 participants. Additionally, audits conducted from 2019 to 2024 revealed no significant deficiencies in cybersecurity risks.

Item	Operational Situation		Summary Explanation	Differences from the Code of Corporate Governance Practices for Listed Companies, Including Reasons.
	Yes	No		
<p>9. Please describe the improvements that have been made to the results of the corporate governance evaluation released by the Corporate Governance Center of the Taiwan Stock Exchange Corporation in the most recent year and propose priorities and measures to enhance those that have not yet been improved.</p> <p>(1) Each year, the Company reviews the recent corporate governance evaluation results and the most recent corporate governance evaluation to individually examine the indicators that still meet the scoring standards. Improvement schedules are arranged to continuously improve most of the items that have not yet met the standards.</p> <p>(2) The Company will strengthen the promotion of integrity management and internal work rules throughout the Company, enhance the promotion of unethical behavior reporting and its whistleblowing system, and disclose relevant rules and regulations on the company's website.</p>				

Note 1: Standards for the Independence Assessment of Accountants

Item	Result
1. As of the most recent engagement, there have been no instances of not changing for five years.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
2. There is no significant financial conflict of interest with the client.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
3. Avoid any inappropriate relationships with the client.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
4. Accountants must ensure that their assistants adhere to honesty, fairness, and independence.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
5. Financial statements of the service organization within the two years prior to practice must not be audited.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
6. The name of the accountant must not be used by others.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
7. No shares of this Company or related enterprises are held.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
8. There are no monetary lending transactions with this Company or related enterprises.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
9. There are no joint investments or profit-sharing relationships with this Company or related enterprises.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
10. There is no concurrent employment with this Company or related enterprises, receiving a fixed salary.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
11. There is no involvement in the decision-making management functions of this Company or related enterprises.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
12. There is no concurrent operation of other businesses that may compromise independence.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
13. There is no relationship with the management team of this Company involving a spouse, direct blood relatives, or in-laws.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
14. No commissions related to business have been received.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
15. To date, there have been no circumstances that have compromised the principle of independence.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Note 2: Accountant Independence Declaration

Letter

Recipient: Maxigen Biotech Inc.

Issuance No.: PwC 24007022

Subject: At MBI's request, the firm has evaluated its independence in accordance with Statement No. 10 of the Code of Professional Ethics for Certified Public Accountants, titled "Integrity, Fairness, Objectivity, and Independence." The evaluation results and the issued statement are as follows for your review.

Explanation:

1. Per Article 4 of The Bulletin of Norm of Professional Ethics for Certified Public Accountant of the Republic of China No. 10 (hereinafter referred to as "Bulletin No. 10"), when auditing or reviewing financial statements," the accountant needs to maintain independence, not only in substance but also in form. Accordingly, members of the audit service team, other certified public accountants in common practice, the firm, and affiliates of the firm (hereinafter referred to as members of the audit service team and affiliates of the firm) are required to maintain their independence from the audited client. In addition, Article 7 of Bulletin No. 10 states that "independence may be affected by self-interest, self-assessment, defense, familiarity, and coercion. Therefore, the Firm would like to declare to the Company that the independence of the Firm is not affected by any of the factors mentioned in Article 7 that may affect independence.
2. Independence from self-interest: The Firm declares that the members of the audit service team and affiliates of the firm do not have (i) direct or significant indirect financial interests, (ii) close business relationships, (iii) potential employment relationships, or (iv) financing or assurance practices with the Company or its directors and supervisors.
3. Independence is not affected by self-assessment: The Firm states that no member of the audit services team is currently or has been a director or supervisor of the Company or has held a position directly and materially affecting an audit case within the last two years. The Firm has not provided non-audit services that directly affect a material aspect of an audit case.

4. Independence not affected by advocacy: The Firm represents that members of the audit services team have not been engaged to advocate for the Company's positions or opinions or to act as intermediaries on behalf of the Company in coordinating conflicts with other third parties.
5. Independence not affected by advocacy: The Firm represents that members of the audit services team have not been engaged to advocate for the Company's positions or opinions or to act as intermediaries on behalf of the Company in coordinating conflicts with other third parties.
6. Independence is not affected by coercion: The Firm declares that the members of the audit service team have not been subjected to or perceived to be subjected to improper requests from the Company's management regarding the selection of accounting policies or the disclosure of financial statements, or the reduction of audit work to be performed on the grounds of reducing public expenses, which would affect the objectivity and professional doubt.
7. The above matters have been carried out per the relevant procedures of the Firm in relation to customer independence verification, and professional caution has been exercised.

PwC Taiwan

Ping-Chun Chih

Accountant

Tsung-Hsi Lai



December 10, 2024

2024 Directors' and Supervisors' training:

Title	Name	Appointment Date	Course Date	Organizer	Course Name	Course Hours	Does the course comply with the regulations for further education (Note 1)	Notes
Legal entity director Representative	Yung-Hsiang Lin	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		
Legal entity director Representative	Xiu-Yuan Li	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		
Legal entity director Representative	Zhenzhen Fu	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		
Legal entity director Representative	Ching-Ting Chen	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		
Legal entity director Representative	Shih-Ming Lai	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		
Legal entity director Representative	Chih-Cheng Tsai	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		
Independence director	Sung-Yuan Liao	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		
Independence director	Zhong-Ming Zeng	2024/06/13	2024/12/13	WBSD	Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment	3.0	Yes	
			2024/12/13	WBSD	Development of Artificial Intelligence and International Governance Trends	3.0		

3.4 If the Company has established a Compensation Committee, it should disclose its composition, responsibilities, and operational status:

(1) Information on Compensation Committee members

April 13, 2025

Title (Note 1)	Conditions		Professional Qualifications and Experience (Note 2)	Independence Status (Note 3)	Number of other publicly traded companies where members serve on the Compensation Committee
	Name				
Independent Director	Zhong-Ming Zeng		Engineering Technology and Tissue Leadership Experience in business-related industries	Meets independence criteria 1. I, my spouse, and my second-degree relatives do not serve as directors, supervisors, or employees of this company or its related enterprises. 2. I, my spouse, and my second-degree relatives (or using another person's name) do not hold any shares or proportions of shares in the company. 3. I do not serve as a director of any company that has a specific relationship with this company. 4. There have been no remuneration amounts received in the past three years for providing business, legal, financial, accounting, or other services to this company or its related enterprises.	0
Independent Director	Sung-Yuan Liao		Life sciences and organizational management Experience in the Education-Related Industry	Meets independence criteria 1. I, my spouse, and my second-degree relatives do not serve as directors, supervisors, or employees of this company or its related enterprises. 2. I, my spouse, and my second-degree relatives (or using another person's name) do not hold any shares or proportions of shares in the company. 3. I do not serve as a director of any company that has a specific relationship with this company. 4. There have been no remuneration amounts received in the past three years for providing business, legal, financial, accounting, or other services to this company or its related enterprises.	1
Independent Director	Shih-Ming Li		Medicine and Tissue Leadership Experience in the Medicine-Related Industry	Meets independence criteria 1. I, my spouse, and my second-degree relatives do not serve as directors, supervisors, or employees of this company or its related enterprises. 2. I, my spouse, and my second-degree relatives (or using another person's name) do not hold any shares or proportions of shares in the company. 3. I do not serve as a director of any company that has a specific relationship with this company. 4. There have been no remuneration amounts received in the past three years for providing business, legal, financial, accounting, or other services to this company or its related enterprises. Note: Resigned on December 13, 2024, due to personal reasons.	1

(2) Information on the Operational Situation of the Compensation Committee

A. The Company has 3 members on its Compensation Committee.

For 2024 (Term of Office: June 13, 2024 to June 12, 2027), the Compensation Committee held 5 meetings (A), and as of December 31, 2024, the attendance of the committee members is as follows:

Title	Name	Actual Attendance Count (B)	Number of Authorized Attendances	Actual Attendance Rate (%) (B/A)(Note)	Remarks
Chair	Zhong-Ming Zeng	5	0	100%	
Committee Member	Sung-Yuan Liao	5	0	100%	
Committee Member	Shih-Ming Li	4	0	100%	Resignation due to personal reasons on December 13, 2024.
<p>Other matters to be recorded:</p> <p>1. If the board of directors does not adopt or amend the recommendations of the Compensation Committee, it shall specify the date of the board meeting, the period, the content of the proposal, the outcome of the board resolution, and how the opinions of the Compensation Committee were addressed (if the salary compensation approved by the board exceeds the recommendations of the Compensation Committee, the differences and reasons shall be detailed). Our company has no objections or reservations to be recorded or explained for the year 2024.</p> <p>2. For matters decided by the Compensation Committee, if any member has opposing or reserved opinions that are recorded or stated in writing, the date of the Compensation Committee meeting, the period, the content of the proposal, all members' opinions, and how those opinions were addressed shall be specified. Our company has no objections or reservations to be recorded or explained for the year 2024.</p>					

Note:

- (1) For any members of the Compensation Committee who resign prior to the end of the fiscal year, the resignation date must be noted in the Remarks Column, and the Actual Attendance Rate (%) should be calculated based on the number of Compensation Committee meetings held during their tenure and their Actual Attendance Count.
- (2) If there is a re-election of Compensation Committee members before the end of the fiscal year, both newly appointed and former members must be listed, and the Remarks Column should specify whether the member is former, newly appointed, or re-elected, along with the re-election date. The Actual Attendance Rate (%) is calculated based on the number of meetings held by the Compensation Committee during the employment period and the Actual Attendance Count.
- (3) Proposal content, resolution results, and the Company's handling of the Compensation Committee's opinions.

Compensation Committee	Proposal Content.	Resolution	MBI's Response to the Resolution
1st meeting of 2024 2024.03.12	<p>Proposal 1: Explanation of the Employee Compensation Distribution for the fourth quarter of 2022.</p> <p>Proposal 2: Proposal for the allocation of director compensation and employee compensation for Fiscal Year 2023.</p> <p>Proposal 3: Adjustment of Manager Salary-Related Matters for This Company.</p>	Approved without objection	Approved by the Board of Directors

Compensation Committee	Proposal Content.	Resolution	MBI's Response to the Resolution
2nd meeting of 2024 2024.05.03	Proposal 1: Explanation of Employee Compensation Distribution for This Company for Fiscal Year 2024 Quarter.	Approved without objection	Approved by the Board of Directors
3rd meeting of 2024 2024.07.29	Proposal 1: Explanation of Employee Compensation Distribution for This Company for Fiscal Year 2023.	Approved without objection	Approved by the Board of Directors
4th meeting of 2024 2024.11.07	Proposal 1: Explanation of Employee Compensation Distribution for This Company for Fiscal Year 2023. Proposal 2: Adjustment of Manager Salary-Related Matters for This Company.	Approved without objection	Approved by the Board of Directors
5th meeting of 2024 2024.12.19	Proposal 1: Matters Related to the Distribution of Year-End Bonuses for Managers of This Company for 2024.	Approved without objection	Approved by the Board of Directors

(3) Information on Nominating Committee members and operations

A. The qualifications and responsibilities of the members of the Company's Nominating Committee are described.

B. Professional qualifications and experience of the members of the Nominating Committee and their operation:

A. The Company has a total of three members on the Nomination Committee.

B. For 2024 (Term of Office: June 13, 2024, to June 12, 2027), the Nomination Committee convened once (A), and the professional qualifications and experience of the members, as well as their attendance status as of December 31, 2024, are as follows:

Title	Name	Professional qualifications and experience	Actual Attendance Count (B)	Number of Authorized Attendances	Actual Attendance Rate (%) (B/A)(Note)	Remarks
Chair	Sung-Yuan Liao	Please refer to page 11 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	
Member	Zhong-Ming Zeng	Please refer to page 11 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	

Title	Name	Professional qualifications and experience	Actual Attendance Count (B)	Number of Authorized Attendances	Actual Attendance Rate (%) (B/A)(Note)	Remarks
Member	Shih-Ming Li	Please refer to page 11 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	Resignation due to personal reasons on December 13, 2024
Member	Yung-Hsiang Lin	Please refer to page 9 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	
<p>Other matters to be recorded:</p> <p>The meeting date, session number, content of the main proposals of the nomination committee, the content of recommendations or oppositions by the members of the nomination committee, the resolution results of the nomination committee, and the company's handling of the nomination committee's opinions.</p> <p>Our company has no objections or reservations to be recorded or explained for the year 2024.</p>						

Nomination Committee	Proposal Content.	Result	MBI's Response to the Resolution
1st meeting of 2024 2024.03.12	<p>Proposal 1: Proposal for the comprehensive re-election of the Company's directors at the 2024 Annual General Meeting of Shareholders.</p> <p>Proposal 2: Proposal for the list of candidates for directors (including independent directors).</p>	Approved without objection	Approved by the Board of Director

Note:

- (1) For any member of the Nomination Committee who resigns prior to the end of the fiscal year, the resignation date should be noted in the Remarks Column, and the Actual Attendance Rate (%) should be calculated based on the number of meetings held during their tenure and their Actual Attendance Count.
- (2) If there is a re-election of the Nomination Committee prior to the end of the fiscal year, both newly appointed and former members of the Nomination Committee should be listed, with the Remarks Column indicating whether the member is former, newly appointed, or re-elected, along with the re-election date. The Actual Attendance Rate (%) is calculated based on the number of meetings held by the Nomination Committee during the term of office and the actual attendance count.

(4) Information on the members of the Risk Management Committee and their operational status.

A. Describe the qualifications and responsibilities of the members of the Company's Risk Management Committee.

B. Professional qualifications and experience of the Risk Management Committee members and their operational status:

(A) The Company's Risk Management Committee consists of 5 members.

(B) In 2024 (Term of Office: June 13, 2024, to June 12, 2027), the Risk Management Committee held 1 meeting (A), and the professional qualifications and experience of the members, as well as their attendance status as of December 31, 2024, are as follows:

Title	Name	Professional qualifications and experience	Actual Attendance Count (B)	Number of Authorized Attendances	Actual Attendance Rate (%) (B/A)(Note)	Remarks
Chair	Sung-Yuan Liao	Please refer to page 11 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	
Member	Zhong-Ming Zeng	Please refer to page 11 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	
Member	Yung-Hsiang Lin	Please refer to page 9 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	
Member	Ching-Ting Chen	Please refer to page 10 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	

Title	Name	Professional qualifications and experience	Actual Attendance Count (B)	Number of Authorized Attendances	Actual Attendance Rate (%) (B/A)(Note)	Remarks
Member	Shih-Ming Li	Please refer to page 11 of the annual report for disclosure of directors' professional qualifications and independence of independent directors.	1	0	100%	Resignation due to personal reasons December 13, 2024.

Other matters to be recorded:

This document outlines the meeting dates, periods, content of proposals, suggestions or objections from members of the Risk Management Committee, the resolutions made by the Risk Management Committee, and the Company's response to the opinions of the Risk Management Committee.

Our company has no objections or reservations that need to be published and supplemented in 2024.

Note:

- (1) For any member of the Risk Management Committee who resigns before the end of the fiscal year, the resignation date should be noted in the Remarks Column, and the Actual Attendance Rate (%) shall be calculated based on the number of meetings held during their tenure and their actual attendance count.
- (2) Prior to the end of the fiscal year, if there is a re-election of the Risk Management Committee, both the newly appointed and former members of the Risk Management Committee should be listed, and the Remarks Column should indicate whether the member is former, newly appointed, or re-elected, along with the date of re-election. The Actual Attendance Rate (%) is calculated based on the number of meetings held by the Risk Management Committee during their term and their actual attendance count.
- (3) Content of the proposal, resolution results, and the Company's handling of the opinions from the Risk Management Committee.

Risk Management Committee	Content of the Proposal	Resolution	MBI's Response to the Resolution
1st meeting of 2024 2024.12.19	Proposal 1: To formulate the Company's Risk Management Plan for 2025.	Approved without objection	Approved by the Board of Director

3.5 The status of implementing sustainable development and the differences from the sustainable development practices code for listed companies, along with the reasons:

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
1. Has the Company established a governance structure to promote sustainable development, created dedicated (or part-time) units for this purpose, and authorized the Senior Management Team to manage these efforts, with oversight from the board of directors?	V		<p>(1) This Company established the Greenhouse Gas Inventory Committee in May 2022 to promote sustainable development.</p> <p>(2) The members of the Committee are responsible for the following tasks: This Company approved the Risk Management Regulations on May 13, 2020, which define various types of risks in accordance with the Company's operational policies, aiming to prevent potential losses within an acceptable risk range and achieve optimal resource allocation. This Company does not have a dedicated risk management unit; rather, it emphasizes comprehensive risk control by all employees, conducting risk analysis in conjunction with annual budget management at the end of each year to effectively implement risk management. Overall, the risks faced by the Company can be categorized into six major types, as outlined below:</p> <ol style="list-style-type: none"> 1. Market Risk: The impact on the Company's industry due to external changes such as domestic and international economic factors, technology, environmental conditions, and shifts in consumer behavior. 2. Investment Risk: This encompasses fluctuations in the market value of short-term investments and the operational management of long-term investments in the invested companies, as well as risks associated with interest rates, exchange rates, finance, and lending capital to others. 3. Credit Risk: The risk of loss arising 	No significant differences.

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>from a counterparty's failure to fulfill its obligations or responsibilities.</p> <p>4. Operational Risk: Refers to losses incurred by the Company due to deficiencies in internal control, quality control in research and development, or improper or erroneous management by personnel.</p> <p>5. Legal Risk: Refers to the risk of financial or reputational loss arising from inadequately detailed contracts, improper authorization, incomplete legislation, or other factors that hinder the enforcement of contractual obligations by counterparties.</p> <p>6. Risk Management of Information Systems: The scope of the information systems business includes manufacturing facilities and investment companies. To ensure the normal operations of the business, the Company has implemented disaster protection measures, including an uninterruptible power supply system and fire protection in the data center. To mitigate risk and establish a remote backup mechanism, a computer room with capabilities equivalent to those of the headquarters has been constructed to minimize the impact of unforeseen incidents.</p> <p>7. Labor safety and health risk control: Taking into account both routine and non-routine activities, as well as the effects of legally mandated infectious viruses, control measures are enforced for all individuals entering the workplace, including employees, contractors, and visitors. For high-risk operations and significant</p>	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>changes to the environment or processes, an assessment should be conducted prior to occurrence to identify risks, determine the priority of risk management, and implement tiered management and phased control based on the assessed risk levels. Consideration should be given to the order of elimination, substitution, engineering controls, signage/warnings, administrative controls, personal protective equipment, and emergency response measures to mitigate risks.</p> <p>8. Natural Disasters and Climate Change: The Company should assess the impact of natural disasters and climate change on operational activities to mitigate potential losses.</p> <p>9. Other Risks: This refers to risks that are not included in the aforementioned categories but may lead to significant losses for the Company.</p> <p>This Company implemented risk management analysis and review at the end of 2024 and presented a report to the board of directors on December 19, 2024, concerning the risk assessment analysis related to environmental, social, and corporate governance issues associated with the Company's operations.</p>	
2. Has the Company conducted a risk assessment related to environmental, social, and corporate governance issues associated with its operations in accordance with the principle of materiality, and established	V		<p>(1) This Company has established a Corporate Social Responsibility Policy and will report to the Board of Directors annually starting from 2019.</p> <p>(2) The promotion of Corporate Social Responsibility within this Company is organized by the Office of the General Manager, with the primary members being the supervisors of each</p>	No significant differences.

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
relevant risk management policies or strategies?			<p>department.</p> <ol style="list-style-type: none"> 1. Key Responsibilities of Corporate Social Responsibility <ol style="list-style-type: none"> 1) Propose the mission or vision of Corporate Social Responsibility and formulate the Corporate Social Responsibility Policy, systems, or related management guidelines. 2) Integrate Corporate Social Responsibility into the Company's operational activities and development direction, and approve specific plans for promoting Corporate Social Responsibility. 3) Ensure the timeliness and accuracy of information disclosure related to Corporate Social Responsibility. 2. Additionally, the work description: <p>Annually report significant social welfare, corporate governance, and corporate integrity issues to the board of directors.</p> <ol style="list-style-type: none"> 1) On July 3, 2015, the board of directors reported the donation of Hyaluronic Acid wound dressings to the Ministry of Health and Welfare. 2) In response to the needs of educational institutions, we also make irregular donations of Cosmetic Skincare Products to students in beauty-related departments each year. For instance, in October 2018, we donated 450 boxes of High-Efficiency Brightening Tightening Eye Cream, 3,320 boxes of Crystal Radiance Delicate Cream, and 900 boxes of High-Efficiency Moisturizing Hyaluronic Acid Essence to Chang Gung University 	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>of Science and Technology, Hungkuang University, and Tzu Chi University of Science and Technology. In May 2019, Hungkuang University and Liming University provided 500 boxes of Crystal Pure Cleansing Milk and 700 boxes of Purifying Cleansing Mud. In January 2020, Liming University provided 500 boxes of Crystal Refined Hydrogel and 500 boxes of Moisturizing Masks, among others, to assist the nation in cultivating beauty professionals.</p> <p>3) In September 2018, charitable concerts and other relief activities were held at Fu Jen Catholic University Hospital.</p> <p>4) On December 18, 2019, and December 14, 2020, reports on the implementation status of Corporate Social Responsibility were submitted to the board of directors.</p> <p>5) In 2022, we donated intra-articular injections to Tzu Chi Hospital, Taitung Guanshan Branch.</p> <p>6) On September 23, 2022, we participated in the clean-up of Guanyin Mountain and received the 2022 Green Enterprise Certification.</p> <p>7) We received subsidies and incentives for the low-carbon technology industry from 2022 to 2024 and were awarded the Outstanding Energy Conservation and Carbon Reduction Achievement by the Taoyuan City Government.</p> <p>8) 2023 ACES Asia Corporate Leadership and Sustainable</p>	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>Development Award.</p> <p>9) 2023 Silver Award for Happy Enterprises.</p> <p>10) In 2023, we conducted a total of 21 health education seminars for elderly community care.</p> <p>11) In March 2024, a digital intraoral wired scanner was donated to assist the Periodontal Department of Tri-Service General Hospital in enhancing clinical diagnosis and treatment.</p> <p>12) In April 2024, MBI delivered an industry-academia lecture in the field of medical devices at National Tsing Hua University, inspiring students to pursue their future endeavors with greater courage.</p> <p>13) Beginning in April 2024, MBI has partnered with the renowned domestic medical aesthetics brand, Jingyan Medical Aesthetics, to jointly promote the 'Charity Program for Pico Laser Tattoo Removal,' assisting adolescents and disadvantaged groups in tattoo removal. Monthly donations of skin care products will be made based on actual needs to serve as post-tattoo removal care treatments.</p> <p>14) In May 2024, MBI collaborated with the Meishan Social Welfare Foundation to provide Dragon Boat Festival gift boxes. In January 2025, they partnered with the Down Syndrome Foundation to offer New Year gift boxes, and in May 2025, they collaborated with the Syin-Lu Social Welfare Foundation for Dragon Boat</p>	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>Festival gift boxes, assisting individuals with disabilities in developing self-reliance and conveying care and warmth to every corner of society.</p> <p>15) From 2024 to April 2025, a total of 8 community public welfare health education seminars were conducted, focusing on disadvantaged groups and fulfilling corporate social responsibility.</p> <p>16) In January 2025, all employees of MBI donated the funds raised from last year's Christmas voluntary contributions to the Taiwan Baseball Development Association, supporting grassroots baseball education and reading promotion, thereby contributing to the cultivation of Taiwan's national sport at the grassroots level.</p>	
3. Environmental Issues (1) Has the Company established an appropriate environmental management system in accordance with the characteristics of its industry?	V		This Company operates in the low-pollution medical devices and medical aesthetics skincare products industry; however, in response to environmental protection requirements, it is gradually establishing an Environmental Management System.	No significant differences.
(2) Is the Company committed to enhancing the efficiency of resource utilization and utilizing renewable materials that have a low environmental impact?	V		This Company is dedicated to improving the efficiency of resource utilization and minimizing unnecessary resource waste. The raw materials used by this Company consist of beef tendon extract collagen, which is manufactured into related biomimetic products that do not cause pollution and comply with applicable environmental protection regulations.	No significant differences.
(3) Has the Company	V		Extreme climate change is increasingly	No significant

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
evaluated the potential risks and opportunities associated with climate change for the enterprise both currently and in the future, and adopted response measures related to climate issues?			impacting global ecosystems and human survival, becoming a 'truth that must be confronted.' In response, this Company is coordinated by the management department, which establishes reduction targets based on sustainability principles and actively promotes management measures such as energy conservation and carbon reduction to mitigate the potential impacts of climate change on the Company. These considerations are integrated into the Company's overall operations to provide early warnings and reduce the impact of risks on the Company's operations. The primary climate risks currently identified include extreme weather events such as typhoons and floods, which may result in production stoppages, interruptions in production, transportation difficulties, and disruptions in the supply chain. 2. Extreme variations in rainfall have increased the difficulty of planning for the acquisition and utilization of water resources. 3. Rising temperatures may affect process conditions, leading to increased equipment investment and higher electricity consumption. 4. There may be delays in delivery or reductions in production, among other issues. We analyze factors such as the probability of occurrence and the degree of impact, and develop relevant countermeasures to mitigate the impact of climate risk.	differences.
(4) Has the Company tracked greenhouse gas emissions, water usage, and total waste weight over the past two years, and established policies for energy conservation and carbon reduction, greenhouse gas reduction, water usage	V		1. The annual greenhouse gas emissions, conducted greenhouse gas inventory, and certified by a third party, were 2,479.859 tons of carbon in 2021; 2,516.2475 tons in 2022; 2,597.5804 tons in 2023; and 2,610.9041 tons in 2024. In 2025, an energy monitoring system was introduced with a target of reducing electricity costs by 1% annually.	No significant differences.

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
reduction, or other waste management?			<p>2. Water consumption was 14,262 degrees in 2021 (carbon emissions of 2.2 tons) and 12,792 degrees in 2022 (carbon emissions of 1.9 tons); In2023, water consumption was 11,615 degrees (carbon emissions of 1.8 tons) with a target of reducing water costs by 1% annually, and in 2024, water consumption remained at 11,615 degrees (carbon emissions of 1.8 tons) with the same target.</p> <p>3. The total weight of waste: 26.1 tons in 2021; 25.02 tons in 2022; 24.18 tons in 2023; with a target of a 1% annual reduction.</p> <p>The overall strategy for energy conservation and carbon reduction, as well as greenhouse gas reduction, is as follows:</p> <p>(1) Regarding water resource conservation: The factory office building utilizes water-saving facilities to minimize waste and consumption of water resources, including the recycling of air conditioning condensate, controlling faucet water flow, sensor-operated urinal flushers, and water-saving toilets.</p> <p>(2) Regarding energy conservation in the air conditioning system: Dual-pressure chiller units, variable frequency air conditioning boxes, variable flow chilled water systems, variable frequency cooling towers, sand filtration systems, and energy-saving controls for office air conditioning.</p> <p>(3) Regarding energy conservation for lighting equipment: We will enhance the management of lighting usage (such as turning off lights during lunch breaks and ensuring lights are</p>	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>switched off when not in use). In 2024, traditional T8 fluorescent tubes will be gradually replaced with LED lights. Sensor-activated lighting has been installed in office corridors, stairwells, parking areas, and sign lights, complemented by timers to achieve energy-saving results.</p> <p>(4) Regarding waste classification and recycling: We will establish waste classification and resource recycling bins in response to the Environmental Protection Administration's policy of 'disposing of tissue paper in the toilet.' We will fully replace short-fiber tissue paper to achieve waste reduction and resource recycling, thereby ensuring a clean and protected environment.</p> <p>(5) The aforementioned strategies and practices will be communicated periodically to all employees through announcements and implemented accordingly.</p>	
<p>4. Social Issues</p> <p>(1) Has the Company established relevant management policies and procedures in accordance with applicable regulations and international human rights conventions?</p>	V		<p>This Company has long established 'Work Rules' that comply with the Labor Standards Law and implements them accordingly. Additionally, to fulfill its corporate social responsibility and safeguard the basic human rights of all employees, clients, and stakeholders, MBI Company adheres to the principles set forth in the Universal Declaration of Human Rights and the International Labour Organization conventions, respecting internationally recognized fundamental human rights, including freedom of association, care for disadvantaged groups, prohibition of child labor, elimination of all forms of forced labor, and elimination of employment and</p>	No significant differences.

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>occupational discrimination, while strictly complying with labor-related regulations in the jurisdiction where the Company operates. The relevant human rights policies are outlined as follows:</p> <ol style="list-style-type: none"> 1. Diversity and Equal Opportunity: The diverse characteristics of all Employees must be embraced, and no Employee or job applicant protected by law shall be discriminated against based on any characteristic. This includes gender, color, race, ethnicity, nationality, religion, age, marital status, sexual orientation, disability, pregnancy, military status, and political affiliation. We ensure that employment policies provide equal treatment, implement fairness and equity in hiring, compensation and benefits, training, evaluation, and promotion opportunities, and offer effective and appropriate grievance mechanisms to prevent and respond to situations that harm Employee Rights, thereby striving to create a work environment free from discrimination and harassment. 2. Reasonable Working Hours: To ensure that employees are not exposed to the risk of excessive working hours, we establish clear regulations regarding working hours and overtime, and regularly monitor and manage employee attendance. 3. Health and Safety in the Workplace: In compliance with occupational safety and health policies, we provide a safe and healthy work environment and implement necessary and effective measures to minimize hazards in the workplace as much as possible under feasible conditions, thereby preventing health risks to employees from accidents 	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>occurring during work or related to work. To mitigate potential health and safety risks associated with work patterns, the Company conducts annual reviews of employee health and safety.</p> <p>4. Compliance with Laws: This Company strictly adheres to the Labor Standards Act and does not employ individuals under the age of sixteen, nor does it require employees to pay deposits or surrender identification documents at the start of employment.</p> <p>5. Labor-Management Negotiation: Establish open communication channels and hold regular labor-management meetings to ensure the rights and interests of both parties.</p> <p>6. Privacy Protection: To fully safeguard the privacy rights of clients and all stakeholders, a comprehensive information security management mechanism is established, adhering to strict control standards and protective measures.</p> <p>7. This Company has incorporated human rights risk explanations into the training and education for new employees since July 2020. On December 14, 2020, it reported to the board of directors the risk assessment report, which included the status of human rights risk assessments. Furthermore, training on the Prevention of Sexual Harassment and illegal infringement will be conducted in July 2024.</p>	
(2) Has the Company established and implemented reasonable Employee Welfare Measures (including compensation, leave, and other benefits), and does it	V		This Company has implemented various employee welfare policies. In addition to the statutory labor insurance, health insurance, retirement fund contributions, and parental leave, the Company also conducts annual health check-ups for employees, awards performance bonuses,	No significant differences.

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
appropriately reflect operational performance or results in employee compensation?			provides support for weddings and celebrations, and offers group insurance for employees. Furthermore, employee compensation is allocated based on the Company's profitability.	
(3) Does the Company provide a safe and healthy working environment for employees and regularly conduct safety and health education for them?	V		<ol style="list-style-type: none"> 1. This Company is dedicated to establishing comprehensive environmental facilities to ensure a comfortable, safe, and healthy workplace for employees. This includes implementing necessary access control measures, conducting regular labor safety training, enforcing a complete indoor smoking ban, and providing related education and training. 2. In the fiscal year 2024, there were no fire incidents, no casualties, and no occupational injury cases. This Company conducts at least two fire drills annually and implements relevant occupational safety and health training for laboratory personnel, along with monthly reports on occupational injuries to ensure a safe and healthy working environment for employees. In the fiscal year 2024, fire safety and labor safety educational training sessions were conducted, totaling 3.5 hours. 3. In compliance with legal requirements, this Company participates in labor insurance, national health insurance, and group insurance, and conducts regular health check-ups for employees to promote their well-being. 4. This Company has established an Employee Welfare Committee to organize various welfare activities, including employee travel, aimed at promoting physical and mental well-being and strengthening the bonds among colleagues. Family members are also invited to participate, allowing 	No significant differences.

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>them to further experience the vitality of the Company's team. Additionally, free annual health check-ups for employees are conducted regularly to maintain their physical and mental health.</p> <p>5. This Company holds quarterly labor-management meetings to provide a communication channel between the Company and its employees. Furthermore, the Chairman of the Board and the General Manager periodically convene employees to discuss the Company's operational status and future direction.</p>	
(4) Does the Company establish an effective career development training plan for its employees?	V		<p>In alignment with the Company's objectives, training courses will be conducted periodically to enhance the knowledge of employees, managers, and directors. Additionally, external training will be provided to improve the professional capabilities of employees, managers, and directors. The succession planning for the members of the Company's board of directors and key management is outlined as follows:</p> <p>1. Regarding the members of the board of directors:</p> <p>(1) The appointment of directors of this Company shall be conducted in accordance with the director election procedures, unless otherwise stipulated by legislation or the Articles of Association, taking into account the overall composition and diversity of the board of directors, and adjusting the composition of members in a timely manner based on the results of performance evaluations. In the succession planning, the successor must meet the company's required standards</p>	No significant differences.

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>and possess the capability to fulfill the responsibilities.</p> <p>(2) Among the attendees of the board of directors of this company, General Manager Ching-Ting Chen meets the criteria for board membership and has therefore served as a director since November 2021.</p> <p>(3) All members of the board of directors of this company are professionals from the industry-academia sector, possessing practical experience in managing publicly listed companies or holding management positions in government agencies. They are equipped with leadership decision-making skills, crisis management capabilities, and insights into the international market, ensuring a smooth succession process.</p> <p>2. Important Management Team Section:</p> <p>(1) The Company's succession plan for key management emphasizes the cultivation of a talent pool, the identification of high-potential employees, and the establishment of a comprehensive training and education system along with promotion pathways, thereby providing continuous improvement and development opportunities to meet the future succession needs of key management.</p> <p>(2) The Company encourages employees to enhance their skills; in addition to internal training, they may also participate in external training to improve their professional competencies.</p> <p>(3) The Company's management team is organized hierarchically, with senior</p>	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
			<p>and middle-level supervisors in each department. All employees have completed job descriptions and designated successors, who receive training and development. Additionally, key talent rotation will be implemented in accordance with the development strategy to facilitate talent succession. Moreover, employee performance evaluations will be conducted biannually, with the assessment criteria for Assistant Managers and above being:</p> <ul style="list-style-type: none"> A. Department performance achievement rate (30 points) B. Annual goal plan/execution (30 points) C. Decision-making and problem-solving abilities (20 points) D. Innovation and reform capabilities (10 points) E. Leadership and empowerment in the utilization of subordinate human resources (10 points) <p>(4) Concerning the succession of the General Manager, senior management can identify areas for improvement and personal expectations through the aforementioned performance evaluations, and the assessment results will serve as a reference for the General Manager's succession plan. In recent years, this Company has appointed Lai Bo-Hong as Vice President as part of the succession planning for the Senior Management Team (General Manager candidates) at MBI Company.</p>	
(5) Regarding issues related to customer health and safety, client privacy,	V		This Company has established a customer service unit and a dedicated hotline, staffed with specialized personnel to	

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
marketing, and product labeling, does the Company comply with relevant regulations and international standards, and have policies and complaint procedures in place to protect consumer or client rights?			address related issues. The Company will comply with relevant regulations and international standards in the marketing and labeling of its products and services. This Company is an ISO-certified enterprise and has implemented supplier evaluation and management policies. It adheres to relevant regulations concerning environmental protection, safety, and hygiene, and is dedicated to enhancing corporate social responsibility.	
(6) Has the Company established a supplier management policy that mandates suppliers to comply with relevant regulations on environmental protection, occupational safety and health, or labor rights, and what is the status of its implementation?	V		<p>This Company establishes partnerships with Suppliers based on the principle of mutual benefit, creating a stable Supply Chain, ensuring thorough communication, and fostering win-win situations. In addition to the quality of the Products procured, greater emphasis is placed on the social responsibility of Suppliers. In September 2019, the Supplier Social Responsibility Guidelines were approved, with the following requirements:</p> <ol style="list-style-type: none"> 1. Supplier Implementation Strategy <ol style="list-style-type: none"> (1) This Company emphasizes collaboration with Suppliers and, when necessary, employs interviews, questionnaires, and Training and Education to understand Suppliers' awareness and execution of social responsibility. (2) Taking into account the legal regulations of the Supplier's location, the characteristics of the Industry, the geographical environment, operational conditions, employee structure, and organizational scale, we encourage a collective commitment to practicing social responsibility. (3) When This Company enters into contracts with major Suppliers, the contract may include provisions for compliance with both parties' Corporate Social Responsibility 	

Item	Operational Situation		Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	
			<p>Policy. Should a Supplier violate the policy and cause significant impacts on the environment and society of the sourcing community, the Supplier must submit a remediation plan. If remediation is not feasible or the situation is severe, provisions for termination or dissolution of the contract may be included.</p> <p>2. This Company shall consider the following labor issues when selecting suppliers:</p> <ol style="list-style-type: none"> (1) Prohibition of child labor. (2) Prohibition of forced labor. (3) Working hours and compensation must comply with local legal regulations. (4) Prohibition of any form of discrimination. (5) Respect for freedom of association and collective bargaining. (6) Establishment of regulations related to health and safety matters. <p>3. Labor Health and Safety Suppliers shall commit to complying with labor safety and health regulations and other relevant legal provisions, and agree to unconditionally adhere to the safety, health, and environmental management measures established by this Company.</p> <p>4. Environmental Conservation</p> <ol style="list-style-type: none"> (1) This Company should evaluate the impact of procurement activities on the environment and society of the sourcing communities, and encourage Suppliers to collectively commit to implementing Corporate Social Responsibility. (2) Suppliers should endeavor to reduce or eliminate various forms of Waste, including water and energy. Suppliers may implement energy-saving measures in equipment, maintenance, or production

Item	Operational Situation		Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	
			<p>processes, or achieve energy efficiency through recycling, reuse, or alternative materials.</p> <p>(3) Suppliers should commit to minimizing emissions of pollutants, toxic substances, and Waste, and should ensure proper management of Waste. The management of waste must comply with relevant regulations to minimize the impact on the natural environment.</p> <p>5. Ethical Standards for Integrity Management</p> <p>(1) This Company shall adhere to the Integrity Management Code and the guidelines for integrity management. When selecting suppliers, the ethical standards of vendors must be considered, including but not limited to integrity in operations, fair trade, transparency of information, avoidance of unlawful gains and false advertising, as well as compliance with intellectual property regulations.</p> <p>(2) When entering into contracts with suppliers, both parties shall adhere to the principles of Integrity Management and conduct transactions in an open and transparent manner. If one party engages in Dishonest Conduct that is significant enough to render this contract unperformable, the other party may terminate or rescind the contract at any time.</p> <p>(3) In 2020, a total of 8 social responsibility commitment letters were requested from new trading suppliers. Starting in 2021, it is planned to incorporate social responsibility clauses into contracts with key suppliers and to conduct self-assessments of corporate social responsibility execution by suppliers.</p>

Item	Operational Situation			Differences from and Reasons for Deviations from the Corporate Sustainability Best Practice Principles for TWSE/TPEX Listed Companies
	Yes	No	Summary Explanation	
5. Does the Company refer to internationally recognized reporting standards or guidelines when preparing sustainability reports and other disclosures of non-financial information? Has the aforementioned report received assurance or verification opinions from a third-party verification entity?		V	This Company has been preparing sustainability reports and other disclosures of non-financial information in accordance with internationally recognized reporting standards or guidelines since 2024, and has obtained a limited assurance report from PwC.	No significant differences.
6. the Company has established its own sustainability development code in accordance with the 'Practical Guidelines for Sustainable Development of Listed Companies,' please describe the operation and any differences from the established code: A Corporate Social Responsibility Policy has been formulated and implemented sequentially, with no differences.				
7. Other important information that aids in understanding the implementation of sustainable development: This Company utilizes beef tendon extract collagen and Hyaluronic Acid as raw materials to manufacture related products, and there are no violations of applicable environmental protection regulations.				

3.6 Climate-related information for TWSE/TPEX Listed Companies:

(1) Status of climate-related information implementation

Item	Implementation status
<p>1. Describe the oversight and governance of the board of directors and the management team concerning climate-related risks and opportunities.</p>	<p>To address the climate-related risks and opportunities, as well as the high uncertainty and rapid changes in policies and markets, this Company convenes senior executives from various departments annually to identify significant climate risks and opportunities, thereby addressing the potential impacts arising from climate change and timely assessing and estimating the possible effects of climate change. Simultaneously, we further assess the risks that floods, droughts, typhoons, and high temperatures may pose to the Company, with the aim of understanding the climate changes in the external environment and market dynamics, thereby comprehensively considering the overall operational strategy planning.</p> <p>The board of directors has established a 'Risk Management Committee,' authorized to consist of five members with expertise and capabilities in corporate sustainability. This committee convenes annually and is responsible for formulating, promoting, and strengthening the Company's important policy action plans and capital expenditures related to sustainable development (including climate-related issues), as well as reviewing, tracking, and revising the implementation and effectiveness of sustainable development and risk management, and reporting to the board of directors. The Committee also has a Risk Management Team responsible for managing the promotion of policies and procedures, reporting, assisting and supervising, coordinating and communicating. This team is comprised of several supervisors from various fields to advance the Company's sustainable development plan, which encompasses issues related to climate-related risks, the latest legal regulations concerning industry climate risks, and updates on the identification results of climate risks and opportunities.</p> <p>Additionally, other functional committees are responsible for the governance of certain climate-related issues, including:</p> <p>The Audit Committee convenes quarterly to discuss relevant matters and regularly receives reports from the Audit Supervisor regarding the effectiveness of the design and implementation of the Internal Control System for climate-related risks conducted by the Internal Audit Department, as well as findings from the audits.</p>
<p>2. The impact of identified climate risks and opportunities on the Enterprise's Business, Strategy, and Finance (short-term, medium-term, long-term).</p>	<p>The Company actively develops solutions, assessing climate risks and opportunities across short-term, medium-term, and long-term horizons, and implements measures to enhance resilience in response to climate change, ensuring stable operations and sustainable development.</p>

Item	Implementation status			
	Risk Factors/ Opportunities	Financial and Business Impact	Timeframe (Short-term, Medium-term, Long-term)	Response Strategies
	The increase in extreme climate events	Extreme weather events, such as typhoons and floods, may disrupt the supply chain, affecting the supply of raw materials and production operations, which could lead to a decrease in sales revenue and an increase in operating costs.	Short-term Medium-term Long-term	<ol style="list-style-type: none"> 1. Establish a diversified supply chain to reduce reliance on a single supplier. 2. Develop an emergency response plan and a disaster response plan. 3. Invest in green energy equipment.
	Changes in regulations and policies	Changes in regulatory requirements, such as carbon emissions restrictions and energy efficiency standards, result in increased compliance costs and impact production and operations.	Short-term Medium-term	<ol style="list-style-type: none"> 1. Continuously monitor and assess regulatory changes to proactively adjust the company's strategy. 2. Enhance the efficiency of products and production processes.
	Transformation risk.	The market demand for environmentally friendly products is increasing, which may impact the sales of traditional products in the future, thereby affecting the company's finances and market competitiveness.	Short-term Medium-term Long-term	<ol style="list-style-type: none"> 1. Strengthen research and development investments to enhance technological innovation capabilities. 2. Continuously monitor and synchronize market demand and trends to swiftly adjust market strategies. 3. Expand the product line by developing and promoting environmentally friendly products.
	Risk Factors/ Opportunities	Financial and Business Impact	Timeframe (Short-term, Medium-term, Long-term)	Response Strategies
	Resource Scarcity.	Climate change may result in the scarcity of certain resources, such as water resources, which can affect production and operational costs, thereby increasing financial pressure.	Short-term: Medium-term: Long-term	<ol style="list-style-type: none"> 1. Implement water-saving measures and optimize water management practices. 2. Pursue renewable energy sources (such as solar energy), acquire energy-efficient equipment, and foster technological innovation. 3. Strengthen environmental awareness and resource protection by adopting an Environmental Management System to monitor energy usage.

Item	Implementation status
<p>3. Articulate the financial impacts of extreme climate events and transformation actions.</p>	<p>This Company's strategy for addressing the financial impacts of extreme climate events and transformation actions is as follows:</p> <ol style="list-style-type: none"> 1. Strengthening the Supply Chain: Establishing a diversified Supply Chain Management system to reduce reliance on a single Supplier, thereby mitigating supply disruptions caused by extreme climate events. Additionally, we will establish an emergency response plan and disaster response plan to ensure the continuity of Production and the Supply Chain, thereby reducing the risk of increased Production costs. 2. Advance Planning: We will continuously monitor and assess changes in climate-related regulations and Policies, proactively implementing technological transformation and Equipment Upgrades to ensure compliance. By introducing clean energy and enhancing energy efficiency, we aim to reduce long-term compliance costs while minimizing our impact on the environment. 3. Enhancing infrastructure: Upgrading infrastructure to withstand the impacts of extreme climate events. For instance, establishing backup power and water supply systems to ensure the stability of production operations and mitigate financial losses caused by disasters. 4. Strengthening resource management and conservation: In response to resource scarcity issues, the Company has implemented energy-saving measures and optimized the production process to improve resource utilization efficiency, thereby reducing the impact of resource shortages on production and costs. Furthermore, we promote recycling and reuse to decrease our reliance on natural resources. 5. Employee Training and Awareness Enhancement: Strengthening employee training on climate change and environmental protection to enhance overall environmental awareness and the capacity to respond to climate risks. Encouraging the participation of all employees in energy conservation, emission reduction, and environmental protection through internal education and training.
<p>4. Explaining how the processes of identifying, assessing, and managing climate risks are integrated into the overall risk management system.</p>	<ol style="list-style-type: none"> 1. As mentioned in the first point, this Company is responsible for promoting, reporting, assisting, and supervising risk management through the Risk Management Team in the Office of the General Manager, with multiple center supervisors collaboratively advancing the sustainable development plan. The Risk Management Team functions as a cross-departmental communication platform to identify sustainability issues, develop strategies and policies, and implement annual plans. It monitors performance to ensure the effective execution of strategies. Furthermore, in the fiscal year 111, the Risk Management Committee was established to review the Risk Management Policy in accordance with regulations. The Risk Management Team provides regular progress reports to the board of directors at the end of each fiscal year, oversees the plan, and makes timely adjustments. In the past two years, the Risk Management Committee met on December 18, 2023, and December 19, 2024.

Item	Implementation status												
	<p data-bbox="689 212 2058 284">2. The climate risk management process of this Company is primarily divided into five major steps: risk identification, risk measurement, risk monitoring, risk reporting, and risk response, which are detailed as follows:</p> <table border="1" data-bbox="696 296 2051 1166"> <thead> <tr> <th data-bbox="707 304 909 379">Management Process</th> <th data-bbox="909 304 2040 379">Content</th> </tr> </thead> <tbody> <tr> <td data-bbox="707 387 909 547">Risk Identification</td> <td data-bbox="909 387 2040 547">This Company conducts risk identification and assessment related to its operations based on the principle of materiality, encompassing economic (including corporate governance), environmental, social, and other dimensions. The types of risks include market risk, operational risk, environmental risk, and human resources risk.</td> </tr> <tr> <td data-bbox="707 555 909 786">Risk Measurement</td> <td data-bbox="909 555 2040 786">This Company and its Subsidiaries, after identifying the potential risks they may encounter, should establish appropriate measurement methods to serve as the foundation for Risk Management. Risk Measurement encompasses the analysis and assessment of risks, which involves evaluating the likelihood and impact of risk events to determine their effects on the Company, thereby serving as a reference for prioritizing Risk Control and selecting response measures.</td> </tr> <tr> <td data-bbox="707 794 909 914">Risk Monitoring.</td> <td data-bbox="909 794 2040 914">This Company should monitor the risks associated with its Business, and the Department should propose countermeasures, providing both the risks and the proposed countermeasures to the Risk Management Team.</td> </tr> <tr> <td data-bbox="707 922 909 1042">Risk Report</td> <td data-bbox="909 922 2040 1042">The Risk Management Team shall regularly adjust control mechanisms in response to changes in the internal and external operational environment, consolidate the risk status from various units, and provide regular reports to the Risk Management Committee and the board of directors.</td> </tr> <tr> <td data-bbox="707 1050 909 1161">Risk Response</td> <td data-bbox="909 1050 2040 1161">Following the assessment and consolidation of risks, the various units and subsidiaries of this Company shall implement four measures to address the risks they encounter: risk avoidance, risk reduction, risk sharing, and risk acceptance.</td> </tr> </tbody> </table>	Management Process	Content	Risk Identification	This Company conducts risk identification and assessment related to its operations based on the principle of materiality, encompassing economic (including corporate governance), environmental, social, and other dimensions. The types of risks include market risk, operational risk, environmental risk, and human resources risk.	Risk Measurement	This Company and its Subsidiaries, after identifying the potential risks they may encounter, should establish appropriate measurement methods to serve as the foundation for Risk Management. Risk Measurement encompasses the analysis and assessment of risks, which involves evaluating the likelihood and impact of risk events to determine their effects on the Company, thereby serving as a reference for prioritizing Risk Control and selecting response measures.	Risk Monitoring.	This Company should monitor the risks associated with its Business, and the Department should propose countermeasures, providing both the risks and the proposed countermeasures to the Risk Management Team.	Risk Report	The Risk Management Team shall regularly adjust control mechanisms in response to changes in the internal and external operational environment, consolidate the risk status from various units, and provide regular reports to the Risk Management Committee and the board of directors.	Risk Response	Following the assessment and consolidation of risks, the various units and subsidiaries of this Company shall implement four measures to address the risks they encounter: risk avoidance, risk reduction, risk sharing, and risk acceptance.
Management Process	Content												
Risk Identification	This Company conducts risk identification and assessment related to its operations based on the principle of materiality, encompassing economic (including corporate governance), environmental, social, and other dimensions. The types of risks include market risk, operational risk, environmental risk, and human resources risk.												
Risk Measurement	This Company and its Subsidiaries, after identifying the potential risks they may encounter, should establish appropriate measurement methods to serve as the foundation for Risk Management. Risk Measurement encompasses the analysis and assessment of risks, which involves evaluating the likelihood and impact of risk events to determine their effects on the Company, thereby serving as a reference for prioritizing Risk Control and selecting response measures.												
Risk Monitoring.	This Company should monitor the risks associated with its Business, and the Department should propose countermeasures, providing both the risks and the proposed countermeasures to the Risk Management Team.												
Risk Report	The Risk Management Team shall regularly adjust control mechanisms in response to changes in the internal and external operational environment, consolidate the risk status from various units, and provide regular reports to the Risk Management Committee and the board of directors.												
Risk Response	Following the assessment and consolidation of risks, the various units and subsidiaries of this Company shall implement four measures to address the risks they encounter: risk avoidance, risk reduction, risk sharing, and risk acceptance.												
<p data-bbox="163 1198 667 1423">5. When employing scenario analysis to evaluate resilience against climate change risks, the scenarios, parameters, assumptions, analytical factors, and significant financial impacts utilized must be clearly articulated.</p>	<p data-bbox="689 1198 2058 1305">As of the publication date of this Annual Report, this Company has not yet employed scenario analysis to assess resilience against climate change risks. Should such analyses be utilized in the future, they will be disclosed in the Annual Report.</p>												

Item	Implementation status																								
<p>6. If there are any transformation plans to address climate-related risks, please provide a description of the plan's content, along with the indicators and targets used to identify and manage physical risks and transition risks.</p>	<p>In relation to the transformation plans for managing climate-related risks, this Company has established the following plan content, as well as the indicators and targets for identifying and managing physical risks and transition risks:</p> <p>1. Plan Content:</p> <table border="1" data-bbox="719 384 2056 935"> <thead> <tr> <th data-bbox="719 384 967 435">Item</th> <th data-bbox="967 384 1420 435">Content</th> <th data-bbox="1420 384 2056 435">Implementation Steps</th> </tr> </thead> <tbody> <tr> <td data-bbox="719 435 967 683">Carbon Reduction Plan:</td> <td data-bbox="967 435 1420 683">The Company will gradually reduce carbon emissions, promote low-carbon production technologies and processes, introduce clean energy, and enhance energy efficiency.</td> <td data-bbox="1420 435 2056 683"> <ol style="list-style-type: none"> 1. Assess the current production processes and energy usage. 2. Establish carbon reduction targets and select appropriate low-carbon equipment. 3. Implement technological transformation and equipment upgrades in phases. </td> </tr> <tr> <td data-bbox="719 683 967 935">Resource Management Plan:</td> <td data-bbox="967 683 1420 935">This Company will optimize resource management, promote energy-saving and water resource management plans, and implement a circular economy model.</td> <td data-bbox="1420 683 2056 935"> <ol style="list-style-type: none"> 1. Review the current resource usage and identify opportunities for optimization. 2. Establish energy-saving and water-saving targets to promote resource reuse. 3. Introduce resource management technology to enhance resource utilization efficiency. </td> </tr> </tbody> </table> <p>2. Indicators and Targets:</p> <table border="1" data-bbox="719 999 2056 1406"> <thead> <tr> <th data-bbox="719 999 967 1050">Item</th> <th data-bbox="967 999 1532 1050">Indicators</th> <th data-bbox="1532 999 2056 1050">Targets</th> </tr> </thead> <tbody> <tr> <td data-bbox="719 1050 967 1137">Carbon Emissions:</td> <td data-bbox="967 1050 1532 1137">Annual Carbon Emissions (tons):</td> <td data-bbox="1532 1050 2056 1137">Aim to reduce carbon emissions by 1% each year.</td> </tr> <tr> <td data-bbox="719 1137 967 1230">Energy Use Efficiency:</td> <td data-bbox="967 1137 1532 1230">Energy consumption per unit product (kilowatt-hours/product):</td> <td data-bbox="1532 1137 2056 1230">Aim to increase energy use efficiency by 2% each year.</td> </tr> <tr> <td data-bbox="719 1230 967 1318">R&D Investment Ratio:</td> <td data-bbox="967 1230 1532 1318">Proportion of annual R&D investment to total revenue (%):</td> <td data-bbox="1532 1230 2056 1318">Annual R&D investment constitutes 15% of total revenue.</td> </tr> <tr> <td data-bbox="719 1318 967 1406">Employee Training Participation Rate</td> <td data-bbox="967 1318 1532 1406">Percentage of Employees Participating in Climate Change Training and Education (%)</td> <td data-bbox="1532 1318 2056 1406">Ensure that 90% of employees participate in relevant training and education each year.</td> </tr> </tbody> </table>	Item	Content	Implementation Steps	Carbon Reduction Plan:	The Company will gradually reduce carbon emissions, promote low-carbon production technologies and processes, introduce clean energy, and enhance energy efficiency.	<ol style="list-style-type: none"> 1. Assess the current production processes and energy usage. 2. Establish carbon reduction targets and select appropriate low-carbon equipment. 3. Implement technological transformation and equipment upgrades in phases. 	Resource Management Plan:	This Company will optimize resource management, promote energy-saving and water resource management plans, and implement a circular economy model.	<ol style="list-style-type: none"> 1. Review the current resource usage and identify opportunities for optimization. 2. Establish energy-saving and water-saving targets to promote resource reuse. 3. Introduce resource management technology to enhance resource utilization efficiency. 	Item	Indicators	Targets	Carbon Emissions:	Annual Carbon Emissions (tons):	Aim to reduce carbon emissions by 1% each year.	Energy Use Efficiency:	Energy consumption per unit product (kilowatt-hours/product):	Aim to increase energy use efficiency by 2% each year.	R&D Investment Ratio:	Proportion of annual R&D investment to total revenue (%):	Annual R&D investment constitutes 15% of total revenue.	Employee Training Participation Rate	Percentage of Employees Participating in Climate Change Training and Education (%)	Ensure that 90% of employees participate in relevant training and education each year.
Item	Content	Implementation Steps																							
Carbon Reduction Plan:	The Company will gradually reduce carbon emissions, promote low-carbon production technologies and processes, introduce clean energy, and enhance energy efficiency.	<ol style="list-style-type: none"> 1. Assess the current production processes and energy usage. 2. Establish carbon reduction targets and select appropriate low-carbon equipment. 3. Implement technological transformation and equipment upgrades in phases. 																							
Resource Management Plan:	This Company will optimize resource management, promote energy-saving and water resource management plans, and implement a circular economy model.	<ol style="list-style-type: none"> 1. Review the current resource usage and identify opportunities for optimization. 2. Establish energy-saving and water-saving targets to promote resource reuse. 3. Introduce resource management technology to enhance resource utilization efficiency. 																							
Item	Indicators	Targets																							
Carbon Emissions:	Annual Carbon Emissions (tons):	Aim to reduce carbon emissions by 1% each year.																							
Energy Use Efficiency:	Energy consumption per unit product (kilowatt-hours/product):	Aim to increase energy use efficiency by 2% each year.																							
R&D Investment Ratio:	Proportion of annual R&D investment to total revenue (%):	Annual R&D investment constitutes 15% of total revenue.																							
Employee Training Participation Rate	Percentage of Employees Participating in Climate Change Training and Education (%)	Ensure that 90% of employees participate in relevant training and education each year.																							

Item	Implementation status
7. If internal carbon pricing is utilized as a planning tool, the basis for price determination should be clearly explained.	The Company commenced its assessment of greenhouse gas emissions in the fiscal year 2021. Following the carbon assessment, it identified emission sources and implemented mechanisms to reduce these sources and lower emissions, including workflow improvements, equipment upgrades, and the replacement of all company lighting with LED fixtures. The Company continues to monitor relevant carbon pricing mechanisms in the countries where its subsidiaries are located, evaluating the benefits of promoting internal carbon pricing, and subsequently planning and implementing strategies.
8. If climate-related targets are established, the activities covered, the scope of greenhouse gas emissions, the planning timeline, and the annual progress achieved should be detailed; If carbon offsets or Renewable Energy Certificates (RECs) are utilized to meet relevant targets, the source and quantity of the offset carbon reductions or the number of Renewable Energy Certificates (RECs) should be specified.	This Company established climate risk-related targets at the beginning of 2024 and is committed to enhancing its efforts to achieve these targets. Future updates regarding the implementation of climate-related targets will be disclosed in the Annual Report or on the Company's official website.
9. Greenhouse gas inventory and verification status, reduction targets, strategies, and specific action plans.	As of the publication date of this Annual Report, this Company presents the inventory results for the fiscal years 2023 and 2024, as shown in the table below.

(2) Greenhouse gas inventory & assurance

Basic information of the Company <input type="checkbox"/> Capitalization of over NT\$10 billion, steel industry, cement industry <input type="checkbox"/> Capitalization of over NT\$5 billion but less than NT\$10 billion. <input checked="" type="checkbox"/> Capitalization less than NT\$5,000 million		According to the sustainable development roadmap of listed companies, at least the following shall be disclosed <input checked="" type="checkbox"/> Parent company's individual inventory <input type="checkbox"/> Consolidated financial report subsidiary's inventory <input checked="" type="checkbox"/> Parent company's individual assurance <input type="checkbox"/> Consolidated financial reporting subsidiaries' assurance	
Scope of Assurance Execution		2023	2024
MBI	Scope 1 Direct greenhouse gas emissions	130.7379	142.4941
	Scope 2 Indirect greenhouse gas emissions	1945.0756	1940.8272
	Total	2075.8135	2083.3213
Assurance institution			TUV NORD Taiwan Co., Ltd.
Statement of assurance			ISO 14064-3:2018 Reasonable Assurance
Assurance opinion/conclusion			None

3.7 Ethical Corporate Management Implementation and Deviations from TWSE/TPEX Best Practices with Explanations:

Item	Operational Situation			Deviations from the Ethical Corporate Management Principles for TWSE/TPEX Listed Companies and Explanations
	Yes	No	Summary Explanation	
<p>1. Establishment of Integrity Management Policies and Programs</p> <p>(1) Has the Company established an Integrity Management Policy approved by the board of directors, and is this policy clearly articulated in the regulations and external documents, along with the commitment of the board of directors and the Senior Management Team to actively implement the management policy?</p> <p>(2) Has the Company established a risk assessment mechanism for dishonest conduct, regularly analyzing and evaluating operating activities within its scope that present a higher risk of dishonest conduct, and based on this, formulated an Anti-Dishonest Conduct Program that includes preventive measures for the behaviors specified in Article 7, Paragraph 2 of the Integrity Management Code for Listed Companies?</p> <p>(3) Does the Company clearly define operational procedures, behavioral guidelines, penalties for violations, and a complaint system within the Anti-</p>	V		<p>(1) The Company has established the 'Integrity Management Operational Guidelines' and the 'Integrity Management Operational Procedures and Conduct Guidelines,' as well as the Employee Code of Conduct, to explicitly articulate the policy of Integrity Management. It is clearly stipulated that employees shall not exploit their authority for illegal benefits, accept hospitality, gifts, or kickbacks, misappropriate public funds, or engage in any other illegal benefits, with the aim of eliminating dishonest behavior that could adversely affect business relationships or transactions.</p> <p>(2) The Company has established the 'Integrity Management Operational Guidelines' and the 'Integrity Management Operational Procedures and Conduct Guidelines,' along with the Employee Code of Conduct, to regulate the code of conduct for employees and to provide training for new employees in accordance with the regulations. Additionally, a risk prevention operational process has been established, with regular reports on the status of implementation.</p> <p>(3) To prevent dishonest conduct, the Company has established the 'Integrity Management Operational Guidelines' and the 'Integrity Management Operational Procedures and Conduct Guidelines,' which clearly outline the</p>	No significant differences.

Item	Operational Situation			Deviations from the Ethical Corporate Management Principles for TWSE/TPEX Listed Companies and Explanations
	Yes	No	Summary Explanation	
Dishonest Conduct Program, ensure its implementation, and regularly review and amend the aforementioned program?			ethical standards that employees must follow when engaging in any operating activities.	
2. Implementation of Integrity Management (1) Does the Company evaluate the integrity records of its business partners and explicitly include integrity conduct clauses in the contracts signed with them?	V		(1) Prior to engaging in formal transactions with business partners, the Company conducts various assessments, including those related to Dishonest Conduct, to avoid transactions with individuals or entities that have a record of such conduct. Relevant contracts have incorporated Integrity Management.	There is no significant difference.
(2) Has the Company established a dedicated (or part-time) unit under the board of directors to promote corporate integrity management, and does it provide regular reports (at least once a year) to the board of directors regarding its integrity management policies and the implementation of the anti-dishonest conduct program?	V		(2) This Company promotes Integrity Management under the auspices of the Office of the General Manager, with the primary members being the supervisors of the business units. The Company has established the 'Integrity Management Operational Guidelines' and the 'Integrity Management Operational Procedures and Conduct Guidelines.' Furthermore, on March 22, 2023, the board of directors amended the 'Integrity Management Operational Guidelines' and the 'Integrity Management Operational Procedures and Conduct Guidelines' to provide a more solid foundation for the implementation of Integrity Management. This Company reports annually to the board of directors on the status of Integrity Management implementation, starting from the fiscal year 108.	
(3) Has the Company established a policy to prevent conflicts of interest, provided appropriate channels for disclosure, and effectively implemented it?	V		(3) The Company provides various channels for employees to submit information at any time, which will be compiled by designated personnel and reported regularly on operational status.	

Item	Operational Situation			Deviations from the Ethical Corporate Management Principles for TWSE/TPEX Listed Companies and Explanations
	Yes	No	Summary Explanation	
(4) Has the Company established an effective accounting system and internal control system to implement integrity management, and has the internal audit unit developed relevant audit plans based on the assessment results of dishonest conduct risks to verify compliance with the anti-dishonest conduct program, or engaged an accountant to conduct the audit?	V		(4) This Company requires employees to strictly comply with the Company Act, Securities Trading Act, Political Donations Act, Anti-Corruption Act, Government Procurement Act, and relevant internal regulations regarding audits and internal controls that employees must adhere to, as well as to follow the Company's 'Integrity Management Operational Guidelines' and 'Integrity Management Operational Procedures and Conduct Guidelines' as the foundation for implementing Integrity Management.	
(5) Does the Company regularly conduct training and education on integrity management for both internal and external stakeholders?	V		(5) This Company conducts both internal and external training and education programs related to Integrity Management and associated activities. <ol style="list-style-type: none"> 1. In 2022, newly appointed directors and incumbent managers signed a total of 10 copies of the 'Integrity Management Declaration.' 2. On December 13, 2024, the Company requested the Management and Sustainable Development Association to conduct annual training for directors and managers on the 'Gender Equality Work Act and Practical Measures for the Prevention of Sexual Harassment, Development of Artificial Intelligence, and International Governance Trends,' with a total of 8 participants, each receiving 6 hours of training. 3. On October 24, 2024, a physical course was conducted to prevent Insider Trading; The 113th year of the trade secrets protection course provides employees with a comprehensive understanding of legal compliance, emphasizing the importance of corporate integrity. 	

Item	Operational Situation			Deviations from the Ethical Corporate Management Principles for TWSE/TPEX Listed Companies and Explanations
	Yes	No	Summary Explanation	
<p>3. The operational status of the company's reporting system.</p> <p>(1) Has the company established a specific reporting and reward system, created convenient reporting channels, and assigned appropriate personnel to handle reported cases?</p> <p>(2) Has the company established standard operating procedures for investigating reported matters, determined subsequent measures to be taken after the investigation is completed, and implemented relevant confidentiality mechanisms?</p> <p>(3) Does the Company implement measures to protect whistleblowers from improper treatment as a result of their reporting?</p>	V		<p>(1) The Company provides a reporting mailbox along with related disciplinary measures for violations, and conducts regular reviews and revisions.</p> <p>(2) This Company has clearly defined operational procedures in its 'Handling Procedures for Reporting Illegal, Unethical, or Dishonest Conduct,' ensuring confidentiality for all parties involved.</p> <p>(3) The Company adopts an open approach to encourage Employees to report improper conduct, which may also be done anonymously through a designated mailbox to protect the whistleblower.</p>	No significant differences.
<p>4. Strengthening Information Disclosure</p> <p>Does the Company disclose the contents and implementation results of its Integrity Management Code on its website and the Public Information Observatory?</p>	V		<p>(1) A website has been established, and there are active plans to include information regarding financial operations and corporate governance on the website.</p> <p>(2) The Company has designated personnel responsible for the collection of disclosed information and has implemented a Spokesperson System.</p>	No significant differences.
<p>5. If the Company has its own Integrity Management Code in accordance with the 'Integrity Management Code for Listed Companies,' please describe the differences between its operation and the established code:</p> <p>The Company has established its own Integrity Management Code in accordance with the 'Integrity Management Code for Listed Companies' and informs all employees during training and education sessions.</p> <p>Integrity in Operations: (1) Avoid conflicts of interest arising from personal work interactions with suppliers, customers, and others. (2) Unlawful Gains: (1) All employees are prohibited from obtaining benefits through improper means. (2) Any form of bribery is strictly prohibited. (3) All employees must report to the highest supervisor of their department for approval before accepting gifts or hospitality.</p>				

Item	Operational Situation			Deviations from the Ethical Corporate Management Principles for TWSE/TPEX Listed Companies and Explanations
	Yes	No	Summary Explanation	
6. Other important information that aids in understanding the Company's Integrity Management Operational Situation (such as the Company's review and revision of the Integrity Management Code established by the Company): This Company continuously monitors the development of domestic and international regulations related to Integrity Management and, accordingly, reviews and improves the Company's Integrity Management Policy to enhance the effectiveness of Integrity Management.				

3.8 Other important information that can enhance the understanding of the Company's corporate governance operations may be disclosed together: This Company continues to strengthen its corporate governance operations, and the Company's official website (<https://mbi-bio.com/zh-hant/governance/>) features a dedicated section for corporate governance, explaining the operational situation of corporate governance.

3.9 Status of Implementation of the Internal Control System.

- (1) For the Internal Control System Declaration, please refer to the Public Information Observatory > Single Company > Corporate Governance > Company Regulations/Internal Control > Announcement of the Internal Control Declaration. <https://mops.twse.com.tw/mops/#/web/t06sg20>
- (2) For projects entrusted to accountants for the review of the Internal Control System, the accountant's review report should be disclosed: None.

3.10 Important Resolutions of the Shareholders' Meeting and the Board of Directors for the most recent fiscal year and up to the date of the Annual Report publication.

(1) Review of important resolutions of the Shareholders' Meeting and their implementation status.

Meeting Category	Meeting Date	Important Resolutions	Resolution Result	Implementation status
Annual General Meeting of Shareholders	2024.6.13	1. Approval of the Fiscal Year 2023 Business Report and Financial Statements.	The resolution was passed unanimously after consultation with all attending Shareholders by the Chairman.	Not applicable.
		2. Approval of the Fiscal Year 2023 Earnings Distribution.		July 29, 2024, is the record date for distribution, and August 16, 2024, is the Distribution Date. A Cash Dividend of NT\$1 per share was distributed.
		3. Approval of the amendment to the Company's Articles of Incorporation.		The amendment has been processed in accordance with the revised procedures.
		4. Approval of the re-election of directors.		Registered and announced by the Ministry of Economic Affairs on July 8, 2024.
		5. Approval of the resolution to lift the non-compete restrictions on the newly appointed directors and their representatives.		Related significant information was released following the approval at the shareholders' meeting on June 13, 2024.

(2) Important resolutions of the board of directors for the most recent fiscal year and up to the date of the annual report printing.

Meeting Date.	Category	Significant resolutions passed by the board of directors.
1 st meeting of 2024 2024.03.12	Board of Directors	<p>Proposal 1: This Company's Internal Control System Declaration for Fiscal Year 2023.</p> <p>Proposal 2: This Company's Business Report and Financial Statements for Fiscal Year 2023.</p> <p>Proposal 3: Explanation of the distribution of employee compensation for the fourth quarter of the Company's 2022 fiscal year.</p> <p>Proposal 4: Proposal for the allocation of director compensation and employee compensation for Fiscal Year 2023.</p> <p>Proposal 5: Proposal for the adjustment of salary compensation for the Company's managers.</p> <p>Proposal 6: Proposal for the compensation of the Certified Public Accountant for Fiscal Year 2024.</p> <p>Proposal 7: Proposal to establish the Capital Increase Record Date.</p> <p>Proposal 8: Proposal to appoint the Company's Representative in accordance with Article 223 of the Company Act, as recommended by the Audit Committee.</p> <p>Proposal 9: Proposal to amend the Company's Articles of Incorporation.</p> <p>Proposal 10: Proposal for the comprehensive re-election of the Company's directors at the 2024 Annual General Meeting of Shareholders.</p>

Meeting Date.	Category	Significant resolutions passed by the board of directors.
		<p>Proposal 11: Proposal for the Nomination of Candidates for Directors (including Independent Directors).</p> <p>Proposal 12: Proposal to Lift the Non-Compete Restrictions on Newly Appointed Directors and their Representatives.</p> <p>Proposal 13: Proposal to Determine the Date, Location, and Agenda for the 2024 Annual General Meeting of Shareholders.</p>
2 nd meeting of 2024 2024.05.03	Board of Directors	<p>Proposal 1: The Company's consolidated financial statements for the first quarter of 2024.</p> <p>Proposal 2: The Company's earnings distribution for Fiscal Year 2023.</p> <p>Proposal 3: Explanation of the Distribution of Employee Compensation for the First Quarter of Fiscal Year 2024.</p> <p>Proposal 4: Proposal to Amend Management Regulations, including the 'Audit Committee Organization Regulations' and 'Board of Directors Meeting Rules.'</p> <p>Proposal 5: Proposal to establish the Capital Increase Record Date.</p>
3 rd meeting of 2024 2024.07.29	Board of Directors	<p>Proposal 1: The Company's consolidated financial statements for the second quarter of 2024.</p> <p>Proposal 2: Explanation of the Distribution of Employee Compensation for Fiscal Year 2023.</p> <p>Proposal 3: Amendment to the Company's Internal Audit System and Implementation Rules.</p> <p>Proposal 4: Establishment of the Company's Sustainability Report Preparation and Verification Procedures.</p> <p>Proposal 5: Proposal for the Company's Fiscal Year 110 Private Placement of Common Stock to be Converted to a Public Offering and Application for Listing.</p>
4 th meeting of 2024 2024.11.07	Board of Directors	<p>Proposal 1: This Company's consolidated financial statements for the third quarter of 2024.</p> <p>Proposal 2: This Company has established the 'Sustainability Information Management Regulations' proposal.</p> <p>Proposal 3: This Company's amendment proposal for the 'Code of Corporate Governance Practices.'</p> <p>Proposal 4: This Company's amendment proposal for the 'Approval Authority Table.'</p> <p>Proposal 5: Proposal to establish the Capital Increase Record Date.</p> <p>Proposal 6: Explanation of the Company's Employee Compensation Distribution for Fiscal Year 2023.</p> <p>Proposal 7: Adjustment of Matters Related to Manager Salaries.</p>
5 th meeting of 2024 2024.12.19	Board of Directors	<p>Proposal 1: This Company's Fiscal Year 2025 Operations Plan and Budget Proposal.</p> <p>Proposal 2: Proposal to Establish This Company's Fiscal Year 2025 Audit Plan.</p> <p>Proposal 3: Assessment of the Independence and Competence of This Company's Certified Public Accountant.</p>

Meeting Date.	Category	Significant resolutions passed by the board of directors.
		<p>Proposal 4: Proposal to Apply for Financing Loan Limits from Financial Institutions.</p> <p>Proposal 5: Proposal to Establish the Company's Risk Management Plan for Fiscal Year 2025.</p> <p>Proposal 6: Matters Related to the Distribution of Year-End Bonuses for Managers in Fiscal Year 2024.</p>
1 st meeting of 2025 2025.02.26	Board of Directors	<p>Proposal 1: This Company's Business Report and Financial Statements for Fiscal Year 2024.</p> <p>Proposal 2: his Company's Internal Control System Declaration for Fiscal Year 2024.</p> <p>Proposal 3: Amendment to the Articles of Incorporation.</p> <p>Proposal 4: Amendment to the Procedures for Acquiring or Disposing of Assets.</p> <p>Proposal 5: Explanation of the Employee Compensation Distribution for Fiscal Year 2023.</p> <p>Proposal 6: Proposal for the Distribution of Director Compensation and Employee Compensation for Fiscal Year 2024.</p> <p>Proposal 7: Adjustment of Manager Salary Compensation.</p> <p>Proposal 8: Compensation Proposal for the Certified Public Accountant for Fiscal Year 2025.</p> <p>Proposal 9: Proposal to Elect One Independent Director.</p> <p>Proposal 10: Proposal to Lift the Non-Compete Restrictions on Newly Appointed Directors.</p> <p>Proposal 11: Proposal to Establish the Capital Increase Record Date.</p> <p>Proposal 12: Proposal to Set the Date, Location, and Agenda for the 2025 Annual General Meeting of Shareholders.</p>
2 nd meeting of 2025 2025.04.29	Board of Directors	<p>Proposal 1: Proposal for the Company's Consolidated Financial Statements for the First Quarter of 2025.</p> <p>Proposal 2: Proposal for the Company's Earnings Distribution for Fiscal Year 2024.</p> <p>Proposal 3: Proposal for the Nomination of Candidates for Independent Directors.</p> <p>Proposal 4: Explanation of the Company's Employee Compensation Distribution for Fiscal Year 2024.</p> <p>Proposal 5: Appointment of the Audit Supervisor and Compensation Proposal for This Company.</p> <p>Proposal 6: Proposal to Establish the Capital Increase Record Date.</p>

3.11 For the most recent fiscal year and up to the date of the annual report publication, there are no differing opinions or written statements from directors or supervisors regarding important resolutions passed by the board of directors.

4. Information on the Public Fees of the Certified Public Accountant

4.1 If the non-audit public fees paid to the certified public accountant, the office of the certified public accountant, and their related enterprises exceed one-fourth of the audit public fees, the amounts of audit and non-audit public fees and the content of non-audit services must be disclosed.

Unit: New Taiwan Dollar (thousands)

Accounting Firm Name	Accountant's Name	Audit Period	Audit Public Expenses	Non-Audit Public Expenses	Total	Remarks
PwC	Ping-Chun Chih	2024.01.01-2024.12.31	2,500	0	2,500	
	Tsung-Hsi Lai					

4.2 If the audit public expenses incurred after changing the accounting firm and fiscal year are less than those of the previous fiscal year: There is no such situation.

4.3 If the audit public expenses decrease by more than ten percent compared to the previous fiscal year, the amount, percentage, and reason for the decrease should be disclosed: There is no such situation.

5. Information on Change of Accountant

5.1 Regarding the Former Accountant

Change Date	Approved by the Board of Directors on December 18, 2023		
Reason for Change and Explanation	In accordance with internal adjustments at PwC Certified Public Accountants, effective from the first quarter of 2024, the Certified Public Accountants for the Financial Statements were changed from Accountant Ming-Chuan Hsu and Accountant Ping-Chun Chih to Accountant Ping-Chun Chih and Accountant Tsung-Hsi Lai.		
The explanation pertains to the termination of appointment by the appointer or the accountant's refusal to accept the appointment.	Party Concerned		Accountant
	Situation		Appointor
	Voluntary Termination of Appointment		Not Applicable
	No Longer Accepting (Continuing) Appointment		Not Applicable
Opinions and Reasons for Audit Reports Issued in the Last Two Years Other Than Unqualified Opinions	None		
Whether There Are Differing Opinions with the Issuer	Yes		Accounting Principles or Practices
			Disclosure of Financial Reports
			Scope or Procedures of the Audit
			Others
	None	V	
	Explanation: None		
Other Disclosure Items (Items 4 to 7 of Paragraph 6 of Article 10 of This Guideline Must Be Disclosed)	None		

5.2 Regarding the Successor Accountant

Name of the Office	PwC
Name of the Accountant	Accountants Ping-Chun Chih and Tsung-Hsi Lai
Date of Appointment	Approved by the Board of Directors on December 18, 2023
Consultation matters and results regarding the accounting treatment methods or accounting principles for specific transactions prior to the appointment, as well as any opinions that may be issued on the financial report	Not Applicable
Written opinions from the successor accountant regarding matters of disagreement with the predecessor accountant	Not Applicable

5.3 The predecessor accountant's response concerning the matters specified in Article 10, Paragraph 6, Items 1 and 2 of these standards: Not applicable.

6. The chairman of the board, general manager, or manager responsible for finance or accounting affairs of the company, who has served in the office of the certified public accountant or its related enterprises within the last year, shall disclose their name, title, and the duration of their service in the office of the certified public accountant or its related enterprises: No such circumstances.

7. Changes in the shares held and pledged by directors, supervisors, managers, and major shareholders holding over 10% of outstanding shares in the most recent year and up to the publication of the annual report

7.1 Changes in equity of directors, supervisors, managers, and major shareholders.

Unit: Shares

Title	Name	2024		As of April 30, 2025	
		Number of Shares Held Increase (Decrease) Amount	Pledged Shares Increase (Decrease) Amount	Number of Shares Held Increase (Decrease) Amount	Pledged Shares Increase (Decrease) Amount
Chairman of the Board	TCI Co., Ltd.	2,527,000	—	1,906,000	—
	TCI Co., Ltd. Representative: Yung-Hsiang Lin	464,000	—	—	—
Director	TCI Co., Ltd.	2,527,000	—	1,906,000	—
	TCI Co., Ltd. Representative: Ching-Ting Chen	145,000	—	—	—
Director	TCI Co., Ltd.	2,527,000	—	1,906,000	—
	TCI Co., Ltd. Representative: Zhen-Zhen Fu	—	—	—	—
Director	TCI Co., Ltd.	2,527,000	—	1,906,000	—
	TCI Co., Ltd. Representative: Chih-Cheng Tsai	—	—	—	—
Director	China Investment and Development Co., Ltd.	—	—	—	—
	China Investment and Development Co., Ltd. Representative: Xiu-Yuan Li	—	—	—	—
Director	Formosa Biomedical Technology Corp.	—	—	—	—
	Formosa Biomedical Technology Corp. Representative: Shih-Ming Lai	—	—	—	—
Independent Director	Sung-Yuan Liao	—	—	—	—
Independent Director	Shih-Ming Li	—	—	—	—
Independent Director	Zhong-Ming Zeng	—	—	—	—
General Manager	Ching-Ting Chen	145,000	—	—	—
Deputy General Manager	Po-Hong Lai	—	—	—	—
Accounting Supervisor Chief Financial Officer	Ruei-Yi Wu	—	—	—	—
Major Shareholder	TCI Co., Ltd.	2,527,000	—	1,906,000	—

7.2 There are no related parties among the counterparties for the transfer or pledge of equity.

8. Information on whether the top ten shareholders by shareholding ratio are related parties or have spousal or second-degree kinship relationships with each other

Unit: Shares / April 13, 2025

Name	Shares Held (Self)		Shares Held by Spouse and Minor Children		Total shares held in the name of others		The top ten shareholders by shareholding ratio are related parties or have spousal or second-degree kinship relationships with each other. Related parties, including their names or titles and relationships		Remarks
	Number of shares	Shareholding Ratio	Number of shares	Shareholding Ratio	Number of shares	Shareholding Ratio	Name (or title)	Relationship	
TCI Co., Ltd.	24,670,762	27.51%	—	—	—	—	Yongying Investment Company	Chairman	—
Formosa Biomedical Technology Corp.	8,702,040	9.70%	—	—	—	—	—	—	—
NuVasive, Inc., USA	4,758,600	5.31%	—	—	—	—	—	—	—
Global Investment Holdings	3,520,510	3.93%	—	—	—	—	Grand Cathay Venture Capital Co.,Ltd.; China Investment and Development Co., Ltd.	Chairman	—
Grand Cathay Venture Capital Co.,Ltd.	2,440,481	2.72%	—	—	—	—	Global Investment Holdings; China Investment and Development Co., Ltd.	Chairman	—
Yongying Investment Company	1,427,580	1.59%	—	—	—	—	TCI Co., Ltd.	Chairman	—
China Investment and Development Co., Ltd.	1,376,688	1.54%	—	—	—	—	Global Investment Holdings; Grand Cathay Venture Capital Co.,Ltd.	Chairman	—
Jin-Lian Li	968,592	1.08%	—	—	—	—	—	—	—
Bing-zhang Chang	943,100	1.05%	—	—	—	—	—	—	—
Qi-Ya Chang	751,525	0.84%	—	—	—	—	—	—	—

9. The number of shares held by the company's directors, supervisors, managerial officers, and enterprises directly or indirectly controlled by the company in the same reinvested enterprise, with the total shareholding ratio calculated on a consolidated basis.

Unit: shares (%) / April 13, 2025

Investment Business	Investment by MBI		Investment by MBI's Directors, Supervisors, Mangers and its directly or indirectly controlled business		Total Investment	
	Shares	%	Shares	%	Shares	%
Maxigen Biotech Inc. (Shanghai) (Note 1)	—	100%	—	—	—	100%
Horay Inc. (Note 2)	—	—	—	—	—	—

Note 1: The Company's direct investment in Mainland China is in the form of a limited liability company with no shares. The company was formerly known as Dingshi Trading (Shanghai) Co., Ltd. and the Company name was changed to Maxigen Biotech Inc. (Shanghai) on February 22, 2022.

Note 2: The company conducted liquidation procedures in 2023, and the liquidation process was completed on July 18, 2024.

III. Fundraising Activities

1. Capital and Shares

1.1 Source of Share Capital

(1) Formation of Share Capital

Unit: Thousand Shares; New Taiwan Dollar (Thousand)

Year/ Month	Issue price (per share)	Authorized Capital		Capital Stock		Notes		
		Shares	Amount	Shares	Amount	Source of Share Capital	Shares offset by property other than cash	Others
1998/12	10	30,000	300,000	10,000	100,000	Establishment	—	—
2000/03	10	30,000	300,000	19,800	198,000	Capitalization by Cash 98,000	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-089114639 received on May 11, 2000.
2002/07	13	30,000	300,000	26,000	260,000	Capitalization by Cash 62,000	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-0911308790 received on August 12, 2002.
2003/12	15	40,000	400,000	30,000	300,000	Capitalization by Cash 40,000	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-09233233950 received on December 31, 2003
2006/12	10	40,000	400,000	37,000	370,000	Capitalization by Cash 70,000	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-09631567820 received on January 17, 2007.
2007/05	16	60,000	600,000	41,120	411,200	Capitalization by Cash 41,200	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-09632228870 received on June 6, 2007.
2010/02	20	60,000	600,000	50,120	501,200	Capitalization by Cash 90,000	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-09901049980 received on March 19, 2010.
2011/09	10	60,000	600,000	50,306	503,600	Employee stock option of NT\$1,860	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10001213260 received on September 14, 2011.
2011/12	10	60,000	600,000	50,620	506,200	Employee stock option of NT\$3,140	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10001294180 received on December 30, 2011.
2012/02	10	60,000	600,000	50,814	508,140	Employee stock option of NT\$1,940	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10101015680 received on February 3, 2012.

Year/ Month	Issue price (per share)	Authorized Capital		Capital Stock		Notes		
		Shares	Amount	Shares	Amount	Source of Share Capital	Shares offset by property other than cash	Others
2012/07	10	60,000	600,000	50,982	509,820	Employee stock option of NT\$1,680	—	The approval letter, the Letter No. Ministry-of- Economic-Affairs- Commerce-Department- 10101131590 received on July 12
2012/11	10	60,000	600,000	51,281	512,810	Employee stock option of NT\$2,990	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10101237920 received on November 15, 2012.
2013/04	22.5	100,000	1,000,000	61,281	612,810	Capitalization by Cash 100,000	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10201061770 received on April 11, 2013.
2013/04	10	100,000	1,000,000	62,054	620,540	Employee stock option of NT\$7,730	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10201061770 received on April 11, 2013.
2013/04	10	100,000	1,000,000	62,106	621,060	Employee stock option of NT\$520	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10201095770 received on May 27, 2013.
2013/08	10	100,000	1,000,000	62,294	622,940	Employee stock option of NT\$1,880	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10201171330 received on August 20, 2013.
2014/01	35	100,000	1,000,000	70,084	700,840	Capitalization by Cash 77,900	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10301000640 received on January 1, 2014.
2014/11	18.7	100,000	1,000,000	70,349	703,490	Employee stock option of NT\$2,650	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10301238900 received on November 19, 2014.
2015/03	18.7	100,000	1,000,000	70,464	704,640	Employee stock option of NT\$1,150	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10401035200 received on March 17, 2015.
2015/05	18.7	100,000	1,000,000	70,837	708,370	Employee stock option of NT\$3,730	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10401097100 received on May 21, 2015.
	23.7							
2015/08	23.7	100,000	1,000,000	70,847	708,470	Employee stock option of NT\$100	—	The approval letter, Letter No. Ministry-of-Economic- Affairs-Commerce- Department-10401183860 received on August 26, 2015.

Year/ Month	Issue price (per share)	Authorized Capital		Capital Stock		Notes		
		Shares	Amount	Shares	Amount	Source of Share Capital	Shares offset by property other than cash	Others
2015/11	27.1225	100,000	1,000,000	78,757	787,570	Private placement convertible preferred stock of \$79,100	—	The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-10401251100 received on November 27, 2015.
2019/04	-	100,000	1,000,000	77,375	773,750	Cancellation of treasury shares NT\$13,820	—	The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-10801045500 received on April 18, 2019.
2020/02	-	100,000	1,000,000	69,465	694,650	Cancellation of private equity share NT\$79,100	—	The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-10901018570 received on February 26, 2020
2021/09	-	100,000	1,000,000	76,999	769,990	Private equity NT\$75,342	—	The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-11001152840 received on September 10, 2021.
2022/12	-	100,000	1,000,000	84,699	846,990	Transfer of earnings to issue new shares of NT\$76,999		The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-111012300220 received on December 07, 2022
2023/11	-	100,000	1,000,000	88,934	889,341	Converting surplus into capital and issuing new shares of NT\$42,350		The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-11230196210 received on November 03, 2023
2024/04		100,000	1,000,000	88,957	889,571	Employee stock option of NT\$23		The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-11330059870 received on April 15, 2024
2024/06	41.6	100,000	1,000,000	89,070	890,701	Employee stock option of NT\$113		The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-11330102640 received on June 28, 2024
	33.8							
2024/12	40.8	100,000	1,000,000	89,163	891,631	Employee stock option of NT\$93		The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-11330212380 received on November 03, 2024
	33.1							
2025/04	40.8	100,000	1,000,000	89,676	896,761	Employee stock option of NT\$513		The approval letter, Letter No. Ministry-of-Economic-Affairs-Commerce-Department-11430044290 received on April 07, 2024
	33.1							

(2) Types of Shares

Unit: Shares/ April 13, 2025

Types of Shares	Approved Share Capital			Notes
	Issued shares	Unissued Shares	Total	
Common Stock	89,676,115	10,323,885	100,000,000	Listed Company Stocks
Preferred Stock	—	—	—	—
Total	89,676,115	10,323,885	100,000,000	

1.2 List of major shareholders

Unit: Shares/ April 13, 2025

Name of Major Shareholders	Shares	Number of Shares Held	Shareholding Ratio
TCI Co., Ltd.		24,670,762	27.51%
Formosa Biomedical Technology Corp.		8,702,040	9.70%
NuVasive, Inc., USA		4,758,600	5.31%
Global Investment Holdings		3,520,510	3.93%
Grand Cathay Venture Capital Co.,Ltd.		2,440,481	2.72%
Yongying Investment Company		1,427,580	1.59%
China Investment and Development Co., Ltd.		1,376,688	1.54%
Jin-Lian Li		968,592	1.08%
Bing-Zhang Zhang		943,100	1.05%
Qi-Ya Zhang		751,525	0.84%

1.3 Company's Dividend Policy and Implementation Status

(1) Dividend policy as stipulated in the Articles of Incorporation:

This Company shall, upon the annual financial closing, pay all taxes as required by law, offset any losses from previous years, and if there are remaining profits, allocate ten percent to the statutory surplus reserve; However, when the accumulation of the statutory surplus reserve reaches the total capital of this Company, it shall not be subject to this limitation, and a special surplus reserve shall be allocated or reversed in accordance with relevant legal regulations. If there are still profits along with undistributed earnings from the beginning of the same period, the board of directors shall draft a distribution plan, which will be executed following a resolution by the shareholders' meeting.

This Company is a technology and capital-intensive enterprise currently in a growth phase. To align with the Company's long-term capital planning for sustainable operations and stable growth, the adopted dividend policy is a residual dividend policy.

The amount of cash dividends to be distributed shall be based on at least 50% of the net profit after tax for the fiscal year, following the allocation of various reserves in accordance with legal regulations. However, in accordance with the principle of balancing dividends, retained earnings from previous years may be utilized when the net profit after tax for the current year is insufficient for distribution. In the distribution of dividends, the primary considerations are the Company's future expansion plans and cash flow requirements, with at least 50% allocated to stock dividends and the remainder to cash dividends.

However, the types and proportions of this earnings distribution may be adjusted based on the actual profitability and capital situation for the fiscal year, as resolved by the shareholders' meeting.

- (2) The proposed distribution of dividends at this Shareholders' Meeting (approved by the board of directors, pending approval by the Shareholders' Meeting) is as follows:

On April 29, 2025, the board of directors of this Company resolved the earnings distribution plan for the fiscal year 2024 as follows: The net profit after tax for the fiscal year 2024 amounts to NT\$190,167,279, reduced by the recognition of Employee Stock Options in retained earnings totaling NT\$1,924,433, increased by the remeasurement amount of the defined benefit plan of NT\$378,267, reduced by the legally mandated allocation to the Statutory surplus reserve of NT\$18,862,111, and reduced by the legally mandated allocation to the special surplus reserve of NT\$122,937,503, resulting in distributable earnings of NT\$74,664,037, calculated to the nearest dollar, with amounts below one dollar being discarded, and the total of any rounding adjustments being included in the other income of this Company; The distribution of cash dividends for common stock shareholders is set at NT\$0.83 per share, totaling NT\$74,431,175. This cash dividend calculation is rounded to the nearest whole number, with amounts below one dollar being unconditionally discarded. Any fractional amounts totaling less than one dollar will be adjusted in descending order based on the decimal digits and account numbers to ensure compliance with the total cash dividend distribution amount. Subject to approval by the Annual General Meeting of Shareholders, the chairman of the board is authorized to determine the ex-dividend date, distribution date, and other related matters. In the event of changes to this Company's share capital that affect the number of shares outstanding, resulting in changes to the dividend payout ratio, it is proposed that the Annual General Meeting of Shareholders authorize the chairman of the board to handle this matter in accordance with the Company Act or relevant legal regulations.

- (3) Is there any significant change expected in the dividend policy? No.
- (4) The proposed bonus shares at this Shareholders' Meeting and their impact on the Company's operational performance and earnings per share: Not applicable.

(5) Employee bonuses and compensation for directors and supervisors

- A. The percentage or scope of employee bonuses and compensation for directors and supervisors as stated in the Articles of Incorporation:

If this Company generates profits during the fiscal year, it shall allocate no less than 5% for employee compensation (of this amount, at least 20% should be distributed to frontline employees), which shall be resolved by the board of directors to be distributed in stocks or cash, and the recipients shall include employees of subsidiaries who meet certain conditions; This Company may allocate no more than five percent of the aforementioned profit amount as director compensation, as resolved by the board of directors. The assignment of employee compensation and director compensation shall be reported to the Shareholders' Meeting.

However, if the Company still has accumulated losses, it shall first reserve an amount for compensation before allocating employee compensation and director and supervisor compensation according to the aforementioned ratio.

The percentage of compensation for directors and supervisors shall be determined by considering the overall operational performance of the Company, the future operational risks and development trends of the industry, and the allocation rates of peers to provide reasonable compensation. Additionally, individual contributions to the Company will be taken into account. The relevant compensation will be reviewed by the Compensation Committee and the board of directors and reported to the Shareholders' Meeting, aiming for a balance between sustainable operations and risk control.

- B. The basis for estimating employee bonuses and the compensation amounts for directors and supervisors for this period, the calculation basis for the number of stocks assigned as bonuses, and the accounting treatment in the event that the actual distribution amount differs from the estimated amount:

For this period, the basis for estimating the compensation amounts for employees and directors and supervisors can be found in the explanation of the percentage provisions outlined in the aforementioned Articles of Incorporation.

The calculation basis for the number of stocks assigned as employee compensation for this period: This Company did not distribute employee compensation in the form of stocks during this period; therefore, it is not applicable.

The accounting treatment for instances where the actual distribution amount differs from the estimated amount is as follows: The amount resolved by the board of directors for distribution shall be recognized as operating expenses for the fiscal year. However, if the actual distribution amount resolved by the shareholders' meeting subsequently differs from the estimated amount, it shall be recorded in the profit and loss for the following fiscal year.

C. Circumstances under which the board of directors approved the assignment of compensation:

(A) The amounts of employee compensation and compensation for directors and supervisors distributed in cash or stocks. If there is a difference from the estimated amount recognized for the fiscal year, the difference, reason, and treatment should be disclosed:

On February 26, 2025, the board of directors of this Company resolved to allocate the employee compensation amount for 2023 to be NT\$21,129,698, and the director and supervisor compensation amount to be NT\$5,300,000, both to be distributed in cash.

The aforementioned amounts are consistent with the estimated amounts recognized as expenses for the fiscal year.

(B) The amount of employee compensation allocated in stocks and its proportion to the net income after tax of the current period or individual financial report and the total employee compensation: No stock dividends were distributed.

D. The actual distribution of employee bonuses and director and supervisor compensation for the previous fiscal year (including the number of shares, amounts, and stock prices), along with any discrepancies from the recognized employee bonuses and director and supervisor compensation, should be detailed, including the differences, reasons, and handling of the resolution:

The board of directors of this Company resolved on March 12, 2024, to allocate the employee compensation amount for 2022 as NT\$21,455,033, and the director and supervisor compensation amount as New Taiwan Dollar 5,400,000. The aforementioned amounts are consistent with the estimated amounts recognized in the fiscal year and will be distributed in cash.

(6) The Company repurchased its own Shares Situation: None.

2. Corporate bonds handling situation: None.

3. Preferred Stock handling situation: None.

4. Overseas depositary receipts handling situation: None.

5. Employee Stock Option Issued

April 13, 2025

Types of Employee Stock Option Certificate (Note 2)	First issuance of employee stock options in 2021 (Note 5)
Effective date of declaration and total number of units.	September 27, 2021
Issue Date (Note 4)	November 3, 2021 August 3, 2022
The Number of Units Issued	2,630,000 Share (November 03, 2021) 770,000 Share (August, 03, 2022)
The Number of Units Available for Issuance	0 (November 03, 2021) 0 (August, 03, 2022)
Ratio of the Number of Shares Available for Subscription to the Total Number of Shares Issued	3.41562% (November 03, 2021) 1.00000% (August, 03, 2022)
Duration of Subscription	6 years (November 03, 2021 - November 02, 2027) 6 years (August 03, 2022 - August 02, 2028)
Method of Performance (Note 3)	The employee's options certificate shall be delivered by the Company by issuing new shares.
Restrictive Subscription Period and Ratio (%)	Not applicable
Number of Shares Subscribed	646,000 Shares (2021/11/3) 100,000 Shares (2022/8/3)
Amount of Shares Subscribed	NT\$26,465,600 NT\$3,310,000
Number of Shares yet to be Subscribed	1,984,000 Shares (2021/11/3) 670,000 Shares (2022/8/3)
Subscription Price Per Share for the Unsubscribed Shares	NT\$41.6(2021/11/3) NT\$33.8(2022/8/3)
Ratio of the Unsubscribed Shares to the Total Number of Shares Issued (%)	2.23%(2021/11/3) 0.75%(2022/8/3)
Impact on Shareholders' Equity	Not Applicable

Note 1: The status of Employee Stock Option Certificates includes both ongoing public and private placements of Employee Stock Option Certificates. Ongoing public Employee Stock Option Certificates refer to those that have already taken effect in this meeting; The Employee Stock Option Certificates currently being processed refer to those that have been approved by the Shareholders' Meeting.

Note 2: The number of columns will be adjusted according to the actual number of transactions.

Note 3: It should be specified whether the shares delivered are from issued shares or newly issued shares.

Note 4: If the issuance (processing) dates differ, they should be listed separately.

Note 5: For private placements, this should be prominently labeled.

Name of the managers with employee stock option certificates obtained, the top-10 employees with stock option certificates obtained, the respective acquisition and subscription.

April 13, 2025

	Title (Note 1)	Name	Number of Shares acquired	Ratio of Subscribed Shares to Total Number of Shares Issued (Note 4)	Subscribed (Note 2)				Unsubscribed (Note 2)			
					Number of Shares Subscribed	Price of Shares Subscribed (Note 5)						
Manager	General Manager	Ching- Ting Chen	380,000	0.43%	96,000	41.6	3,993,600	0.11%	267,000	40.8	10,893,600	0.30%
	General Manager	Ching- Ting Chen	380,000	0.43%	17,000	40.8	693,600	0.02%	267,000	40.8	10,893,600	0.30%
	General Manager	Ching- Ting Chen	80,000	0.09%	32,000	33.1	1,059,200	0.04%	48,000	33.1	1,588,800	0.05%
Employee (Note 3)	Manager	Su-Mei Liu	30,000	0.03%	12,000	41.6	499,200	0.01%	18,000	41.6	748,800	0.02%
	Manager	Su-Mei Liu	50,000	0.06%	20,000	33.1	662,000	0.02%	30,000	33.1	993,000	0.03%
	Assistant Manager	Yu-Zhen Zhang (resigned)	15,000	0.02%	6,000	41.6	249,600	0.01%	9,000	41.6	374,400	0.01%
	Deputy Manager	Yu-Zhen Zhang (resigned)	15,000	0.02%	6,000	33.1	198,600	0.01%	9,000	33.1	297,900	0.01%
	Section Chief	Shu-Yu Huang	20,000	0.02%	8,000	41.6	332,800	0.01%	12,000	41.6	499,200	0.01%
	Section Chief	Shu-Yu Huang	20,000	0.02%	8,000	33.1	264,800	0.01%	12,000	33.1	397,200	0.01%
	Senior Researcher	Guan-Hao Huang	15,000	0.02%	6,000	41.6	249,600	0.01%	9,000	41.6	374,400	0.01%
	Senior Researcher	Guan-Hao Huang	15,000	0.01%	0	33.1	0	0%	15,000	33.1	496,500	0.01%
	Specialist	Ru-Han Yang (Resigned)	30,000	0.03%	8,000	41.6	332,800	0.01%	22,000	41.6	1,040,000	0.03%
	Specialist	Ru-Han Yang (Resigned)	10,000	0.01%	0	33.1	0	0%	10,000	33.1	331,000	0.01%

Note 1: This includes Managers and Employees (those who have resigned or passed away should be noted). Individual names and titles must be disclosed, although acquisition and subscription details may be presented in a summarized manner.

Note 2: The number of columns may be adjusted based on the actual number of issuances.

Note 3: The top ten employees eligible for stock options refer to employees other than Managers.

Note 4: The total number of issued shares refers to the number of shares listed in the registration information amended by the Ministry of Economic Affairs.

Note 5: The subscription price for executed Employee Stock Options should disclose the price at the time of execution.

Note 6: The subscription price for unexecuted Employee Stock Options should disclose the adjusted subscription price calculated in accordance with the issuance regulations.

6. Merger or Acquisition of Shares of other Companies and Issuance of New Shares:
None.

7. Restricted Employee Shares: None.

8. Capital Utilization Plan Implementation:

This Company has completed the execution of all previous plans for issuing Securities according to schedule, and the benefits have been realized.

IV. Overview of Operations

1. Business Activities

1.1 Scope of Business

The primary business activities of this Company include purification of collagen, research and development, production, and sales of implantable biomedical medical devices, as well as the production, manufacturing, wholesale, and retail of cosmetic skincare products and health supplements.

(1) Main Content of Business Operations

- 1) F108031 Wholesale of Medical Equipment .
- 2) F108011 Wholesale of Traditional Chinese Medicine .
- 3) F108021 Wholesale of Western Medicine .
- 4) F108040 Cosmetics Wholesale Industry.
- 5) IG01010 Biotechnology Services Industry.
- 6) C802100 Cosmetics Manufacturing Industry.
- 7) C801030 Precision Chemical Materials Manufacturing Industry.
- 8) CF01011 Medical Equipment Manufacturing Industry.
- 9) CE01030 Optical Instrument Manufacturing Industry.
- 10) C802060 Animal Medicine Manufacturing Industry.
- 11) F102040 Beverage Wholesale Industry.
- 12) F102170 Food and Grocery Wholesale Industry.
- 13) F107070 Animal Medicine Wholesale Industry.
- 14) F203010 Food and Grocery, Beverage Retail Industry.
- 15) F207070 Retail Sector for Veterinary Pharmaceuticals
- 16) F208031 Retail Sector for Medical Equipment
- 17) ZZ99999 Except for licensed businesses, the Company may engage in activities not prohibited or restricted by legislation

(2) Business Proportion

Unit: New Taiwan Dollar (thousands)

Primary Products	2023		2024	
	Amount	%	Amount	%
Biomedical Products	601,701	96.72%	680,651	100.00%
Consumer Products	20,414	3.28%	0	0
Total	622,115	100.00%	680,651	100.00%

(3) Current Products (Services) Offered by the Company

1) Biomedical Products

A. Joint Injections

(A) ArtiAid Five-Dose Intra-Articular Injection

ArtiAid joint injection is produced using high-purity sodium hyaluronate (also known as hyaluronic acid) derived from microbial fermentation as the raw material. Hyaluronic acid is widely distributed in the vitreous fluid of the eye, synovial fluid of joints, and tissues such as skin in both animals and humans. In patients with traumatic or degenerative arthritis, the insufficient sodium hyaluronate content in the synovial fluid of the joints reduces its lubricating function, resulting in joint pain. Therefore, ArtiAid is suitable as an intra-articular injection for traumatic or degenerative arthritis. It can replenish the concentration of sodium hyaluronate in the synovial fluid, increase the viscoelasticity of the joint fluid, and has functions such as reducing inflammatory responses, providing stress buffering, protecting joint tissue, alleviating joint pain, and improving joint mobility. It serves as an auxiliary medical device product for the relief of symptoms associated with degenerative arthritis. ArtiAid is a five-dose joint injection solution with a Sodium Hyaluronate concentration of 1.0% (wt/wt). The treatment course lasts for five weeks, with one dose administered each week for a total of five weeks. The efficacy of each treatment course depends on the patient's condition, with a general effectiveness lasting between six to nine months. Clinical trials have demonstrated that this product can alleviate pain for 26 weeks, achieving over 70% satisfaction. This product has been marketed in Taiwan, the European Union, Russia, the Middle East, and Southeast Asia.

(B) ArtiAid Plus Three-Dose Intra-Articular Injection

ArtiAid Plus Joint Injection is a three-dose intra-articular injection developed by MBI Company to enhance patient convenience and address the demands of the international market. In comparison to the first-generation product ArtiAid, the concentration of Sodium Hyaluronate in ArtiAid Plus has been increased to 1.5% (wt/wt), thus reducing the number of injections required during treatment, which alleviates patient discomfort and inconvenience. ArtiAid Plus can effectively enhance the viscoelastic properties of joint fluid, reducing inflammatory responses, providing stress buffering, protecting joint tissue, alleviating joint pain, and improving joint mobility. ArtiAid Plus is a joint injection solution available in three dosage forms, with a treatment course lasting three weeks, administering one dose each week, and the efficacy of each treatment course lasts for six to nine months. With equivalent efficacy, ArtiAid Plus can reduce the frequency of patient visits and injections, thereby enhancing the convenience of medical treatment for patients while also alleviating the manpower burden on hospitals and clinics. Clinical

trials indicate that this product can alleviate 26 weeks of pain with over 70% satisfaction. This product has been sold in Taiwan, the European Union, Russia, Egypt, the Middle East, and Southeast Asia.

(C) ArtiBest Single-Dose Intra-Articular Injection

ArtiBest joint injection is a next-generation intra-articular injection derived from MBI's hyaluronic acid cross-linking technology. This product is a single-dose joint injection that can significantly shorten the current clinical treatment regimen (currently consisting of 5 or 3 doses), effectively eliminating patients' arthritis symptoms in just one treatment. Following the launch of this product, it will enhance MBI Company's comprehensive product line of joint injections (5 doses, 3 doses, and 1 dose), significantly improving the competitiveness of MBI Company's joint injection products in the domestic market. This product has been marketed in Taiwan, Russia, Australia, Peru, the Middle East, and Southeast Asia.

(D) ArtiBest Extend Single-Dose Intra-Articular Injection

The ArtiBest Extend long-lasting joint injection represents the latest generation of intra-articular injections developed using MBI's hyaluronic acid cross-linking technology. This product is a single-dose joint injection with an effective duration of 12 months, significantly reducing the current clinical treatment course (which is typically 6 months). A single treatment can eliminate the symptoms of arthritis in patients. It can reduce the overall consultation time for physicians and decrease the frequency of hospital visits for patients, further alleviating the burden on medical resources. This product is currently available for sale in Taiwan.

B. Collagen Medical Devices

(A) SurgiAid Collagen Wound Dressing

SurgiAid is composed of high-purity medical-grade collagen and features a porous sponge-like structure. In comparison to conventional wound dressings primarily made from materials such as cellulose, collagen serves as the main matrix of skin tissue, comprising up to 70% of the skin, and is a crucial regulatory factor in wound repair and the coagulation mechanism. Its porous sponge-like structure can absorb blood and wound exudate, promote platelet aggregation, accelerate coagulation, and facilitate wound repair, making it suitable for tissue preservation and repair during dental implant surgery.

The SurgiAid collagen wound dressing is formulated using fiber-type collagen, and its pore structure closely resembles the extracellular matrix (ECM) of normal human skin tissue, effectively promoting cell migration, growth, and tissue regeneration, thereby facilitating wound healing. This product is available in Taiwan, the United States, the Middle East, and Southeast Asia.

(B) FormaAid collagen guided tissue regeneration membrane for dentistry

FormaAid collagen dental Guided Tissue Regeneration Membrane (GTR) is a soft membrane that covers periodontal defects and facilitates the regeneration process of the periodontal tissue in the affected area. Given that the growth rate of new bone regeneration for teeth is generally slower than that of soft tissues such as gingival connective tissue, the application of dental Guided Tissue Regeneration Membranes (GTR) following periodontal disease treatment can prevent the encroachment of soft tissues, thereby mitigating the issue of inadequate regeneration of new bone tissue in the defect area. The application of FormaAid following periodontal disease surgery can facilitate the growth of gingival connective tissue over the defect while preserving the space necessary for the growth of periodontal ligament and alveolar bone tissue, thus enabling the regeneration and reconstruction of periodontal tissue at the site of the defect. The FormaAid collagen dental guided tissue regeneration membrane is formulated using high-purity medical grade collagen as its substrate. Besides exhibiting excellent biocompatibility, collagen serves as a crucial matrix for the repair of human tissues. FormaAid is formulated using collagen in a fiber type, and its pore structure closely resembles that of normal human bone tissue, effectively promoting cell embedding, growth, and tissue regeneration. Additionally, FormaAid is further enhanced for surgical operability through the Company's unique crosslinking technology. The FormaAid collagen dental guided tissue regeneration membrane is fully absorbable by the human body, eliminating the need for a second surgery to remove FormaAid, thus increasing convenience for clinical use. This product is available in Taiwan, the Middle East, and Southeast Asia.

(C) HealiAid Collagen Wound Dressing.

HealiAid Collagen Wound Dressing is made from high-purity medical grade collagen and features a porous sponge structure. In comparison to conventional wound dressings primarily made from materials such as cellulose, collagen serves as the main matrix of skin tissue, comprising up to 70% of the skin, and is a crucial regulatory factor in wound repair and the coagulation mechanism. The porous sponge structure effectively absorbs blood and wound exudate, promotes platelet aggregation, accelerates coagulation, and facilitates wound repair, making it suitable for general wounds, burns, and surgical trauma applications.

The HealiAid collagen wound dressing is formulated using fiber-type collagen, and its pore structure closely resembles the extracellular matrix (ECM) of normal human skin tissue. This product effectively promotes cell migration, growth, and tissue regeneration, thereby enhancing wound healing. As a result, it exhibits superior safety and efficacy in hemostasis and healing compared to conventional non-collagen wound healing products available in the market. It has been marketed in Taiwan, the United States, the Middle East, and Southeast Asia.

(D) NasoAid nasal dressing

NasoAid nasal dressing is suitable for postoperative care following various nasal surgeries, including septoplasty, turbinate reduction, chronic sinusitis surgery, and rhinoplasty. Its primary functions are to provide postoperative nasal support, effectively control bleeding, prevent tissue adhesion, and promote wound healing. NasoAid is composed of collagen and cellulose, making it one of only two nasal dressings on the market that contain collagen; Additionally, through an exclusive process, NasoAid demonstrates exceptional clinical operational characteristics, including: dual hemostatic effects, anti-adhesion properties, promotion of wound healing, and natural degradation within 7 to 14 days without the need for removal, thereby minimizing patient discomfort. This product is currently available for sale in Taiwan and the United States.

C. Dermal Filler

(A) Formaderm Hyaluronic Acid Dermal Filler

Within the body, hyaluronic acid exists in a gel-like form in the dermis of the skin, primarily serving to help maintain moisture and enhance skin volume. As individuals age, the collagen and Hyaluronic Acid in the skin gradually diminish, resulting in the formation of wrinkles on the facial skin; therefore, the injection of Hyaluronic Acid not only restores the ability to retain moisture, but also increases the volume of the skin. However, in its natural state, Hyaluronic Acid can only be sustained for 1-2 days before being metabolized. In light of this, MBI Company employs cross-linking core technology for Hyaluronic Acid to produce stable Hyaluronic Acid products—Formaderm—designed to enhance facial tissue, correct wrinkles, and plump lips. Formaderm can naturally integrate into the tissue, and although its density decreases during the absorption process after decomposition, its volume can remain unchanged, thereby continuing to maintain the contour of the affected area until the Hyaluronic Acid is completely absorbed. The duration of Formaderm's effect in the body varies depending on the patient's condition, typically lasting about six to nine months. This product has been marketed in Taiwan, China, Russia, the Middle East, and Southeast Asia.

(B) Formaderm Young Hyaluronic Acid Dermal Filler

Formaderm Young Dermal Filler is the second product in MBI Company's medical aesthetics and aesthetic plastic surgery series. Formaderm Young Dermal Filler is one of the products developed using MBI Company's proprietary hyaluronic acid cross-linking technology platform. Unlike Formaderm Dermal Filler, which is injected into the mid-dermis, Formaderm Young Dermal Filler is injected into the sub-dermal layer and the superficial subcutaneous layer to address deeper skin defects. This product is available in Taiwan, China, Russia, and the Middle East.

(C) Formaderm Charming Hyaluronic Acid Dermal Filler

The Formaderm Charming Dermal Filler is the third product in MBI Company's medical aesthetics and plastic surgery series. The Formaderm Charming Dermal Filler is one of the products developed using MBI Company's proprietary cross-linked hyaluronic acid technology platform. It is injected into the subcutaneous tissue to repair deeper skin defects. This product is available for sale in Taiwan and Russia.

(D) Formaderm (with Lidocaine) Hyaluronic Acid Dermal Filler

Formaderm (with Lidocaine) Dermal Filler is the fourth product in MBI Company's medical aesthetics and plastic surgery series. Formaderm (with Lidocaine) Dermal Filler is one of the products developed using MBI Company's proprietary cross-linked hyaluronic acid technology platform. It shares the same clinical applications as Formaderm Dermal Filler, with the addition of an anesthetic to enhance user comfort. This product is available in Taiwan, Russia, and the Middle East.

(E) Formaderm Young (with Lidocaine) Hyaluronic Acid Dermal Filler

Formaderm Young (with Lidocaine) Dermal Filler is the fourth product in MBI Company's medical aesthetics and plastic surgery series. Formaderm Young (with Lidocaine) Dermal Filler is one of the products developed using MBI Company's proprietary cross-linked hyaluronic acid technology platform. It shares the same clinical applications as Formaderm Young Dermal Filler, with the addition of an anesthetic to enhance user comfort. This product has been marketed in Taiwan, Russia, and the Middle East.

D. Synthetic Bone Graft

(A) Formagraft Collagen Bone Graft Matrix, AttraX Scaffold

Formagraft Collagen Bone Graft Matrix is a synthetic material used to fill defects and gaps in the skeletal system, including the limbs, spine, and pelvis. As a filler for bone defects, Formagraft gradually integrates with and is replaced by the body's own newly formed bone tissue during the bone repair process. Formagraft bone graft combines high-purity medical grade collagen with hydroxylapatite/ β -tricalcium phosphate (HAP/ β -TCP) biphasic ceramic granules, whose structure and chemical composition are identical to those of human cancellous bone matrix. Formagraft can incorporate the patient's bone marrow prior to surgical implantation, which contains various bone repair protein factors and stem cells. These components can bind with the collagen in Formagraft, stimulating and inducing the migration, proliferation, and differentiation of the patient's own osteoblasts. Consequently, it exhibits both osteoconductive and osteoinductive properties, effectively promoting bone regeneration. According to the results of clinical trials conducted in the United States, Formagraft mixed with bone marrow demonstrates a

bone defect repair and regeneration rate equivalent to that of the patient's autologous bone, exhibiting efficacy comparable to autologous bone. Furthermore, the second-generation bone material 'Attrax Scaffold,' developed in collaboration with Nuvasive, not only incorporates a novel bioceramic with bone induction properties but is also produced using a unique collagen composite technology, resulting in an artificial bone material with exceptional clinical operability, which received U.S. FDA market approval in December 2016. Formagraft and Attrax Scaffold have been marketed in Taiwan and the United States.

(B) GingivAid Collagen Dental Bone Graft and BestAid Collagen Bone Graft

GingivAid Collagen Dental Bone Graft is a synthetic filler designed to reinforce and repair defects in the gums, teeth, periodontal bone, and dental implant sites. The structure and chemical composition of GingivAid Collagen are identical to those of human cancellous bone matrix, effectively providing an optimal environment for the attachment and growth of osteoblasts, thereby accelerating the synthesis of new bone matrix and facilitating the repair of bone tissue. In the process of dental tissue repair, GingivAid can be absorbed by the human body and gradually replaced by newly formed bone tissue. In clinical applications, GingivAid can also be mixed with the patient's own blood or Platelet Concentrate (platelet-rich plasma, PRP), allowing it to adsorb active ingredients or growth factors from the blood, thereby accelerating tissue regeneration. Furthermore, it can be shaped according to the form or size of the defect, enhancing the operability and convenience of clinical use. This product is available in Taiwan and Southeast Asia. BestAid Collagen Bone Graft is a synthetic material designed to fill bone fractures, reinforcing and repairing defects. The structure and chemical composition of BestAid product are identical to those of human cancellous bone matrix, effectively providing osteoblasts with an optimal environment for adhesion and growth, thereby accelerating the synthesis of new bone matrix and completing the repair of bone tissue. During the process of bone tissue repair, BestAid can also be absorbed by the body and gradually replaced by newly formed bone. In clinical applications, BestAid can also be combined with the patient's own blood or platelet concentrate (platelet-rich plasma, PRP), allowing it to adsorb active ingredients or growth factors from the blood, thereby accelerating tissue regeneration. Additionally, it can be shaped according to the form or size of the defect, enhancing operational efficiency and convenience in clinical settings. This product has been marketed in Taiwan and Southeast Asia.

(C) Foramic Bone Substitute Granules

Foramic is a bone filling material designed and manufactured by

integrating the advantages of two medical devices: HAP and β -TCP. It consists of a biphasic calcium phosphate ceramic composed of 60% hydroxylapatite (HAP) and 40% β -Tricalcium Phosphate (β -TCP). Another notable feature of Foramic is its excellent biporous structure. The pore structure primarily provides a space for human cells (such as osteoblasts) to attach, grow, and reside, while also serving as a channel for oxygen and waste metabolism. The pore structure of Foramic consists of 60% macropores (with pore sizes ranging from 300 to 600 μm) and 40% micropores (with pore sizes of approximately 10 μm). Initially, during surgery, the volume of osteoblasts (50 μm) is larger than that of the micropores, preventing them from embedding and attaching within the micropores (thus they only embed and proliferate within the macropores). However, as Foramic gradually degrades in the body, adjacent micropores gradually merge to form larger pores, thereby providing an environment for the next wave of osteoblasts to attach and grow. This excellent dual-pore structure and distribution create a continuous environment for osteoblast proliferation, enhance the mechanical properties and mass transfer effects of Foramic bone material, and accelerate the repair of bone tissue. This product has been sold in Taiwan, China, and Southeast Asia.

E. Other Medical Devices

(A) Viscaid Cohesive Ophthalmic Viscoelastic

Viscaid Cohesive Ophthalmic Viscoelastic is a surgical auxiliary medical device manufactured from high-purity hyaluronic acid through microbial fermentation. It is suitable for various ophthalmic surgeries, including cataract extraction, artificial lens implantation, corneal transplantation, glaucoma filtration surgery, and retinal detachment surgery. Furthermore, it is utilized as a vitreous substitute in both vitrectomy and retinal detachment procedures. Hyaluronic Acid exhibits properties such as lubrication, viscoelasticity, transparency, and the ability to protect corneal endothelial cells. Its application in ophthalmic surgery aids in reducing the interaction between corneal endothelial cells and surrounding tissues, maintaining the depth of the anterior chamber, and enhancing visibility during the procedure. Furthermore, it can be applied to the intraocular lens and the surfaces of surgical instruments prior to artificial lens implantation surgery to prevent potential trauma to the eye caused by surgical instruments. During ophthalmic surgery, when utilized to fill the anterior and posterior segments of the eye, Viscaid also helps maintain tissue integrity and ensures clear visibility. This product is non-antigenic, non-pyrogenic, and does not cause immune allergic reactions. The human eye exhibits good tolerance to it. This product has been marketed in Taiwan, China, and Southeast Asia.

(B) PreviscAid Dispersive Ophthalmic Viscoelastic

Unlike ViscAid, which is a cohesive ophthalmic binder, PreviscAid is a dispersible ophthalmic binder that contains small molecules of microbially fermented high purity hyaluronic acid and medical grade Chondroitin Sulfate, which is superior in protecting corneal endothelial cells and reducing the interaction between corneal endothelial cells and tissues. PreviscAid is suitable in all types of ophthalmic surgeries. Due to its lubricity, viscoelasticity and transparency, it can be used to cover the lens of the inner eye and the tip of the surgical instrument to prevent possible trauma caused by the surgical instrument. This product has been sold in Taiwan and Indonesia.

(C) BiVisc Ophthalmic Viscoelastic System

BiVisc Ophthalmic Viscoelastic System is a combination product of current existing PreviscAid Ophthalmic Viscoelastic and ViscAid Ophthalmic Viscoelastic. In conjunction with clinical use, we provide two doses of adhesive products for pre- and post-operative use, effectively enhancing the convenience of clinical use.

2) Health Supplement Products

A. Good Joint 633 Lactobacillus Capsule

The Good Joint 633 Lactobacillus Capsule contains hyaluronic acid. The main ingredients are the exclusive patented TCI633 hyaluronic acid self-generating bacteria, organic sulfide-MSM and acerola unripe fruit, without animal-derived raw materials, and vegetarian. The use of patented probiotics can contribute to the generation of hyaluronic acid, with the exclusive proprietary ProBio-Ark technology greatly enhances the survival of probiotics; thus, providing dynamic energy and strong gait to support health.

B. Radiant Collagen

The Radiant Collagen contains a high concentration of collagen tripeptides, created through proprietary manufacturing technology to create small molecules well absorbed by the human body. It is also combined with Streptococcus zooepidemicus (Sodium hyaluronate) and konjac ceramide to maintain healthy skin. It is patented in five countries and has won six awards.

(4) Planned Development of New Products (Services)

1) Hyaluronic Acid Crosslinking Core Technology Derivatives

A. Injectable Anti-adhesion Filler

The injectable anti-adhesive filler is a cross-linked hyaluronic acid product mainly used to prevent adhesions after spinal surgery, gynecological surgery, or hepatobiliary and gastrointestinal surgery. Currently, the clinical anti-stick

products are in the form of thin films, which often limit the clinical effect due to the dispersion of the adhesive area in operation. This product is an injectable dosage form that is suitable for coating various surface shapes and greatly enhances the convenience of current clinical operations. This product will provide the best option for optimal post-operative recovery for abdominal surgery patients in the future.

2) New resorbable bone material with osteoconductive properties.

MBI has built up a wide range of orthopedic products, including intra-articular injectables, calcium phosphate ceramics, injectable bone cement and collagen /ceramic composite bone materials, which have been marketed in Taiwan, the European Union and Southeast Asia. To continue to deepen the product line, the Company is developing new bone materials with osteo-induction properties based on our current bone material products with osteo-conduction properties, combined with new active factors and a special loading method with patent protection. This is an innovative product that has not yet been launched. It is expected that the introduction of this technology and product will lay one of the foundations for the development of a medical product that is an international benchmark for MBI. The product technology has started the relevant research and development work, and is expected to complete the pre-market clinical testing, successive clinical trials and application for product marketing approval in 3~4 years.

3) Vegan Collagen Wound Dressing

The medical device sector includes animal tissues and other animal-derived materials. Compared to non-animal derived materials, animal-derived materials may provide some therapeutic and biocompatible effects; however, their use in medical devices also has the risk of transmitting disease from animals to humans. Thus, there is potential for non-animal-derived medical materials with biocompatibility in the future. The combination of TCI's collagen cutting and production capabilities and MBI's technology for manufacturing collagen regenerative wound dressing is a long-term development trend. This is an innovative product, which is expected to take 10~15 years to develop, including R&D, biocompatibility, animal efficacy trials, and clinical trials.

1.2 Industry Overview

(1) Current Status and Development of the Industry

1) International Biomedical Market

According to statistics from the United States Census Bureau, the global population aged 65 and older currently accounts for 8.5% of the total population, exceeding 600 million. By 2050, the population aged 65 and older is projected to reach 1.6 billion, approximately 17% of the total. The global average life expectancy is estimated to increase from 68.6 years in 2015 to 76.2 years, with the population aged 80 and above, referred to as the 'super-aged population,' expected to grow from 126.5 million in 2015 to 446.6 million. It can be inferred that the future growth of the medical device market will be significantly driven by these trends. The continuous enhancement of medical efficiency has consistently been an evolving trend, encompassing the simplification and efficiency of surgeries, the improvement of postoperative tissue healing, thereby enhancing patient comfort, and the effective utilization of medical resources. Based on the trends and forecasts analyzed in the aforementioned reports, it is clear that the growth of the medical device market will be significantly propelled.

In the global market, the demand for medical equipment is steadily increasing, primarily due to the aging population, the rise in chronic illness patients, and advancements in medical technology. According to the latest report, the global medical equipment market size for 2025 is estimated to be USD 678.88 billion, and it is projected to reach USD 1.15 trillion by 2034, with an Annual Compound Growth Rate (CAGR) of 6%. This growth is driven by several factors, including an aging population, an increase in chronic illness patients, advancements in healthcare technology, and a rising demand for high-quality medical services.

In the global medical equipment market, innovations in healthcare technology are driving the development of several specialized areas, particularly intra-articular injections, ophthalmic adhesives, dermal fillers, and regenerative medical materials. These products play a significant role in enhancing patients' quality of life and treatment outcomes.

Intra-articular injections: These products, such as hyaluronic acid injections, are primarily used to treat conditions like knee arthritis, effectively alleviating pain and improving joint function. In the future, these products may incorporate nanotechnology to enhance the local retention time and efficacy of the medication.

Ophthalmic Viscosurgical Devices: These products play a critical role in ophthalmic surgeries, such as protecting corneal tissue and maintaining anterior chamber depth during cataract surgery. As society ages, the demand for such products is anticipated to rise, while the development of new formulations may offer improved surgical visibility and enhanced safety.

Dermal Fillers: With advancements in cosmetic medical technology, dermal fillers are gaining increasing recognition in cosmetic surgery and skin regeneration. These products assist in enhancing the structure and appearance of

the skin, and future development trends may concentrate on improving the longevity and naturalness of the filling effects.

Regenerative medical materials: This is a rapidly evolving field that encompasses a variety of materials, ranging from stem cell technology to biodegradable scaffolds. These technologies enable the repair and regeneration of tissues in vivo, and future developments may focus on enhancing the precision and effectiveness of treatments, particularly in supporting tissue repair for patients with chronic illnesses.

The Chinese market benefits from the advancement of economic standards, with a steadily increasing demand for health, and the high-value medical consumables market in China is also encountering significant development opportunities. In recent years, the high-value medical consumables market in China has experienced steady growth, the market size of high-value medical consumables in China in 2023 is approximately 160 billion RMB, and it is anticipated to continue growing steadily in the future. In the Chinese market, the development of dermal fillers and dental regenerative matrices demonstrates significant growth potential. In 2023, the market size of dermal fillers in China reached 35.3 billion RMB, and it is projected to continue expanding at an annual compound growth rate of approximately 8% by 2028. This growth is primarily driven by the increasing demand for cosmetic surgery and consumers' heightened focus on beauty products. Dental regenerative matrices are also experiencing rapid development in China, particularly in the applications of dental implants and the treatment of periodontal disease. Technological innovations in this field, including the use of advanced biomaterials to promote the regeneration of teeth and periodontal tissues, are gradually gaining acceptance in the market.

In analyzing the European market, the majority of the population is concentrated in the western part of Europe, with approximately 420 million people residing in Western Europe. Among them, Italy, Germany, Portugal, Finland, Greece, and Sweden rank among the top ten countries globally in terms of the proportion of the population aged 65 and over. With the continuous increase in the elderly population, the demand for related medical care products is expected to maintain a growth trend.

The medical equipment industry in emerging markets has demonstrated strong growth potential in recent years. In 2023, the industry's size in these markets is estimated to reach 50 billion USD, and it is projected to continue expanding at a compound annual growth rate of 10% over the next five years. This growth is primarily attributed to the rise in health awareness, enhancements in medical infrastructure, and the government's increased spending on healthcare. Moreover, with advancements in technology, especially in the areas of mobile health and telemedicine, it is expected that innovation in medical equipment will be stimulated, thereby offering more solutions to improve patient care. The key to future development will rely on the integration of innovative technologies while enhancing product quality and availability without sacrificing cost-effectiveness.

2) Domestic Biomedical Market

The medical equipment market in Taiwan continues to exhibit a robust growth trend. According to the latest market analysis, the size of the medical equipment market in Taiwan in 2023 is approximately 3 billion USD, and it is projected to continue growing at an annual compound growth rate of about 7.7% from 2024 to 2030. This growth is primarily driven by the increasing aging population in Taiwan, the rising prevalence of chronic diseases, and advancements in healthcare technology.

Among the various sub-markets, medical equipment for dentistry and dermatology applications is receiving particular attention. As awareness of oral health increases, along with the growing demand for aesthetics and anti-aging solutions, the need for related dental regenerative materials and dermal fillers has also risen. Taiwan's innovation in these sectors is particularly remarkable, with numerous new technologies and products consistently emerging to satisfy market demand.

Looking ahead, it is anticipated that Taiwan's medical equipment market will continue to be propelled by innovation, particularly in the realms of digital healthcare and remote monitoring technologies. Government support policies for the medical equipment sector, such as initiatives aimed at enhancing healthcare quality and accessibility, will further facilitate market growth. Furthermore, the connection and collaboration with the international market have provided additional opportunities for Taiwan's medical equipment enterprises to expand and innovate. Driven by globalization trends, the outlook for Taiwan's medical equipment market appears promising, with the potential to assume a more significant role in the global medical equipment market.

3) Nutritional Supplement Market

In response to the aging society, the trend towards health has been steadily growing in recent years, and the cross-border COVID-19 pandemic has heightened consumers' urgent demand for health care. The global dietary supplement market size in 2023 is estimated at USD 86.77 billion, projected to reach USD 182.52 billion by 2032, with an Annual Compound Growth Rate of 8.73%. The growth is primarily driven by increased health awareness, an aging population, and rising demand for functional products related to immune health, mental acuity, and sleep health.

Furthermore, the market size of health and nutritional foods in Taiwan in 2023 is approximately NT\$ 170.8 billion, reflecting a growth of about 6.2% compared to 2022. Among the popular categories are eye health, beauty health, and functional probiotics, with demand for these products continuing to rise, indicating a high level of consumer interest in health and beauty.

The international market consulting firm Innova Market Insights analyzed global dietary supplement new products over the past five years (from October 2017 to September 2022), revealing that 'Immune Health' is the most widely


utilized product claim, accounting for one-third of new products in this category in 2022. Moreover, recent product claims have become increasingly diverse, with significant growth in claims related to 'Mental Acuity,' 'Sleep Health,' 'Lung Health,' 'Energy and Endurance,' and 'Skin Health,' indicating that as consumer demands for daily nutrition become more sophisticated, there remains substantial development potential in the segmented market for dietary supplements.

Aging is one of the most significant challenges facing Taiwanese society. By 2025, Taiwan will enter a super-aged society, with one in five individuals aged 65 or older. In ten years, every 2.7 young adults will need to support one elderly person, compared to the current ratio of 4.5, indicating an increasing burden on the younger generation. However, a crisis also signifies the beginning of new opportunities. Therefore, markets such as cardiovascular health, joint health, dental health, and vision care represent areas ripe for development.

(2) Correlations between Upstream, Midstream, and Downstream Companies.

The products manufactured by this Company, including collagen, Hyaluronic Acid, and other surgical products, cover a broad spectrum of both upstream and downstream sectors within the biotechnology and non-biotechnology industries. With respect to upstream raw materials, this Company acquires processing technology from BSE (Bovine Spongiform Encephalopathy) affected regions in New Zealand and Australia to establish a supply chain for Hyaluronic Acid produced through fermentation engineering. Furthermore, this Company is involved in the preparation of advanced bioceramic raw materials. In terms of upstream equipment, this Company engages directly with precision equipment manufacturers to discuss and design production tailored to specific internal requirements. Following stringent validation, the equipment is employed in the production line for manufacturing. Furthermore, the equipment of this Company also includes medical grade machinery and packaging materials. Medical grade machinery comprises medical grade steel reaction tanks, centrifuges, mixers, crushers, various types of conveying pumps, freeze dryers, high-pressure steam sterilizers, high-temperature dry heat ovens, clean rooms (Class 1000, Class 10,000, Class 100,000), air conditioning systems, ultrafiltration equipment, and concentration equipment. The midstream industry, such as this Company producing medical grade collagen, supplies raw materials to the midstream sector for product manufacturing, including manufacturers of medical equipment and cosmetics.

The downstream industry encompasses a wide range of sectors, including hospitals, pharmacies, clinics, drugstores, and medical aesthetics centers.



(3) Various Development Trends and Competition of Products

1) Product Development Trends

A. Biomedical Materials

The growth of the medical industry is driven by (1). Aging population, (2). Continuous improvement of medical technology, (3). The improvement of economic conditions, and (4). The emergence of new countries. According to United Nations statistics, the global population will reach 9.3 billion in 2050, of which the number of people over 65 years old is about 1.9 billion, which is about three times of the current number. The medical expenditure of the elderly population accounts for 13% of the overall consumption, much higher than the 3.5% of the young group, so with the baby boomers into old age, the business opportunities brought by the aging population cover the entire medical industry, including orthopedics, dentistry, ophthalmology, cardiovascular, psychiatric, etc., with far-reaching effects. In addition, due to the continuous advancement of clinical medicine, new products and new treatment methods are constantly introduced, which is also an important factor to drive the growth of the pharmaceutical industry. In addition, the improvement of economic conditions is also the reason for the pursuit of health and quality of life. Improvements in economic conditions have led to an increase in the proportion of people seeking medical care, especially in emerging countries.

Degenerative arthritis of the knee is a nightmare of many elderly people. Not only does it cause reduced mobility, but pain, swelling and stiffness of the joint also reduce the quality of life. According to statistics, the incidence of arthritis is 20~ 30% at age 50 and up to 70% at age 70 or older. Intra-articular hyaluronic acid injections are injections of hyaluronic acid, a substance that is already present in the joint fluid, to help reduce the burden on the joints. Studies have found that when degenerative knee arthritis occurs, the concentration of hyaluronic acid in the joint decreases significantly, and its ability to protect the cartilage and resist inflammation also decreases significantly. If hyaluronic acid is injected into the joint, it can inhibit inflammation and protect the cartilage through a variety of mechanisms. The global aging population continues to rise, and the growth of the aging population is causing an increase in the number of people seeking medical care for aging-related illnesses. In Taiwan, hyaluronic acid injections are covered by health insurance, and can be used when you are 60 years of age or older, when your symptoms and x-rays reach a certain level of severity, and when you have received conservative treatment for more than six months. Ophthalmology is one of the most important diseases of aging, including age-related macular degeneration, cataracts, amblyopia, glaucoma, and diabetes-related diseases, thus driving the global demand for ophthalmology materials. In China, for example, according to statistics from mainland China, the prevalence of cataracts among able-bodied people over the age of 75 is as high as 90%, and the prevalence of cataracts among people over the age of 60 is also 80%, and

the number of people blinded by cataracts in China is currently as high as 5 million, of which the cataract surgery coverage rate is less than 1/3. In addition, in terms of dentistry, Chinese people generally have poor oral hygiene habits, and the prevalence of caries is as high as 90%, and the rate of periodontal disease is also 70%. With the gradual improvement of the Chinese people's economy and the improvement of medical knowledge, people are paying more and more attention to dental care, and coupled with the trend of orthodontic implants, the dental market has been growing rapidly in recent years, and the future market growth potential is huge.

In addition, in other mature markets such as Europe and the U.S., as mentioned above, the increase in operating costs of medical clinics due to the health care reform policy has forced hospital purchasing departments to look for inexpensive and quality medical products, especially in the area of biomedical consumables, which is an opportunity for MBI products to enter the international market.

B. Nutritional Supplement Products

Due to the pandemic and the information age, there are substantial business opportunities in the health food market in Taiwan for all age groups and markets. On the market side, we can observe a trend towards younger consumers in the health food sector, with 39% of consumers aged between 25 and 40. On the market side, in general, we see that consumers' primary needs are efficacy, disease prevention, and dietary supplementation. Among the main goals of 19-25-year-olds are whitening and detoxification, muscle building, and fat loss, while 31-40-year-olds are anti-aging, freezing, liver and stomach care.

Trend 1: The most lucrative "women's health" market

Dietary supplements for women's health are one of the sectors that has continued to grow over the past decade, with a compound annual growth rate of more than 9% from 2011 to 2020, the second highest after immunization and ahead of digestive health. With women's greater willingness to spend on health, this sector has great potential. For a long time, the women's health market has focused on oral beauty, sports nutrition, and weight management, with a lack of focus on other sub-sectors, including women's hormonal health, anti-fatigue, head/shoulder/lumbar pain, and edema, which need to be further developed.

Trend 2: 1 in 10 people in Taiwan have sleep disorders

Emotional health has become one of the significant health issues of concern to consumers. Primarily because of the pandemic, it has affected consumers' daily lives. A survey conducted by the Taiwan Society of Sleep Medicine found that 1 in 10 people in Taiwan have sleep disorders. The average number of sleeping pills taken each year is the highest in Asia, and insomnia affects not only memory and concentration but also anxiety, obesity,

and chronic diseases. Insomnia continues to rise, and sleep disorders have become a social problem. To improve sleep conditions, more consumers will choose to take sleep supplements.

Trend 3: High prevalence of joint degeneration, predominantly in elderly, but gradually moving towards younger population

According to the Ministry of Health and Welfare, the prevalence of knee joint degeneration is about 15%. About 30% of people over 50 have degenerative arthritis, while the proportion of elders over 70 can reach over 70%. Additionally, there is a growing trend of younger patients in the 30 to 40 age group, indicating an increasing prevalence of health issues among young adults. The proportion of people with arthritis problems is growing, the number of people continues to increase, and the use of health foods is only 30%. The Centre for Communication and Public Opinion Research surveyed joint health awareness at the end of last year and received 505 responses. The results showed that more than 50% of the respondents had joint or knee pain 3.5 times more than 20 years ago. Another 40% of respondents aged 30 to 39 had joint pain. However, nearly 45% of those with joint pain did not take any measures to deal with it. More than 35% chose to use painkillers and ointments. 20% would use massage or acupuncture. Nearly 20% took painkillers. In addition, more than 30% of people will use supplements to protect their bones; 57% take glucosamine, 42% take calcium, and 28% take fish oil.

2) SWOT Analysis and Strategy

Strengths:

- **Product Diversity:** MBI offers a diverse product line, including intra-articular injections, dermal fillers, ophthalmic viscoelastic devices, and regenerative matrices for dentistry and surgery, effectively meeting the needs of various medical fields.
- **Technical Expertise:** The Company exhibits a high level of professionalism and innovation in the fields of biomaterials and regenerative therapy, particularly holding competitive advantages in product research and development process planning, product development, biocompatibility, product efficacy, and certification acquisition.
- **Global Certification:** With certifications including Taiwan QMS, ISO 13485, Korea KGMP, and U.S. FDA inspection records, the company demonstrates compliance capabilities that meet the entry barriers of the global market.
- **Policy Support and Market Recognition:** Thanks to the strong support from the Taiwan government for the biotech and medical industry, along with market recognition of high-quality domestic products, the company benefits from a favorable development environment and a solid market reputation.

Weaknesses:

- **Market Competition Pressure:** In the face of numerous competitors both domestically and internationally, particularly multinational companies that hold advantages in technology and market development, MBI must continuously enhance its innovation to sustain competitiveness.
- **Limitations on scale expansion:** The Company's size and resources are relatively constrained, which may impact its speed and scope of expansion into new markets, especially in highly competitive international markets.

Opportunities:

- **Growing market demand:** As the global population ages and health awareness increases, the demand for high-quality medical equipment continues to rise, particularly in the areas of arthritis, skin aesthetics, ophthalmic surgery, and dental treatment.
- **Technological partnerships and international expansion:** By forming technological collaborations and strategic alliances with international companies, the Company seeks to expand into overseas markets, particularly in other regions of Asia and emerging markets.
- **Trends in Regenerative Therapy and Minimally Invasive Products:** The market trend is shifting towards the regenerative applications of collagen/HA combined with stem cells or bioactive factors, which represents the direction for MBI to enhance its differentiated future technology strategy.

Threats:

- **Rapid technological changes:** The medical equipment sector undergoes swift technological iterations, necessitating ongoing Research and Development Investment to keep pace with advancements; otherwise, it risks falling behind.
- **Regulatory risks:** The medical equipment industry is subject to stringent international and regional regulations, and any changes in these regulations could impact product market access or sales.

The following outlines the strategy of this Company to leverage strengths, overcome weaknesses, seize opportunities, and address threats:

Strategies for Leveraging Strengths

- **Strengthening product innovation and research and development:** Continuously invest in product R&D, particularly in the fields of intra-articular injections and regenerative matrices, to develop more innovative and competitive products.
- **Exploring advanced technologies such as bioprinting and 3D printing for applications in regenerative matrices in dentistry and surgery.**
- **Group synergies:** Combine the R&D capabilities of TCI and TCI Gene to jointly develop regenerative medical products for the same indications.

Strengthening Brand Development and Market Promotion:

- By educating the market and enhancing brand awareness to increase recognition of our products, this company continues to conduct both online and offline professional seminars and public courses, with an increase in offline activities for overseas exchanges this year.
- Utilizing social media and digital marketing strategies to enhance brand visibility and market share, consistently posting on professional medical platforms, LinkedIn, Instagram, Facebook, and Line.

Strategies for Overcoming Weaknesses

- Expand International Market Share: Seek international partners for cross-border investments or joint ventures, especially in target-rich Asian markets..
- Participate in international medical exhibitions to enhance interaction and collaboration opportunities with international buyers.
- Enhance production efficiency and cost control by optimizing the production process and supply chain management to reduce production costs and improve the price competitiveness of products. Implement advanced manufacturing technologies and automation equipment to boost production efficiency.

Strategy for Seizing Opportunities.

- Develop products that align with market trends: Focus on the increasing demographics of the elderly population and patients with chronic illnesses, and create customized medical equipment tailored to these groups.
- Actively engage in government and industry initiatives: Participate in government-funded medical research projects and public health programs to enhance the Company's influence and credibility within the industry. Capitalize on opportunities arising from government-driven healthcare reforms and related policies, while seeking policy support and capital subsidies.

Strategies for Addressing Threats

- Strengthen regulatory compliance and risk management: Improve adherence to international and regional regulations through regular compliance reviews and internal training. Establish a comprehensive risk management plan that includes monitoring product quality control and market dynamics.
- Diversification of products and markets: Develop new product lines and services to reduce dependence on a single market or product. Explore synergies with other medical fields, such as innovative products that integrate drug delivery systems with regenerative therapy technology.
- By implementing these strategies, MBI can fully leverage its expertise in the biomedical field to address market challenges and sustain growth and success in the competitive global market.

1.3 Overview of Technology and Research and Development

(1) Technical Level of Business Operations and Research and Development

1) Biomedical Materials

A. Description of Research and Development Operations

The majority of biomedical materials products are intended for human use. Countries worldwide impose strict regulations on the research and development, production, quality control, and sales of medical device products. This Company's development process for biomedical materials products complies with the quality management system regulations established by the Taiwan Department of Health's Good Manufacturing Practice (GMP) for medical devices, ISO 13485, and the United States Food and Drug Administration (FDA) Quality System Regulation (QSR). The objectives of product research and development are to achieve innovation in medical device products, enhance clinical efficacy, and reduce production costs to improve product competitiveness.

MBI's high-quality biomedical research and development team possesses academic backgrounds in chemical engineering, medical engineering, materials science, and biotechnology, along with extensive experience in developing medical products. Building on core technology centered around biopolymer materials, we have continuously grown and developed, successfully creating several second and third-grade medical device products designed for tissue repair and filling functions. Moreover, the research and development team actively monitors trends in the medical device industry and pays close attention to various application fields, developing higher-value medical device products based on market demand and feedback. The application areas of our products, in addition to dentistry, orthopedics, ophthalmology, general surgery, and medical aesthetics, also include significant investments in research and development resources to actively expand into urology, obstetrics and gynecology, and otolaryngology medical device products.

The MBI research and development team consists of talents from various fields, with approximately 35 personnel dedicated to R&D, of whom 90% hold master's degrees or higher and possess substantial experience in medical device product development. Each year, over 10% of total revenue is allocated to research and development funding.

B. Current Progress and Future Work

Item	Current Progress	Future Work
Global Registration Expansion for Intra-articular Injection Products	<ul style="list-style-type: none"> ● Obtained MDSAP certification, facilitating entry into the markets of the United States, Japan, Canada, Australia, and Brazil. ● Intra-articular injection products have expanded into new markets in Southeast Asia, the Middle East, and Africa. ● Collagen products have expanded into new markets in the United States, Southeast Asia, and the Middle East. 	<ul style="list-style-type: none"> ● Intra-articular injection products, medical aesthetic fillers, and collagen products have obtained market approvals in regions such as Australia and South America in accordance with market strategy planning. ● Investment in post-market clinical trials to enhance marketing capabilities and improve registration efficiency in advanced countries.
Novel joint injection	<ul style="list-style-type: none"> ● Evaluation of multifunctional polymers or the introduction of active ingredients. ● Technology inventory and registration strategy. 	<ul style="list-style-type: none"> ● Development of candidate formulations and differentiation analysis. ● Planning and execution of preclinical testing. ● Launch timeline roadmap initiated.
Novel medical aesthetics filler	<ul style="list-style-type: none"> ● Market research and formulation of development direction. ● Establishment of a screening technology platform for active ingredients. ● Development of innovative cross-linking technology. 	<ul style="list-style-type: none"> ● Development of candidate formulations and differentiation analysis. ● Planning and execution of preclinical testing. ● Launch timeline roadmap initiated.
Injectable anti-adhesion filler	<ul style="list-style-type: none"> ● Completion of the establishment of differentiated candidate formulations. ● Establishment of the mass production process. 	<ul style="list-style-type: none"> ● Planning and execution of preclinical testing. ● Launch timeline roadmap initiated.
Novel resorbable bone graft material with osteoinductive properties	<ul style="list-style-type: none"> ● Completion of all preclinical tests. ● Verification of efficacy in multiple animal species. 	<ul style="list-style-type: none"> ● Planning for human clinical trials. ● Launch timeline roadmap initiated.

2) Source of technology

Maxigen Biotech Inc. was established in 1998, and first set up a technology R&D center in California, USA to research and develop collagen purification process technology, and then introduced collagen purification technology and mass production process to Taiwan by “whole factory imports and technology transfer” mode and set up a production factory. MBI focuses on the application of collagen and hyaluronic acid as advanced medical materials. MBI is one of the few medical material companies that have both collagen and hyaluronic acid product development technology and mass production. The Company has had breakthroughs and innovations in biotechnology research and development and have accumulated 14 patents, including 8 patents in the Republic of China, 2 patents in the United States, and 4 patents in the People’s Republic of China. According to this patented technology, MBI has established five core technologies for research and development, including collagen extraction and reconstruction, collagen ceramic compounding and shaping, calcium phosphate synthesis and sintering, hyaluronic acid cross-linking, and custom product development and OEM.

In addition, through the application and implementation of government subsidy programs such as the Ministry of Economic Affairs' Forward-Looking Technology Development Program and the Ministry of Science and Technology's Industry-Academia Cooperation Program, the Company has been able to establish key product technology platforms such as hyaluronic acid cross-linking with the most efficient investment of resources. MBI also has experience in technical cooperation with NuVasive and Exactech in the U.S., as well as experience in on-site factory inspection by the U.S. FDA and experience in planning a new factory in the Hua-Ya Science Park in Lin Kou. The Company has gradually built up complete capabilities in developing the biomedical materials industry, including core competencies in product development, production development, instrumentation validation, factory planning, production management and international certification. Currently, MBI is expanding the cooperation with domestic and foreign research institutions to strengthen the Company's technical capabilities in biomedical materials and believe that the Company will become a benchmark biotech company in Taiwan.

3) Technical Cooperation

The biotechnology and pharmaceutical industry are an industry with a high proportion of research and development, and the biotechnology and pharmaceutical industry in Taiwan started late and the market size is also small. It is difficult to develop internationally competitive products in the short term based on the conditions of domestic enterprises alone. Therefore, the Company actively cooperates with international medical material companies such as NuVasive and Exactech to provide staff with more opportunities to discuss and learn from international teams. In 2009, before MBI was inspected by the U.S. FDA, many personnel from NuVasive's quality control department were stationed to help MBI staff improve their deficiencies and rehearse preparations, which greatly contributed to the improvement of the Company's core competencies such as product development, process validation and auditing. In addition, the Company also actively engaged in industrial-academic cooperation with outstanding academic research institutions and medical schools in Taiwan, in the hope that the research and development capabilities of the academic and medical fields in Taiwan can be implemented in the development of Taiwan's biotechnology industry. In the past five years, units that have established industry-university cooperation with MBI include National Taiwan University, Tsinghua University, National Cheng Kung University, National Taiwan University School of Medicine, and National Cheng Kung University School of Medicine. The collaboration with the College of Dentistry of National Taiwan University and the College of Osteopathic Medicine of National Cheng Kung University has established a number of models for evaluating the efficacy of products in animals and designing products for clinical use, which has greatly contributed to the development of the clinical usefulness of the Company's medical products.

(2) Investment in funding and successful development of technology or products

1) Research and development expenses invested in the most recent fiscal year:

In 2024, the Company invested NT\$111,972 thousand in research and development (R&D), and the ratio of R&D expenses to operating revenues was 16.45%. The Company expects to continue to invest at least NT\$100 million per year starting in 2024. The following table shows the information of the past years:

Unit: New Taiwan Dollar (thousands)

Year	2020	2021	2022	2023	2024
R&D Expenses (A)	69,150	75,681	99,632	68,595	111,972
Net Operating Revenues (B)	457,691	511,976	604,431	622,115	680,651
Ratio (A)/(B)	15.11%	14.78%	16.48%	11.03%	16.45%

2) Successful technology or product development of the most recent year:

A. Research and development results of government-sponsored projects

In 2001-2004, the Company received a subsidy of NT\$14,880,000 from the Ministry of Economic Affairs for the "Collagen Tissue Engineering Application Technology Development Project" and a corporate capital contribution of NT\$33,090,000. During the implementation of this program, MBI established a collagen application technology platform and completed the product development of FormaGraft Collagen Bone Graft Matrix and obtained marketing approval from the U.S. FDA and Taiwan TFDA one after another. In 2007, NuVasive acquired Radius, the U.S. distributor of MBI's FormaGraft, for US\$16 million. In addition to entrusting the Company to continue manufacturing FormaGraft, NuVasive also invested US\$3 million in MBI and cooperated in the development of second-generation products. In 2007, MBI was awarded the Small and Medium Enterprise Research and Innovation Award by the Ministry of Economic Affairs and the First Biomedical Industry Competition by the Science and Technology Advisory Group of the Executive Yuan/Times Foundation for the development of FormaGraft. In addition, another product derived from this technology platform, GingivAid Collagen Bone Graft, was approved by the TFDA in Taiwan in 2011, successfully entering the dental bone filling material market. MBI is currently in the process of obtaining marketing approval for GingivAid in the US FDA, EU CE and China. In terms of economic benefits, at this stage, when MBI is new to the medical materials market and has not yet invested a lot of marketing resources, FormaGraft and GingivAid have already generated an annual turnover of over \$40 million, and with the gradual development of the international market in the future, it is believed that they will generate even higher contributions.

From 2008 to 2010, the Company received a subsidy of NT\$21,600,000 from the Ministry of Economic Affairs for the “Injectable Bone Filling Material Application Technology Development Project,” with a capital contribution of NT\$38,400,000 from MBI. During the implementation of the project, the Company successfully established a cross-linking technology platform for Hyaluronic Acid. This technology platform has also successfully developed the Formaderm Dermal Filler Injection, a product whose functional properties, such as in vivo degradation time, thrust properties and viscoelastic properties, are significantly ahead of domestic products and even comparable to Restylane (70% market share in Taiwan), a product of Q-Med, a major international manufacturer. The Company has already obtained the marketing approval in Taiwan in April 2012 and in China in April 2016, and the EU certification is under application. Due to the large global market for skin fillers, this product will bring huge potential profits to MBI after receiving international certification. The Company has been using this technology platform to develop a number of other new products related to skin filling, and now this series of products are being launched one after another to establish a more complete product line to enhance the competitiveness of MBI’s products and brand image.

In terms of new and innovative biomedical products, the Company has formally launched the development of drug-containing medical materials. The Company’s “Development Project of High-end Implantable Composite Medical Materials Containing Osteogenic Substances” was approved by the Ministry of Economic Affairs’ A+ Enterprise Innovation R&D Cultivation Program (Forward-Looking Technology R&D Program) in August 2018 and received NT\$43.2 million in subsidies. The total development cost for the preclinical stage of this product will exceed NT\$100 million. All preclinical testing has been completed, and we are now seeking international collaboration for joint development to commence human clinical trials and global product strategy planning, enhancing product technology and product lines, and creating innovative biomedical medical device products with a global competitive advantage.

B. System product development results

In addition to the Ministry of Economic Affairs (MOEA) subsidized industrial science project, the Company continues to invest in research and development to establish a more complete core technology and product line, such as ArtiAid Intra-articular Injection and ViscAid Ophthalmic Viscoelastic, of which ArtiAid is the first generation of five-dose injections (5 injections in a course of treatment) for joint injection. In order to further improve user convenience and to meet the needs of the international market, the Company has also completed the launch of ArtiAid-Plus Intra-articular Injection, the

second generation of a three-injection (three injections per treatment), and ArtiAid-Plus Intra-articular Injection, the third generation of a one-dose injection (one injection per treatment). At present, ArtiAid, ArtiAid-Plus and ArtiBest have obtained the marketing approval of TFDA in Taiwan and CE in EU one after another, and have been sold in Taiwan, Southeast Asia and EU. For ophthalmic products, the Company has launched ViscAid Ophthalmic Viscoelastic, a post-operative (cohesive) ophthalmic product, which has been sold in Taiwan, the PRC and Southeast Asia; in addition, the Company has also developed a pre-operative (dispersive) ophthalmic product, PrevisAid Ophthalmic Viscoelastic, which has been sold in Taiwan and Southeast Asia.

1.4 Short-term and Long-term Business Development Plans

(1) Short-term Business Development Plan

1) Marketing Strategy

Actively expand domestic channels to enhance product awareness and visibility, while vigorously developing the business of collagen-based skincare products and medical products.

A. In 2024, we actively participated in various medical associations both domestically and internationally, host overseas seminars, manage the official Line account, and revamp the official website. Below is the list of exhibitions and seminars.

	Specialty	Event Dates for 2024	Region	Organizer	Exhibition Title
Medical Devices	All Specialties	2024/1/29-2/2	Middle East	Informa Markets	2024 ARAB HEALTH International Medical Equipment Exhibition in Dubai
Medical Devices	dentistry	2024/3/16-3/17	Taiwan	Taipei City Dental Association New Taipei City Dental Association	2024 Greater Taipei International Dental Exhibition
Medical Devices	dentistry	2024/4/13-4/14	Taiwan	Taiwan Association of Dental Implants	ADI Taiwan Association of Dental Implants
Medical Devices	dentistry	2024/4/14	Taiwan	Taiwan Academy of Oral Medicine	Digital Dentistry and Intelligent Health
Medical Devices	Medical aesthetics	2024/4/21	Taiwan	Taiwan Society of Aesthetic Medicine	Spring Symposium of the Aesthetic Medicine Association - Satellite Lecture (Dr. Yang Shian)
Medical Devices	Medical aesthetics	2024/5/25-5/26	Taiwan	Taiwan Dermatological Society	Dermatological Society Annual Meeting (Spring) 2024 AMWC Asia
Medical Devices	dentistry	2024/8/17-8/18	Taiwan	Taiwan Asia-Pacific Dental Implant Association	Taiwan Asia-Pacific Dental Implant Association Membership Meeting and Academic Lecture
Medical Devices	dentistry	2024/8/18	Taiwan	Taiwan Periodontal Disease Medical Association	Taiwan Periodontal Disease Medical Association - Summer Symposium
Medical Devices	dentistry	2024/8/25	Taiwan	Taiwan Digital Dental Aesthetics Association	Taiwan Digital Dental Implant Aesthetic Society: To Be a Real Bone Builder
Medical Devices	dentistry	2024/09/08	Taiwan	Yang Ming, National Taiwan University, National Defense Medical Center, and China: Joint Collaboration of Four Institutions	Yang Ming, National Taiwan University, National Defense Medical Center, and China: The 21st Joint Annual Meeting and Academic Lecture of the Four Institutions
Medical Devices	dentistry	2024/10/19-10/20	Taiwan	Taiwan Periodontal Disease Medical Association	2024 Annual Meeting and Academic Seminar: Interdisciplinary Approaches to Periodontal Preservation and Alveolar Regeneration
Medical Devices	dentistry	2024/10/19-10/20	Taiwan	Taiwan Dental Regeneration Research Society	International Academic Conference: The Practice of Occlusion
Medical Devices	All Specialties	2024/10/19-10/20	Taiwan	Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital	2024 Chang Gung Medical Week: New Challenges in Healthcare - Mission, Vision, and Sustainability
Medical Devices	Orthopedics	2024/10/26-10/27	Taiwan	Orthopedic Medical Association of the Republic of China	86th Joint Academic Symposium
Medical Devices	dentistry	2024/11/09-11/10	Taiwan	Taiwan Dental Equipment Industry Exchange and Public Welfare Association & Taiwan Oral Biotechnology and Medical Equipment Industry Development Promotion Association (TAPO)	2024 Asia-Pacific Dental Materials Association Conference and Taiwan World Dental Materials Exhibition
Medical Devices	dentistry	2024/11/16-11/17	Taiwan	Alumni Association of the Department of Dentistry, Taipei Medical University	25th General Assembly: The Struggle Between Bone and Flesh???
Medical Devices	Orthopedics	2024/12/22	Taiwan	Taiwan Association of Integrative Medicine Annual Conference (Kangze)	Taiwan Association of Integrative Medicine 2024 Academic Annual Conference

B. Overseas Marketing Plan

- (A) Enhance brand exposure and awareness through active participation in international exhibitions, such as Arab Health.
- (B) Strengthen strategic partnerships and joint exhibitions with local distributors based on various countries and certifications.
- (C) Enhance the professional image of our brand in regenerative medicine, and increase product brand confidence by collaborating with local distributors to host seminars led by Taiwanese physician KOLs.
- (D) Sales and agency expansion, providing assistance with local medical instrument registration services to lower entry barriers for agents.

C. Marketing plan for the Taiwan market

- (A) Actively engaging in promotion and collaboration with KOLs: the Periodontal Society, TOMA, the Asia-Pacific Dental Implant Medical Association, and KOL clinical testimonials at the Medical Aesthetics Annual Conference: inviting prominent clinics and doctors for practical testing to establish an educational and recommendation cycle.
- (B) Hospital and clinic channels: developing a plan for the introduction of medical centers, regional hospitals, and chain dental and medical aesthetics clinics.
- (C) Promotion of consumer products, introducing health supplements to beauty chains, pharmaceutical e-commerce platforms (such as Momo and PChome), and exclusive sales platforms for physicians.
- (D) Digital and physical integration: Establishing Facebook and Instagram fan pages to promote product application knowledge and co-host health care seminars with distribution channels.

2) Production Strategy.

In response to the demand for flexible production and shipping, the Company's production capacity utilization plan is as follows:

- A. Flexibly utilizing existing production lines to establish a basic safety stock level for key products while fulfilling production orders. In addition to providing ample production capacity, we also fulfill clients' needs for flexible production and shipping.
- B. Enhance process improvement, process management, and equipment maintenance, while ensuring product quality stability through quality control to reduce costs and minimize rework and scrap rates.
- C. Actively seek high-quality raw material suppliers and outsourced testing service providers, maintaining positive interactions with suppliers to mitigate procurement risks and costs, while improving the quality of testing services, in order to establish a stable production line and ensure the safety and reliability of product quality.

D. The acquisition of new equipment will integrate existing processes into new machinery to improve product yield and output, continuously shorten production cycles, and reduce labor input.

3) Operations Management

Enhance training and education to strengthen professionalism and work philosophy, attract and develop exceptional talent, and foster employee cohesion.

(2) Long-term Business Development Plan

1) Marketing Strategy

Actively expand the business department by establishing three primary business teams, consisting of approximately 50 members: a direct sales team in Taiwan, a business team in China, and an international business team, to actively penetrate global markets.

A. Develop a rapid product line derived from core technologies in alignment with channel attributes to establish a revenue base.

B. Actively expand overseas channels for orthopedic and dental biomedical materials products, extending dental and ophthalmic products into the China market.

C. Establish our own brand and strategically penetrate the medical supplies market in mainland China.

D. Continuously enhance core capabilities and increase capital, acquiring new products and establishing intellectual property value through mergers and acquisitions.

E. Develop new products with high added value and significant barriers to entry.

F. Establish strategic alliances for new channel development to enter new industries.

2) Production Strategy.

A. Continuously implement automated machinery and equipment to enhance production efficiency, improve quality management systems, and align with international standards, thereby strengthening product quality commitments and reducing labor requirements.

B. Effectively organize processes based on client (market) orientation to shorten production timelines and minimize inventory stagnation.

C. Manage production processes to reduce costs, enhance quality, and create product value.

3) Operations Management

As this Company expands its business, future product marketing will extend to the global market. Management will empower each business unit to develop independently and will facilitate real-time coordination through online connections; In the financial aspect, we will enhance the management of exchange rate risks, with capital utilization grounded in the principle of stable operations, aiming to achieve the Company's operational objectives of internationalization, industrial specialization, vertical integration, and horizontal development.

2. Market and Production and Sales Overview

2.1 Market Analysis

(1) Primary sales regions of products or services:

Unit: New Taiwan Dollar thousands;%

Sales Region \ Year		2023		2024	
		Sales Revenue Net Amount	Percentage of net sales revenue	Sales Revenue Net Amount	Percentage of net sales revenue
Overseas customers	Americas	198,811	31.96%	196,566	28.88%
	Europe	27,925	4.49%	58,975	8.66%
	Asia	95,817	15.40%	75,121	11.04%
	Others	23,940	3.85%	51,133	7.51%
	Subtotal	346,493	55.70%	381,795	56.09%
Domestic Customers		245,226	275,622	298,856	43.91%
Total		604,431	622,115	680,651	100%

(2) Market Share

The Company's main product, intra-articular injections, is estimated to have a market share of approximately 25% in Taiwan based on the analysis of the usage of special materials by the Central Health Insurance Agency of the Ministry of Health and Welfare in 2022. As for collagen-related products for cosmetic and medical use, the collagen industry in Taiwan is a small and medium-sized enterprise, and because the international market is closed to the collagen industry, effective statistics and analysis are not possible.

(3) Market supply and demand situation and growth in the future

1) Stable Demand in the Medical Market:

According to a new report on the biotechnology industry by The Business Research Company, the global market for medical materials will reach US\$456.9 billion in 2019, with an average compound annual growth rate (CAGR) of 4.4% since 2015. Although global growth is expected to stagnate slightly in 2020 due to the impact of COVID-19, the expected market performance trend is expected to grow at a compound annual growth rate of 6.1% to US\$603.5 billion from 2021 to 2023 as underlying demand remains and the global medical market gradually recovers.

Take the domestic market as an example, Taiwan's overall medical device market demand can be divided into two major levels. The first is the demand for medical care linked to the health insurance system and Long-Term Care 2.0, which is related to epidemiology, the number of people suffering from diseases and the number of people requiring care for long term care, and this demand is growing steadily. The second is self-funded quality of life demand, related to orthodontics, medical aesthetics and self-funded medical care, which is closely related to personal affordability and economic development. The changes in demand for medical devices in Taiwan over the years Main related to the aging and increasing demand for medical care for chronic diseases, and the long-term demand is growing steadily.

2) Growth of the Aging Population Market:

According to the US Census Bureau, 8.5% of the world's population, or more than 600 million people, will be over 65 years old by 2050, and 1.6 billion people, or 17%, will be over 65. The global average life expectancy is estimated to increase from 68.6 years in 2015 to 76.2 years, and the number of "super old" people over 80 years old will increase from 126.5 million in 2015 to 446.6 million. It is estimated that the future growth of the medical materials market will be greatly influenced.

According to the National Development Council of the Republic of China's population projection query system, the country became an aging society in 1993, became an aging society in 2018, and is projected to become a super-aging society in 2025. The number of people over 85 years of age in Taiwan accounts for 10.3% of the elderly population and is expected to increase to 27.4% in 2070. The aging population is not only a social problem in Taiwan, but also a global issue. Therefore, the demand for anti-aging beauty products and assistance for diseases caused by aging is also increasing. For example, degeneration of joint cartilage or degenerative arthritis caused by aging or damage to joint cartilage is one of the cases where effective medical treatment is the only way to reduce discomfort and maintain the health of the patient. The growing number of senior citizens has increased the demand for long-term care services. With the official launch of the Long-Term Care 2.0 policy in January 2017, its objectives hope to bridge the front-end of preventive care, vital aging, and disability reduction, promote the health and well-being of the elderly, enhance the quality of life of the elderly, and promote the improvement of overall medical standards.

3) Drivers of the Medical Aesthetics Market:

As the global economy develops and quality of life improves, the public's focus on appearance and health is increasing, which is driving stable growth in the medical aesthetics industry. According to data from Allied Market Research, the global medical aesthetics market is projected to expand from approximately USD70 billion in 2023, with an annual compound growth rate exceeding 10% before 2030. Medical aesthetic treatments such as intense pulsed light, radiofrequency skin tightening, and injections of hyaluronic acid and collagen have been widely utilized for skin rejuvenation, contour modification, and aging reversal, closely aligning with the demand for post-surgical recovery products. In light of this trend, MBI, with its biomedical background and expertise in the development of regenerative medical materials, holds a distinct advantage in entering the medical aesthetics industry.

In the future, MBI will continue to invest in the expansion of its Medical Aesthetics product line, integrating digital marketing, professional physician training, and participation in academic conferences to enhance the brand's professional medical aesthetics distribution network across Asia, the Americas, and the Middle East, thereby maximizing the potential of regenerative technology in beauty applications.

(4) Competitive Niche

1) High Safety of Raw Materials

The collagen raw material utilized by this Company is sourced from beef tendons, primarily from the New Zealand and Australia regions, which are recognized by the World Health Organization as non-BSE (Bovine Spongiform Encephalopathy) areas, thus presenting an extremely low risk of BSE. The Company's collagen production process employs a virus-free method and has been validated, further ensuring the safety of the raw materials.

2) The raw materials exhibit excellent functionality.

The Company's collagen purification technology is advanced, allowing for the production of both soluble collagen and fibrous collagen, while also enabling control over the length of fibrous collagen. This provides the Company with a variety of raw material specifications to choose from, thereby accommodating the design and development of different product functionalities and characteristics, ultimately leading to the development of optimal product functions that meet clinical needs.

3) The product quality is excellent.

In the collagen extraction process, insufficient extraction technology or high-temperature processing may prevent the complete retention of collagen's original structure. This Company employs a proficient process that yields collagen raw materials with low pyrogen (endotoxin) levels and enhanced resistance to enzymatic degradation in the body.

4) Cost-effective management.

Due to This Company's medical grade collagen production process, which is suitable for large-scale manufacturing, the price of This Company's collagen is significantly lower than that of internationally available medical grade implantable collagen. Competitors will not be able to substantially improve their cost structure in the short term.

5) Highly recognized in the international market

This Company's products have been sold in the United States for many years, with no recorded negative clinical events. Furthermore, the Company successfully passed a routine FDA inspection in October 2009 with no deficiencies. The Company's medical facility has also successfully undergone assessments from major European and American companies, indicating that the international market highly recognizes the quality of the Company's products and production processes.

6) Possesses a high level of technological integration capability

Due to the Company's ability to produce raw materials in-house, it can effectively control key upstream and downstream raw materials and technologies. The Company's high level of technological integration capability and experience can be effectively applied to the research and development, production, and quality control of new products, providing a significant competitive advantage over peers.

(5) Favorable Factors, Unfavorable Factors, and Countermeasures for Development Prospects

1) Favorable Factors:

A. Production technology and equipment superior to competitors

Due to certain Hyaluronic Acid products failing to achieve sterilization after being converted into end products, this Company has independently developed a sterile and automated production system and equipment. In terms of laboratory product technology and practical production techniques, we are more comprehensive than domestic competitors, enabling us to maintain stable product quality and functionality. For collagen products, various production parameters are adjusted to control degradation time, hemostatic rate, and the capacity to induce tissue regeneration.

B. Quality systems certified both domestically and internationally.

(A) Completed FDA facility inspection in 2018 and obtained the Establishment Inspection Report (EIR) in 2019.

(B) Completed TFDA QMS update verification in 2022.

(C) Completed ISO 13485 update verification in May 2023.

(D) Obtained Korean KGMP certification.

(E) Completed MDSAP (United States, Canada, Japan, Brazil) audit in May 2023 and received certification in July.

(F) Conducted TGA facility inspection in Australia in 2023 and obtained quality system certification in 2024.

(G) The MDSAP audit in February 2025 included Australia TGA.

C. Award Recognition

(A) Formagraft collagen-ceramic composite bone filler was marketed in the U.S. and received the Innovation Research Award from the Ministry of Economic Affairs and the First Taiwan Biomedical Industry Selection Competition Award from the Executive Yuan.

(B) Won the National Brand Yushan Award for Excellent Enterprise Category

(C) Won first place for the National Brand Yushan Award for Excellent Enterprise

(D) Awarded the National Brand Yushan Quality Award for Outstanding Corporate Leader.

(E) Awarded the National Brand Yushan Quality Award for Best Popular Brand.

(F) Awarded the National Brand Yushan Quality Award for Best Product.

(G) Received the Outstanding Biotechnology Industry Award - Potential Benchmark Award.

(H) Good Joint 633 Probiotics Capsule obtained the SNQ Symbol of national Quality

(I) MBI's Good Joint 633 won the food industry Oscar - Monde Selection.

(J) 2023 Biotechnology Breakthrough Award in the USA for "Nutritional Health Product of the Year."

(K) 2023 ACES Asia Corporate Excellence & Sustainability Award

(L) 2024 Quality Award by Monde Selection

D. Strategic Alliance with International Major Enterprises

NuVasive, a NASDAQ-listed company in the United States, is a strategic alliance partner of MBI Company, marketing the biomedical products Formagraft and AttraX Scaffold manufactured by this Company in markets including North America and the European Union. The merger of Globus Medical and NuVasive in 2023 further enhances connections within the U.S. orthopedic and surgical markets.

E. Research and Development Capabilities

Leveraging group resources, such as the multifunctional R&D department of TCI and the stem cell research of TCI Gene, allows for the exchange and support of research equipment and collaboration among professionals, leading to cross-disciplinary development and the creation of differentiated medical devices. With nearly 35 R&D personnel, we achieve balanced development in product development processes, creativity, efficacy verification, and product certification capabilities.

F. Market Expansion Capability

The Business Center team of over 50 associates, plus TCI, the parent company's KA, total 150 and extends across China, the U.S., Europe, Japan, and Southeast Asia. As a result, our global business continues to develop and refer, and we can achieve comprehensive results.

2) Adverse Factors:

The process of obtaining international certification for medical devices is time-consuming.

Following the passage of the Food and Drug Regulations by the U.S. Congress in 1976, biomedical materials must undergo rigorous in vitro and animal testing, followed by clinical testing before they can be marketed. Due to the intense competition in the markets of Europe, America, Japan, and other countries, it is essential to obtain certification from the local authorities before sales can commence. The capital and time invested during this period are considerable. Even if certification is successfully obtained, entering the international market remains fraught with challenges without established sales channels.

Response Strategy:

- A. This Company rigorously controls the production process, ensuring that the manufacturing procedures comply with international quality management standards.
- B. This Company actively collaborates with academic research and development institutions to develop new technologies and products, effectively mastering key technologies and patent rights, obtaining favorable clinical data and product usage validation reports, thereby enhancing product advantages.
- C. The Medical Device Products are actively pursuing global certification strategies, with certification timelines of 1 to 5 years becoming an unavoidable issue in the medical device industry. Therefore, the earlier the strategy is implemented, the greater the competitive advantage. Since 2022, we have accelerated our global certification planning, gradually demonstrating results. In 2023, we obtained over 20 market approvals, a record high for the company. In 2024, we secured 13 market approvals, including new market entries in Thailand, Australia, and Peru. We anticipate continued rapid accumulation of market approvals globally in 2025.

2.2 Main Product Uses and Production Processes

(1) Significant Uses of Main Products

The biomedical materials produced by this Company can be classified into three main categories based on material type: biopolymers, bioceramics, and composites, which are primarily used in implantable orthopedic filler materials. Currently, biomedical materials are utilized not only in traditional medical devices but also in the development of materials for tissue engineering. The objective of tissue engineering is to replace body parts that have sustained functional defects due to disease or injury, facilitate wound healing, and enhance the functionality of organs and tissues. This involves repairing or replacing defective or abnormal tissues and organs, and it constitutes one of the foundational studies in regenerative medicine.

(2) Production Process

This Company's medical equipment factory has successfully obtained ISO 13485 certification, as well as compliance with the quality management system guidelines of the Ministry of Health and Welfare in Taiwan, the Good Manufacturing Practice (KGMP) standards of the Ministry of Food and Drug Safety in South Korea, the Quality System Regulation (QSR) of the United States Food and Drug Administration (US FDA), international MDSAP, and certifications from Russia (Roszdravnadzor). In accordance with the relevant QMS regulations, this Company implements stringent quality control measures throughout the production of its products. Quality control inspections from raw material intake to finished product shipment confirm that all incoming materials, semi-finished products during the process, and finished products meet established acceptance standards, ensuring that all products comply with client requirements.

2.3 Names of customers that accounted for more than ten percent of total sales in any of the last two fiscal years, along with their corresponding sales amounts and percentages, and an explanation of the reasons for any increases or decreases.

(1) Major sales customers

Unit: New Taiwan Dollar thousands

Item	2023				2024			
	Name	Amount	Percentage of Total Annual Net Sales (%)	Relationship	Name	Amount	Percentage of Total Annual Net Sales (%)	Relationship
1	Company A	95,166	15.30%		Company A	108,361	15.92%	
2	Company B	83,143	13.36%	Investor with significant influence	Company B	6,564	0.96%	Investor with significant influence
3	Others	443,806	71.34%		Others	565,726	83.12%	
—	Net Sales	622,115	100.00%		Net Sales	680,651	100.00%	

This Company's primary business activities are the manufacturing and sales of biomedical medical device products and skincare products. Both Company A and Company B are clients in the biomedical medical device sector, and the ongoing development and sales of products with clients have driven sustained growth in the international market.

(2) Major Suppliers

Unit: New Taiwan Dollar (thousands)

Item	2023				2024			
	Name	Amount	Percentage of Total Annual Net Sales (%)	Relationship	Name	Amount	Percentage of Total Annual Net Sales (%)	Relationship
1	Company A	28,941	22.51%	Investor with significant influence	Company A	17,247	16.31%	Investor with significant influence
2	Company B	14,594	11.35%		Company B	23,287	22.02%	
3	Company C	20,920	16.27%	The Company's parent company	Company C	719	0.68%	The Company's parent company
4	Company D	26,798	20.84%		Company D	20,972	19.83%	
5	Others	37,310	29.03%		Others	43,523	41.16%	
6	Net Purchases	128,563	100.00%		Net Purchases	105,748	100.00%	

Company A is a supplier of ceramic raw materials, Company B is a supplier of hyaluronic acid raw materials, Company C is a contract manufacturer of skincare products, and Company D is a supplier of materials related to hyaluronic acid products. The changes between the two periods are primarily due to adjustments in sales strategies for different regions, resulting in fluctuations across various product lines.

3. Employee Information

Year		2023	2024	2025/04/30
Number of Employees	Management Staff	18	20	19
	Logistic Staff	19	19	18
	R&D Staff	22	26	23
	Salesperson	23	24	28
	Factory Staff	47	50	52
	Direct Staff	129	139	140
Average age		38.1	39.0	39.1
Average Years of Service		3.96	4.1	4.5
Education	Ph.D	3.9%	3.6%	3.6%
	Master	27.9%	28.1%	25.0%
	Bachelor	56.6%	55.4%	57.1%
	Senior High School	11.6%	12.9%	14.3%
	Lower than Senior High School	100.00	100.00	100.00

Note: Human resources statistics for the entire group (including subsidiaries, full-time dispatch, and contracted staff, excluding temporary manpower).

4. Information on environmental protection expenditures

4.1 Losses suffered due to environmental pollution in the latest year and as of the printing date of the annual report (including compensation and environmental protection audit results for violations of environmental laws and regulations, with the date of sanction, sanction number, provisions of laws and regulations violated, contents of laws and regulations violated, and contents of sanction): None.

4.2 Future response policies (including improvement measures) and possible expenses (including the estimated amount of losses, penalties and compensation that may occur if no response measures are taken): None

5. Labor Relations

5.1 The Company's employee welfare measures, education, training, retirement system and its implementation, the agreement between the employers and the employees, and the implementation of the employee's right protection.

(1) Employee welfare measures, education, training and its implementation

To create a good and harmonious working environment, in addition to the various welfare measures required by the government, the Company also provides several measures to take care of employees.

- 1) Sound rules and regulations, such as promotion, reward and punishment, performance appraisal, attendance, leave, salary and other systems, are all clearly listed in the management rules and regulations. The management rules and regulations are formulated in accordance with the basic spirit of the Labor Standards Law for the purpose of taking care of employees.
- 2) The year-end bonus is calculated based on 2.5 months, with additional performance bonuses awarded quarterly based on performance and MBI Star recognition and rewards.
- 3) Subsidies for the purchase of office information equipment, childcare subsidies, and scholarships for Employees' children, as well as funding for master's and doctoral degree studies.
- 4) Gifts and vouchers are distributed to Employees during the Spring Festival, Dragon Boat Festival, Mid-Autumn Festival, and Labor Day.
- 5) Provides group insurance for each employee.
- 6) A labor welfare committee is established in accordance with the law to allocate welfare funds for organizing employee gatherings, birthday celebrations, team-building activities, travel, and year-end parties.. as well as other measures to promote emotional connections among employees.
- 7) The Company provides parking spaces for vehicles and dormitories for employees.
- 8) Provide employees with delicious and healthy lunch catering, afternoon tea, and overtime dinner. Special meals or snacks are offered during festive occasions.
- 9) A breastfeeding room has been established to uphold the spirit of the Gender Equality Work Act.
- 10) Annual health check-ups for employees are conducted.
- 11) Employees are encouraged to pursue further training while employed.

(2) Retirement System

In accordance with the provisions of the Company's retirement policy, employees who have served for at least 15 years and reached the age of 55 or have worked for at least 25 years, and those who have worked for at least 10 years and reached the age of 60, may apply for retirement; employees who have reached the age of 65 or are mentally or physically disabled and unable to perform their duties may be ordered to retire. The pension benefit is based on the number of years of service, and two bases are provided for each year of service for employees in the old system. However, for each year of service in excess of fifteen years, a base figure will be given, up to a maximum of forty-five base figures. For those who have not completed half a year, they are counted as half a year; for those who have completed half a year, they are counted as one year and are subject to the new labor pension system, the Company shall contribute 6% of their insured salary to their individual pension accounts on a monthly basis.

(3) Agreements between labor and management and various measures for the protection of employee rights.


The Company adopts an open and two-way communication approach to the promotion of policies and understanding of employees' opinions, so as to maintain harmonious relations between employers and employees, and there is no problem of labor disagreement, and holds regular labor-management meetings to provide a platform for the exchange of opinions.

5.2 Losses incurred due to labor disputes during the most recent fiscal year and up to the date of publication of the Annual Report (including violations of the Labor Standards Act as indicated by labor inspection results, specifying the date of disposition, disposition number, violated regulatory provisions, content of the violations, and details of the disposition), along with the disclosure of estimated amounts that may arise currently and in the future, as well as Response Measures: None.

6. Information Security Management

6.1 The status of the information security risk management framework, information security policy, specific management plans, and measures implemented for information security management.

(1) Risk Management Framework



(2) Security Policy

This Company has established its Information Security Policy based on ISO 27001 and BS7799 as reference standards, tailored to the actual management needs of the Company. The primary information security management requirements serve as a foundation, focusing on the relevant information services provided by the strategic data center, as well as the associated departments within the Company.

To maintain the Company's competitive advantage, all employees must adhere to the relevant information protection measures issued by the Company, ensuring effective self-management and possessing information security awareness. In addition to the information security control measures provided by the information systems, we place greater emphasis on protecting the confidentiality, integrity, and availability of important personal and transaction data. Simultaneously, we enhance information security management to ensure the security of data, systems, equipment, and networks, thereby creating a healthy information environment. We implement innovative information security protection technologies and carry out information security management operations to improve the quality of services offered by MBI Biotechnology.

(3) Specific Management Solutions

Our company has established a comprehensive information security management framework and formed an "Information Security Management Committee" to coordinate, manage, and supervise the group's information security operations. We have allocated 10 dedicated information security engineers responsible for planning and executing security tasks. The annual investment in information security is approximately NT\$2 million, covering system setup, testing, education and training, and consulting services. The internal audit unit conducts annual information security audits based on the internal control system's "Electronic Information Cycle" processes to assess the effectiveness of the company's internal controls in information operations.

1) Information Security Protection and Control Measures

- A. Establish access control, authentication for login systems, password management, and access authorization mechanisms.
- B. Regularly perform vulnerability scans, install antivirus software, and promptly update security patches from the vendor.
- C. Control USB access permissions and conduct weekly offsite backup operations.
- D. Establish redundancy mechanisms and endpoint protection measures to reduce the impact of security incidents on operations.
- E. Conduct annual mandatory information security training and testing for all employees to enhance their awareness of security risks.
- F. Perform annual information security audits to ensure the effective operation of security mechanisms.

2) Recent Major Initiatives and Outcomes

- A. Mandatory implementation of email verification (February 2024) Initiated the DMARC policy (Domain-based Message Authentication, Reporting, and Conformance), isolating all emails that did not pass the DMARC check. This mechanism combines DKIM (DomainKeys Identified Mail public/private key encryption technology) and SPF (Sender Policy Framework), effectively preventing spam abuse and reducing junk emails received by users.
- B. Firewall upgrade and high availability integration with AD authentication (March 2024) Upgraded the Palo Alto firewall to improve network traffic processing efficiency and integrated AD authentication, reducing malicious traffic by 80% and improving network speed by 50%, effectively lowering the chances of attacks.

- C. HR, Operations Control, and Finance deploying Deep Instinct AI anti-hacking system (June 2024) Introduced Deep Instinct's deep learning prevention platform, which intercepts and prevents threats before malware execution, enhancing the information security capabilities of core departments.
- D. Establishing EDL (External Dynamic Listing) service servers (June 2024) Established IP blacklisting and URL blacklisting mechanisms to centrally manage and synchronize with 9 Palo Alto firewalls in the group, effectively blocking malicious sources.
- E. Establishment of Information Room Monitoring System (2024/08) Enhance physical security by installing monitoring cameras and other protective equipment in the information room to ensure the safety of critical information facilities.
- F. Mandatory Application of Email MFA Multi-Factor Authentication (2024/09) Fully enforce the activation of multi-factor authentication for the email system to reduce the risk of account theft, decreasing phishing attacks and unauthorized access incidents by 85%, effectively preventing email fraud and human error.
- G. Enabling MFA Multi-Factor Authentication for PA Firewall Administrator Accounts (2024/09) Multi-factor authentication will be fully enabled for administrator accounts of the Palo Alto firewalls (Taipei, Shifang IDC, Hualien, Hsinchu laboratory, Peifu, Panshi, Shanghai Jinshan, Jing'an, and the USA), replacing local account login, reducing the risk of breaches by 80%, and strengthening access control for firewall management.

6.2 Clearly state the losses, potential impacts, and response measures incurred due to significant information security incidents for the most recent year and up to the date of the annual report's publication. If a reasonable estimation is not possible, the facts regarding the inability to provide a reasonable estimate should be explained: None.

7. Significant Contracts

Nature of the Contract	Parties Involved	Contract Start and End Dates	Main Content	Restrictive Clauses
Supply	United States Company	99.06.23~114.06.22	The parties agree on the terms of purchase and sale of goods	No Significant Restrictions

V. Review of Financial Conditions, Financial Performance, and Risk Management

1. Financial Condition

1.1 Major Reasons and Impacts of Significant Changes in Assets, Liabilities, and Shareholders' Equity over the Past Two Years

Unit: New Taiwan Dollar (thousands)

Items	Year	2024	2023	Changes in Increases and Decreases	
				Amount	%
Current Assets		830,334	619,563	210,771	830,334
Property, Plant and Equipment		311,312	432,800	(121,488)	311,312
Right-to-use Assets		430,363	424,178	6,185	430,363
Investment Real Estate		-	-	-	-
Intangible Assets		129	486	(357)	129
Other Assets		10,351	15,959	(5,608)	10,351
Total Assets		1,582,489	1,492,986	89,503	1,582,489
Current Liabilities		205,869	131,373	74,496	205,869
Non-current Liabilities		1,493	510	983	1,493
Total Liabilities		207,362	131,883	75,479	207,362
Share Capital		891,631	889,341	2,290	891,631
Advance Share Capital		5,130	957	4,173	5,130
Capital Surplus		326,932	296,096	30,836	326,932
Retained Earnings		344,120	244,457	99,663	344,120
Other Equity		(192,686)	(69,748)	(122,938)	(192,686)
Total Equity		1,375,127	1,361,103	14,024	1,375,127

The main reasons for significant changes (those with a variation exceeding twenty percent and a monetary change of more than NT\$10 million) and their impact analysis are as follows:

1. Current Assets: This increase is primarily attributed to business growth in 2024, leading to a rise in cash and accounts receivable.
2. Financial Assets Measured at Fair Value through Other Comprehensive Income - Non-current, Other Equity: This adjustment is mainly due to strategic investments evaluated at market price in 2024.
3. Current Liabilities: This increase is primarily due to business growth in 2024, resulting in higher advance payments and increased payments to suppliers.
4. Capital Surplus: Primarily resulting from the conversion of Employee Stock Options in 2024.
5. Retained Earnings: Primarily resulting from strong operating profitability in 2024.

1.2 Significant impacts should be explained regarding future response plans: There is no significant impact on the company's finance or business.

2. Financial Performance

2.1 The main reasons and impacts of significant changes in operating income, operating profit, and pre-tax net profit over the past two years.

Unit: New Taiwan Dollar (thousands)

Items \ Year	2024	2023	Increase (Decrease) Changes	
	Amount	Amount	Amount	Amount
Net Operating Income	680,651	622,115	58,536	680,651
Operating Cost	(197,326)	(198,021)	(695)	(197,326)
Operating Gross Profit	483,325	424,094	59,231	483,325
operating expenses	(303,419)	(274,244)	29,175	(303,419)
Non-operating Income and Expenses	45,639	43,292	2,347	45,639
Pre-tax Net Profit (Loss)	225,545	193,142	32,403	225,545
Net Profit (Loss) for the Period	190,167	165,828	24,339	190,167
The main reasons and impacts of significant changes (those with a change of twenty percent or more and a monetary change exceeding NT\$10 million) are: None.				

(2) Expected Sales Volume and Its Basis, Potential Impacts on the Company's Future Finance and Business, and Response Plans:

Sales volume is determined based on market demand conditions and considering this Company's production capacity. This Company has also reviewed and improved production efficiency and material costs, and it is anticipated that in the future, benefits from economies of scale will significantly contribute to revenue and enhance profitability.

Furthermore, this Company will judiciously employ financial leverage to reduce operating costs and establish a mutually beneficial relationship with banks to enhance financial performance.

3. Cash Flow

3.1 Analysis of Cash Flow Changes for the Recent Fiscal Year

Unit: New Taiwan Dollar (thousands)

Item	Year		Increase (Decrease) Amount	Percentage Change (%)
	2024	2023		
Net Cash Flow from Operating Activities	298,223	171,200	127,023	74.20
Net Cash Flow from Investing Activities	(29,072)	(490,246)	(461,174)	(94.07)
Net Cash Flow from Financing Activities	(59,729)	(41,393)	18,336	44.30
<p>Analysis of Cash Flow Changes:</p> <p>1. Net Cash Flow from Operating Activities: In 2024, there was an increase compared to 2023, primarily due to business growth, increased inventory, and a rise in advance payments received.</p> <p>2. Net cash outflow from investing activities: In 2024, it decreased compared to 2023, primarily due to strategic investments made in 2023.</p> <p>3. Net cash outflow from financing activities: In 2024, it increased compared to 2023, primarily due to an increase in cash dividends distributed in 2024 compared to 2023.</p>				

3.2 Improvement plan for liquidity insufficiency: Not applicable.

3.3 Cash liquidity analysis for the upcoming year

Unit: New Taiwan Dollar (thousands)

Cash Balance, Beginning of the Year	Forecast Net Cash Inflow from Operating Activities	Forecast Net Cash Flow from Investing Activities	Forecast Net Cash Flow from Financing Activities	Forecast Cash Balance (Deficit) (1)+(2)-(3)	Remedial Measures for Cash Shortage	
					investment plan	Financing Plan
639,054	300,000	(100,000)	(80,000)	759,054	—	—
<p>1. Analysis of Cash Flow Changes for the Upcoming Fiscal Year: Operating Activities: Revenue and profitability continue to grow steadily, resulting in a net cash inflow. Investing Activities: Primarily cash outflows for the purchase of equipment. Financing Activities: Primarily cash payments for cash dividends.</p> <p>2. Remedial Measures for Projected Cash Shortage and Liquidity Analysis: Not Applicable.</p>						

4. The Impact of Recent Major Capital Expenditures on Financial Operations: None.

5. Recent year's investment policy, the main reason for its profit or loss, improvement and investment plan for the next year

5.1 Investment Transfer Policy

In response to the development of global clients, this Company's investment transfer strategy aims to expand overseas markets and deepen engagement in key countries, thereby increasing overseas revenue and market share.

5.2 Main reasons for the profitability or loss of the investment transfer business and the corresponding improvement plan

Unit: New Taiwan Dollar (thousands)

Item \ Explanation	Profit or loss amount for 2024	Policy	Profit or Loss Main Reason	Improvement Plan	Future Investment Plans
MBI Biotechnology (Shanghai) Co., Ltd.	(32,891)	Sales of Medical Instruments and Cosmetics	Sales Activities Not on Track	Strengthen Sales Channel Development	None
HeRui Biotechnology Co., Ltd. (Note)	None	None	None	None	None

Note: The company's liquidation process was completed on July 18, Year 113 of the Republic of China.

5.3 Investment Plan for the Coming Year: None.

6. Risks and assessments for the latest year and up to the date of publication

6.1 The Impact of Interest Rates, Exchange Rate Fluctuations, and Inflation on the Company's Profit and Loss and Future Response Measures

(1) The Impact of Recent Annual Interest Rate Changes on the Company's Profit and Loss and Future Response Measures:

1) Impact on Profit and Loss

This Company, adhering to prudent and conservative financial principles, has not taken out any loans during this fiscal year, despite recent market interest rates being at relatively low levels, which has had minimal impact on the Company. In the future, we will continue to monitor domestic and international interest rate changes to better understand future trends and respond in a timely manner.

2) Future Response Measures

Although interest rates have minimal impact on the Company's profit and loss, this Company will continue to maintain strong relationships with banks to stay informed of interest rate changes and will adjust the terms of transactions with various banks based on their capital costs.

(2) The impact of recent fiscal year exchange rate fluctuations on the Company's profit and loss, as well as future response measures:

1) Impact on Profit and Loss

For 2024 and 2025, the Company recognized exchange gains and losses of NT\$10,802 thousand and NT\$4,706 thousand, respectively. The Company adheres to a conservative and prudent approach, monitoring domestic and international macroeconomic and political conditions, tracking exchange rate fluctuations and trends to mitigate the risk of foreign exchange losses and enhance currency value.

2) The future response measures are outlined as follows:

A. The finance department maintains close communication with the foreign exchange departments of various financial institutions, continuously collecting relevant information on exchange rate changes to fully understand domestic and international exchange rate trends and variations, thereby minimizing the negative impacts resulting from exchange rate fluctuations.

B. When quoting to clients, consider the potential impact of exchange rate fluctuations and adopt a more conservative exchange rate as the basis for pricing, thereby reducing the extent to which exchange rate volatility affects profits from confirmed orders.

C. Open foreign currency deposit accounts with correspondent banks to meet foreign exchange capital needs, retain foreign currency positions, and adjust foreign exchange holdings in a timely manner based on exchange rate fluctuations to mitigate their impact.

D. When exchange rate fluctuations are significant, employ other tools to hedge against foreign exchange risk, such as engaging in forward foreign exchange transactions, to effectively mitigate the effects of exchange rate changes.

(3) The impact of recent fiscal year inflation on the Company's Profit and Loss and future Response Measures:

According to the Consumer Price Index (CPI) published by the Executive Yuan's Directorate-General of Budget, Accounting and Statistics, the average annual increase for 2024 is 2.18%. This Company will continue to monitor trends in raw material price fluctuations. Should inflation or other factors lead to an increase in procurement costs, this Company will appropriately adjust sales prices and raw material inventory levels, while continuously seeking multiple sources of supply to mitigate the impact of rising costs on Profit and Loss.

6.2 Policies regarding high-risk, high-leverage investments, lending capital to others, endorsement guarantees, and trading in derivative products, along with the primary reasons for profitability or loss and future response measures.

(1) Lending capital to others: None.

(2) Engaging in high-risk, high-leverage investments, endorsement guarantees, and trading in derivative products: None.

6.3 Future research and development plans and the anticipated investment in research and development expenses.

(1) Biomedical products

This Company's research and development plans for biomedical medical device products will focus on high value-added, implantable medical device product development. Key research and development projects include a series of joint injection products, a series of tissue fillers, new types of artificial bone materials, and injectable anti-adhesion fillers. Over the next five years, approximately NT\$200 million will be invested in research and development expenses, which will cover the establishment of automated equipment for various development items, preclinical testing, clinical trials, and certification costs in various countries. The key products planned for development not only feature high unit prices and strong market competitiveness but also enhance patients' quality of life, positioning MBI as a biotechnology company that supplies advanced implantable medical devices. MBI Company will establish its foundation in Taiwan while aiming for the global market, taking a further step towards its vision of becoming an internationally recognized biotechnology company.

MBI continues to invest resources in the research and development of core technologies and to develop advanced medical device products that meet market demand. We are continuously enhancing the company's quality management system to align with international standards, improving the quality control and risk management of internal operational processes to ensure that products are well-managed throughout their life cycle.

- 1) Product commercialization and the internationalization of distribution channels.
- 2) Cultivating internal talent in technology research and development, as well as technology management capabilities.
- 3) Collaborating with domestic and international research institutions for research, with this company managing mass production and international marketing.
- 4) Gathering niche products with potential market demand through clinical and distribution channels.
- 5) Progressing towards internationalization to become a multinational research and development and management enterprise team.

6.4 The impact of significant domestic and international policy and legal changes on the company's financial operations and corresponding response measures.

This Company has not been affected by significant domestic and international policy or legal changes in the recent fiscal year, as it has implemented appropriate response measures to address such changes, thereby preventing any substantial impact on the Company's finances and operations.

6.5 The Impact of Technological Changes and Industry Shifts on the Company's Financial Operations and Response Measures

This Company continuously monitors developments and changes in the biomedical technology and skincare products industry, swiftly grasping industry dynamics. In conjunction with ongoing enhancements in research and development capabilities, the Company actively seeks to expand the application domains of related biomedical materials and medical aesthetic skincare products in the future. Therefore, technological changes and industry shifts do not pose a significant impact on the Company's financial operations.

6.6 The Impact of Changes in Corporate Image on Crisis Management and Response Measures

This Company places the utmost importance on integrity in its corporate image, refraining from pursuing illegal profits. With a professional research and development team and an internationalized business model, it has established a refreshing image in the industry. Furthermore, it has consistently aimed to promote social and economic development, enhance the environment, and safeguard employee welfare. The Company strictly adheres to the legal regulations set forth by supervisory authorities. To date, the Company's corporate image remains positive, with no significant changes leading to issues in crisis management.

6.7 Expected Benefits and Potential Risks of Mergers and Acquisitions:

This Company has no plans to acquire other companies in the recent fiscal year and up to the date of the public offering statement. In the future, should any merger plans arise, a careful assessment will be conducted, considering the synergies of the merger to safeguard the interests of existing shareholders.

6.8 Expected Duration and Potential Risks of Factory Expansion

This Company is prudently planning its own factory and office construction project, which will not only strengthen the corporate finance structure but will also be entrusted to professional institutions for collaborative planning to mitigate the risk of insufficient capital. Furthermore, due to the management team's extensive experience in the industry and their understanding of product demand, the production items will be adjusted according to the factory environment, thereby fully utilizing the capacity of the newly constructed facility.

6.9 Risks Associated with Concentration of Purchases or Sales

(1) Assessment of Purchase Concentration Risk

In the most recent fiscal year, the Company's purchase amount from a single supplier exceeded 10% for a total of four companies. Considering the characteristics of the Company's industry, the level of purchase concentration is still considered reasonable. However, the Company is actively seeking alternative suppliers to establish purchasing sources in order to mitigate potential purchase concentration risks.

(2) Risk Assessment of Sales Concentration

In the most recent fiscal year, sales from the top five major clients accounted for approximately 50% of total sales. All five major clients are well-known companies, thus presenting no significant credit risk. Furthermore, this Company is actively developing target client sources, such as large brand manufacturers and medical device distributors, as well as establishing regional market channels and large projects for its own brand to mitigate the risk of sales concentration.

6.10 The impact and risks to the Company arising from the transfer or change of equity by directors, supervisors, or major shareholders holding more than ten percent of the equity.

This Company has introduced a strategic investor, Formosa Biomedical Technology Corp., and conducted a private placement of new shares in 2022, resulting in the addition of one director. In 2024, the Company's revenue increased by 9.41% compared to 2023, and the net profit for 2024 rose by 14.68% compared to 2023. The change in equity has not had any negative impact or risk on the Company's operations.

6.11 Impact and Risks of Changes in Management Rights: As of the most recent fiscal year and up to the publication date of this Annual Report, there have been no changes in management rights for this Company; therefore, this is not applicable.

6.12 Litigation or non-litigation events must specify the Company, its directors, supervisors, general manager, substantial responsible persons, major shareholders with a shareholding ratio exceeding ten percent, and subsidiaries that are involved in significant litigation, non-litigation, or administrative disputes that have been adjudicated or are still pending, the outcomes of which may significantly impact shareholders' equity or securities prices. The relevant facts, subject amount, date of commencement of litigation, main parties involved, and the status of the case as of the date of publication of the annual report shall be disclosed: None.

6.13 Other Significant Risks and Response Measures

(1) Cybersecurity Risk Assessment:

This Company established its Information Management Department upon its founding in 1998. The Company conducts annual assessments of cybersecurity risks, which are reviewed and audited by the External Audit Unit and the Internal Audit Unit. Relevant information is reported monthly to the General Manager during Management Conferences. The key points of the Company's information security assessment are as follows: (1) Review of Information Architecture, (2) Review of Internet Activities, (3) Inspection of Network Equipment, Servers, and Terminals, (4) Website Security Testing, (5) Review of Security Settings. The main assessment items and specific management plans are detailed as follows:

1) Review of Information Architecture

A. Assess the appropriateness of measures implemented for business continuity:

Reviewing the structure and operational mechanisms of relevant measures to identify any risks associated with single points of failure, and conducting a risk

analysis regarding the appropriateness of business continuity measures, such as ERP systems and network equipment, while providing the results and recommendations of the information architecture security assessment.

B. Evaluate the maximum impact of single points of failure and the risk bearing capacity:

Evaluate whether the impact falls within the risk tolerance; if not, consider and implement corrective measures.

2) Review of Internet Activities – Examination of access records and account permissions for devices

Assess whether the access records, account permissions granting, and monitoring mechanisms for network equipment, cybersecurity equipment, and servers are in compliance with internal control operational specifications.

3) Network Equipment, Server, and Terminal Testing - Vulnerability Scanning and Repair Operations

Regularly or timely review the policies for network equipment, servers, and terminals, and implement improvements and repair operations for any identified inappropriate policies. Provide assessment recommendations based on the results, with an emphasis on identifying potential weaknesses and vulnerabilities within the architecture for improvement and remediation, thereby reducing overall cybersecurity risks.

A. Website Security Testing - Conducting penetration testing on the website

Penetration testing consists of three steps: Data Collection, Information Analysis, and Target Penetration; The execution method simulates hacker attack behavior by utilizing safety testing tools to conduct penetration testing on websites with open external links, examining for vulnerabilities and implementing necessary repairs.

B. Security Settings Review - Server Security Principles Configuration

Regularly review the server (e.g., Domain Services Active Directory) settings related to 'Password Setting Principles' and 'Account Lockout Policy.' Through manual operations, verify whether the relevant domain security principles comply with internal control regulations.


Cybersecurity training courses are held annually, with a total of 137 participants in cybersecurity training courses conducted in October 2024. Additionally, the audit conducted in 2024 found no significant flaws in the assessment of cybersecurity risks.

7. Other Important Matters: None.

VI. Special Notes

1. Information of the Company's Affiliates

1.1 Organizational Chart of Related Enterprises



Note: The company's liquidation process was completed on July 18, 2024.

1.2 Basic Information of Related Enterprises

Unit: New Taiwan Dollar thousands; Shares/ December 31, 2024

Name	Relationship	Affiliate's Shares in the Company		Affiliate's Shares held by the Company		
		Shares	%	Shares	%	Actual Investment Capital Amount
Maxigen Biotech Inc. (Shanghai) (Note 1)	Subsidiary of MBI (Note 2)	—	—	—	100	58,193
Horay Inc. (Note 3)	Subsidiary of MBI	—	—	—	—	—

Note 1: The company was formerly known as Dingshi Trading (Shanghai) Co., Ltd. and the company name was changed to Maxigen Biotech Inc. (Shanghai) on February 22, 2022.

Note 2: The company was originally a subsidiary of Maxigen Biotech International Investment Corporation Limited, a subsidiary of the Company, and later changed the investor to the Company's direct investment, and the change of registration was completed at the company's location on January 7, 2022.

Note 3: The liquidation process for the company was completed on July 18, 2024.

1.3 If a person is presumed to have a controlling or subordinate relationship in accordance with Article 369-3 of this Law, the following matters shall be disclosed:

There is no presumption of control or affiliation with the Company.

1.4 The related enterprises shall explain the division of business between them

Subsidiary, Maxigen Biotech Inc. (Shanghai) is the local sales office of the Company in China.

1.5 The names of the directors, supervisors and general managers of each affiliated company and their shareholdings or capital contributions to the company:

Unit: Shares/December 31, 2024

Enterprise Name	Title	Person or Representative	Shares Held	
			Shares	%
Maxigen Biotech Inc. (Shanghai)	Director	Yung-Hsiang Lin	—	—
HORAY INC. (note)	—	—	—	—

Note: The company's liquidation process was completed on July 18, 2024.

1.6 Operational Status of Related Enterprises

Unit: New Taiwan Dollar Thousand; Shares/ December 31, 2024

Investment Transfer Business	Main Business	Investment cost	Book Value	Investment Shares		Equity Net Value	Market Price	Accounting Method	Latest Annual Investment Return		Amount of Shares Held in the Company
				Shares	%				Investment Profit and Loss	Distribution of dividends	
Maxigen Biotech Inc. (Shanghai) (Note 1)	Engaged in the business of medical machinery and cosmetics	58,193	—	—	100%	(81,392)	—	Long-term investments recognized under the equity method	(32,891)	—	—
HORAY INC. (Note 2)	Engaged in the import and export business of cosmetics	—	—	—	—	—	—	—	—	—	—

Note 1: The company was formerly known as Dingshi Trading (Shanghai) Co., Ltd. and the company name was changed to Maxigen Biotech Inc. (Shanghai) on February 22, 2022.

Note 2: The company's liquidation process was completed on July 18, 2024.

1.7 Consolidated Financial Statements of Related Enterprises


(1) Statement of Consolidated Financial Statements of Related Enterprises

Statement of Consolidated Financial Statements of Affiliated Companies

For the year ending December 31, 2024 (from January 1, 2024 to December 31, 2024), the companies that should be included in the consolidated financial statements of affiliated companies in accordance with the “Regulations Governing the Preparation of Consolidated Financial Statements of Affiliated Companies and Related Party Reports” are the same as those that should be included in the consolidated financial statements of parent and subsidiary companies in accordance with IFRS 10, and the information required to be disclosed in the consolidated financial statements of affiliated companies has been disclosed in the previous consolidated financial statements of parent and subsidiary companies. The information required to be disclosed in the consolidated financial statements of affiliated companies has been disclosed in the consolidated financial statements of the former parent and subsidiary, thus will not prepare separate consolidated financial statements of affiliated companies.

Hereby declared

Company Name: Maxigen Biotech Inc.



Authorized Person: Yung-Hsiang Lin



February 26, 2025

(2) Consolidated financial statements of related enterprises:

Please refer to the “Affiliated Enterprises Financial Reports” section on the Market Observation Post System (MOPS).

1.8 Affiliated Enterprises Report: Not applicable.

2. The status of issuing private placement securities in the most recent year and up to the publication of the annual report.

Private Securities Information

Item	2021 First private offering (Note 1) Issue Date: August 6, 110				
Type of private securities (Note2)	Common Stock				
Date and amount approved at the shareholders' meeting (Note 3)	Date: July 12, 110 Total Number of Shares Issued: 7,534,235 shares				
Basis and Reasonableness of Price Determination	<p>1. July 27, 2021 used as the pricing date for the private placement. In accordance with the pricing principle resolved at the shareholders' meeting, the higher of (1) the average of the closing prices of the common shares on one, three or five business days prior to the pricing date, less the ex-rights and dividends of the gratis allotment, plus the capital reduction anti-defeasance, or (2) the average of the closing prices of the common shares on 30 business days prior to the pricing date, less the ex-rights and dividends of the gratis allotment, plus the capital reduction anti-defeasance, shall be used as the reference price. The reference price is NT\$41.03.</p> <p>2. Taking into account the Company's operating performance, market conditions and the restriction of the Securities and Exchange Act that the private placement of marketable securities shall not be freely transferable within three years, the price of the private placement is set at NT\$32.83 per share, which is not less than 80% of the reference price and is within the authorization range of the resolution of the shareholders' meeting and should be reasonable.</p>				
Method of selecting specific person (Note 4)	Subject to Article 43-6 of the Securities Exchange Act and the relevant provisions of the Financial Supervisory Authority's June 13, 2002 (2002) Taiwan Certificate No. 0910003455.				
Reasons for private placement	The introduction of strategic investors will help enhance the Company's operational performance and market competitiveness, as well as strengthen the overall financial structure. The funds will be used for future operational development to meet the Company's long-term development needs. The introduction of strategic investors in this private placement will not result in any significant change in operating rights.				
Date of Payment Completion	August 6, 2021				
Private Placement	Private Placement (note 5)	Criteria (note 6)	Number of subscriptions	Relationship with the company	Involvement in the business of the company
	Formosa Biomedical Technology Corp.	Paragraph 3 of Article 43-6 of the Securities and Exchange Act	7,534,235	No-relationship	None
Actual subscription (or conversion) price (Note 7)	NT\$ 32.83				
Difference between the actual subscription (or conversion) price and the reference price (Note 7)	The price of the private common shares was \$32.83 per share, which was not less than 80% of the reference price of \$41.03 with no material difference.				
Effect of private equity on shareholders' equity (e.g., increase in accumulated losses...)	Private placement price exceeds par value per share and capital surplus increases.				
Private Placement Funds Utilization and Plan Implementation Progress	The overall financial structure has been improved and the plan has been implemented.				
Private Placement Benefits	The company's operating performance grew, with revenue increasing 12% in 2021 compared to 2020.				

Note 1: The number of columns is adjusted based on the actual number of transactions; if there are multiple private placements of securities, they should be listed separately.


Note 2: This includes the types of private placement securities such as common stock, preferred stock, convertible preferred stock, warrants attached to preferred stock, common corporate bonds, convertible corporate bonds, warrants attached to corporate bonds, overseas convertible corporate bonds, overseas depositary receipts, and employee stock option certificates.

- Note 3: For corporate bonds that are privately placed and do not require approval from the Shareholders' Meeting, the date and amount approved by the board of directors should be recorded.
- Note 4: For ongoing private placement cases, if the subscribers have been identified, their names and relationship with the Company should be clearly stated.
- Note 5: The number of fields should be adjusted based on the actual figures.
- Note 6: This refers to Article 43-6, Paragraph 1, Subparagraphs 1, 2, or 3 of the Securities Trading Act.
- Note 7: The actual subscription (or conversion) price refers to the price agreed upon at the time of issuing the privately placed securities.

3. Recent year and as of the date of publication of the annual report, the subsidiaries held or disposed of the Company's shares: None.

VII. The occurrence of any events as stated in Section 3 Paragraph 2 in Article 36 of the Securities Exchange Act and had significant impact on shareholders' equity or securities prices in the most recent year and up to the publication of the annual report: None.

Maxigen Biotech Inc.



Chairman of the Board, Yung Hsiang Lin

